UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant
to Section 14(a) of the Securities
Exchange Act of 1934
|
|
Filed by the Registrant
|
|
Filed by a Party other
than the Registrant
|
Check
the appropriate box:
|
|
Preliminary Proxy Statement.
|
|
Confidential, For Use of the Commission
Only (as permitted by Rule 14a-6(e)(2)).
|
|
Definitive Proxy Statement.
|
|
Definitive Additional Materials.
|
|
Soliciting Material under §240.14a-12.
|
COLFAX CORPORATION
(Name of Registrant as
Specified In Its Charter)
(Name of Person(s) Filing
Proxy Statement, if Other Than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
|
|
No fee required.
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1)
and 0-11.
|
|
(1) Title of each class of securities to which transaction
applies:
|
|
(2) Aggregate number of securities to which transaction
applies:
|
|
(3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
(4) Proposed maximum aggregate value of transaction:
|
|
(5) Total fee paid:
|
|
Fee paid previously with preliminary materials.
|
|
Check box if any part of the fee is offset as provided
by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
(1) Amount Previously Paid:
|
|
(2) Form, Schedule or Registration Statement No.:
|
|
(3) Filing Party:
|
|
(4) Date Filed:
|
Notice of 2020
Annual Meeting
of Stockholders
|
Thursday, May 21, 2020
3:00 p.m. Local Time
Maryland Conference Center, 2720 Technology
Drive, Annapolis Junction, Maryland 20701
To Our Stockholders:
Notice is hereby given
that the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of Colfax Corporation will be held at the Maryland
Conference Center located at 2720 Technology Drive, Annapolis Junction, Maryland 20701* on Thursday, May 21, 2020 at 3:00 p.m.,
local time, for the following purposes:
1.
|
To elect the ten members of the
Board of Directors named in the attached proxy statement;
|
2.
|
To ratify the appointment of Ernst &
Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
|
3.
|
To approve the compensation of our named executive
officers on an advisory basis (“say-on-pay”);
|
4.
|
To approve the Colfax Corporation 2020 Omnibus
Incentive Plan; and
|
5.
|
To consider any other matters that properly
come before the Annual Meeting or any adjournment or postponement thereof.
|
The accompanying proxy
statement describes the matters to be considered at the Annual Meeting. Only stockholders of record at the close of business on
April 2, 2020 are entitled to notice of, and to vote at, the Annual Meeting and at any adjournments or postponements thereof.
We are pleased to take
advantage of the Securities and Exchange Commission rules that allow us to furnish our proxy materials and our annual report to
stockholders on the Internet. We believe that posting these materials on the Internet enables us to provide our stockholders with
the information that they need more quickly while lowering our costs of printing and delivery and reducing the environmental impact
of our Annual Meeting.
As a stockholder of Colfax,
your vote is important. Whether or not you plan to attend the Annual Meeting in person, we urge you to vote your shares at your
earliest convenience and thank you for your continued support of Colfax Corporation.
Dated: April 9, 2020
By Order of the Board of
Directors
Bradley J. Tandy
Secretary
*
|
We are actively monitoring the public health
and travel safety concerns relating to the coronavirus (COVID-19) and the advisories or mandates that federal, state, and
local governments, and related agencies, have issued and may issue. In the event it is not possible or advisable to hold our
Annual Meeting as currently planned, we will announce any additional or alternative arrangements for the meeting, which may
include a change in venue or holding the meeting solely by means of remote communication. Please monitor our press releases,
available at http://ir.colfaxcorp.com, and our filings with the SEC for updated information. If you are planning to
attend our Annual Meeting, please check http://ir.colfaxcorp.com the week of the meeting. As always, we encourage you
to vote your shares prior to the Annual Meeting.
|
Table of Contents
PROXY SUMMARY
This summary highlights information contained
elsewhere in this proxy statement. This summary does not contain all of the information that you should consider, and you should
read the entire proxy statement carefully before voting. Page references are supplied to help you find further information in
this proxy statement.
Annual Meeting of Stockholders
Date
and Time:
|
Thursday, May 21, 2020 at 3:00 pm EDT
|
Location:
|
2720 Technology Drive,
Annapolis Junction, Maryland 20701
|
Record
Date:
|
April 2, 2020
|
Availability of Proxy Materials – Use
of Notice and Access
Important Notice Regarding
the Availability of Proxy Materials for the Stockholder Meeting to be Held on May 21, 2020: Our Annual Report to Stockholders
and this Proxy Statement are available at www.proxyvote.com.
Pursuant to the “notice
and access” rules adopted by the Securities and Exchange Commission, we have elected to provide stockholders access to our
proxy materials primarily over the Internet. Accordingly, on or about April 9, 2020, we sent a Notice of Internet Availability
of Proxy Materials (the “Notice”) to our stockholders entitled to vote at the Annual Meeting as of the close of business
on April 2, 2020, the record date of the meeting. The Notice includes instructions on how to access our proxy materials over the
Internet and how to request a printed copy of these materials. In addition, by following the instructions in the Notice, stockholders
may request to receive proxy materials in printed form by mail or electronically by e-mail on an ongoing basis.
Choosing to receive your
future proxy materials by e-mail will save us the cost of printing and mailing documents to you and will reduce the impact of
our annual meetings on the environment. If you choose to receive future proxy materials by e-mail, you will receive an e-mail
next year with instructions containing a link to those materials and a link to the proxy voting site. Your election to receive
proxy materials by e-mail will remain in effect until you terminate it.
Who May Vote
You may vote if you were
a stockholder of record at the close of business on the April 2, 2020, the record date.
How to Cast Your Vote
You can vote by any of the following methods:
|
Via
the internet (www.proxyvote.com) through May 20, 2020;
|
|
|
|
By telephone (1-800-690-6903) through May 20, 2020;
|
|
|
|
By completing, signing and returning your proxy by mail in the envelope
provided or to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NJ 11717 by May 20, 2020; or
|
|
|
|
Via in person attendance and voting at the Annual Meeting. If you
are a stockholder of record, your admission card will serve as proof of ownership. If you hold your shares through a bank,
broker or other nominee, you must bring proof of ownership and, to vote, a valid legal proxy from a stockholder of record.
|
|
- 2020 Proxy Statement
|
5
|
|
|
|
Voting Matters
We are asking you to vote on the following proposals
at the Annual Meeting:
Proposal
|
|
Board Vote Recommendation
|
|
Page
Reference
|
Proposal
1 – Election of Directors
|
|
FOR each director
nominee
|
|
11
|
Proposal
2 – Approval of Auditor
|
|
FOR
|
|
23
|
Proposal
3 – Say-on-Pay
|
|
FOR
|
|
52
|
Proposal
4 – Approval of Colfax Corporation 2020 Omnibus Incentive Plan
|
|
FOR
|
|
54
|
Board and Governance Highlights
|
Balanced Board tenure with
three new independent directors appointed
since 2016
|
|
80% independent Board with two female directors
|
|
Stock ownership requirements for officers and directors
|
|
Anti-hedging, anti-pledging, and clawback policies
|
Board Nominees (page 12)
The following table provides summary information
about each director nominee:
Name
|
|
Age
|
|
Director
Since
|
|
Occupation
|
|
Independent
|
|
Committee
Memberships
|
|
Other Public
Boards
|
Mitchell P. Rales
|
|
63
|
|
1995
|
|
Chairman of the Board,
Colfax Corporation
Chairman of the Executive
Committee, Danaher Corporation
|
|
|
|
N/A
|
|
Danaher Corporation;
Fortive Corporation
|
Matthew L. Trerotola
|
|
52
|
|
2015
|
|
President and Chief Executive Officer, Colfax Corporation
|
|
|
|
N/A
|
|
None
|
Patrick W. Allender
|
|
73
|
|
2008
|
|
Former Executive Vice President and Chief Financial Officer,
Danaher Corporation
|
|
|
|
Nominating (Chair) Audit
|
|
Brady Corporation;
Diebold Nixdorf, Inc.
|
Thomas S. Gayner
|
|
58
|
|
2008
|
|
Co-Chief Executive Officer, Markel Corporation
|
|
|
|
Audit
|
|
Markel Corporation;
Cable One, Inc.;
Graham Holdings, Inc.
|
Rhonda L. Jordan
|
|
62
|
|
2009
|
|
Former President, Kraft Foods Inc.
|
|
|
|
Compensation (Chair) Nominating
|
|
Ingredion, Inc.
|
Liam J. Kelly
|
|
53
|
|
2020
|
|
President and CEO of Teleflex Incorporated
|
|
|
|
N/A
|
|
Teleflex Incorporated
|
A. Clayton Perfall
|
|
61
|
|
2010
|
|
Operating Executive, Tailwind Capital
|
|
|
|
Audit (Chair)
|
|
None
|
Didier Teirlinck
|
|
63
|
|
2017
|
|
Former Executive Vice President, Climate Segment, Ingersoll
Rand
|
|
|
|
Audit
|
|
None
|
Rajiv Vinnakota
|
|
49
|
|
2008
|
|
President, Woodrow Wilson National Fellowship Foundation
|
|
|
|
Compensation Nominating
|
|
None
|
Sharon Wienbar
|
|
58
|
|
2016
|
|
Former Venture Partner, Scale Venture Partners
|
|
|
|
Compensation
|
|
Resideo Technologies, Inc.
|
|
- 2020 Proxy Statement
|
6
|
|
|
|
Of our 10 director nominees:
In accordance with the Company’s
Amended and Restated Bylaws (the “Bylaws”), to be elected each director nominee must receive a majority of the votes
cast with respect to that director’s election. Incumbent directors nominated for election by the Board are required, as
a condition to such nomination, to submit a conditional letter of resignation to the Chairman of the Board. In the event that
a nominee for director does not receive a majority of the votes cast at the Annual Meeting with respect to his or her election,
the Board will promptly consider whether to accept or reject the conditional resignation of that nominee, or whether other action
should be taken. The Board will then take action and will publicly disclose its decision and the rationale behind it no later
than 90 days following the certification of election results.
Corporate Social Responsibility and Sustainability
Our corporate sustainability
program is organized around identifying, assessing and managing on an ongoing basis the environmental, social and governance (“ESG”)
factors that are relevant to our long-term financial performance. Our sustainability program takes into account the interests
of our key stakeholder constituencies, including employees, customers, our communities and our shareholders. ESG issues that we
focus on across the Company include workplace health and safety, energy efficiency, waste management, climate risk, human capital
management, diversity and inclusion, supply chain management, business ethics and compliance, and data privacy and protection.
Selected aspects of our program are discussed below.
|
Governance
We take
ESG-related risks and opportunities into account in our strategic decision-making, both by the Board and management.
|
|
ESG matters are managed and monitored by senior management
throughout the year. The Board exercises oversight over ESG matters at the full Board level and through our relevant committees.
|
|
In furtherance of our focus on long-term business sustainability,
in 2019, we enhanced our oversight process by amending our Nominating and Corporate Governance Committee charter to expressly
task the Committee with reviewing the Company’s undertakings with respect to ESG matters, including our role as a corporate
citizen and policies and programs relating to health, safety and sustainability matters. The Nominating and Corporate Governance
Committee will continue to coordinate with other Board committees on these matters as appropriate.
|
|
- 2020 Proxy Statement
|
7
|
|
|
|
|
Health, Safety and Environment
The protection
of human health, personal safety and environmental quality rank at the highest level of importance to Colfax.
|
|
Recent and ongoing initiatives to reduce incidents
and promote human health and personal safety include the following:
|
|
–
|
Reporting for major injuries, dangerous occurrences
(which are a leading indicator of major injuries) and near misses and enhancing our related data collection processes, trend
analysis and incident response capabilities.
|
|
–
|
Developing and implementing a Fire Safety checklist in all global
plants.
|
|
–
|
Instituting a summer of safety campaign.
|
|
–
|
Rolling out a new driver safety policy, metrics and communication
program.
|
|
–
|
Establishing monthly EHS leader calls and quarterly all-hands
global safety reviews.
|
|
–
|
Enhancing our focus on additional high hazards, specifically
ergonomics (hoists, cranes, lifting and hand safety), electrical and flammable metals.
|
|
–
|
Introducing additional sustainability metrics and enhancing our
environmental management strategy.
|
|
Many of our business units have set objectives for
key environmental aspects, such as lowering energy and water use, and eliminating hazardous substances.
|
|
Labor Principles, Human Rights and
Business Partners and Supply Chain
As an
equal opportunity employer‚ we are committed to a diverse workforce.
|
|
We also are reviewing our gender pay equity across
our businesses and are committed to addressing any issues identified.
|
|
We have publicly stated our commitment to respecting human rights
across all of our business operations in accordance with the Universal Declaration of Human Rights, the UN Guiding Principles
on Business and Human Rights and the ILO Declaration on Fundamental Principles and Rights at Work.
|
|
|
Without limiting the foregoing, we do not
utilize or permit:
Child
labor,
Forced
labor, or
Other
abusive or unsafe working conditions.
|
|
We have adopted a Code of Conduct for Business Partners that
sets out the expectations and standards that apply to any agents, distributors, dealers, contractors, intermediaries, joint
venture partners, suppliers and other business partners doing business with Colfax. Among other things, the Code of Conduct
for Business Partners addresses compliance with law, labor and human rights and health, safety and the environment.
|
|
We recently enhanced our website to include additional information
on our corporate social responsibility program, employee benefits and supply chain practices.
|
In 2020, we intend to undertake a review of
our ESG priorities and programs in connection with a project for the development of a comprehensive business sustainability model.
We will be reviewing selected
ESG-related policies and procedures, with a focus in part on life-cycle impacts for our products, climate-linked emissions, and
resource sustainability. As part of this review and project, we expect to produce and periodically update additional information
on our ESG programs, objectives, and accomplishments.
We recognize the need for investors
to have comparable, decision-useful information on financially material ESG factors. In 2020, the Company intends to enhance
its sustainability reporting. Enhancements are expected to continue into 2021 and beyond, as ESG integration by investors
and reporting framework continue to evolve. Our sustainability reporting will be informed by the Sustainability Accounting
Standards Board standards and the recommendations of the Task Force on Climate-related Financial Disclosures.
|
|
- 2020 Proxy Statement
|
8
|
|
|
|
Auditor Ratification (page 23)
We ask our stockholders
to approve the selection of Ernst & Young LLP as our independent registered public accounting firm for the year ending
December 31, 2020. Below is summary information about fees paid to Ernst & Young LLP for services provided in 2019 and
2018:
Fee Category (fees in thousands)
|
|
2019
|
|
|
2018
|
|
Audit Fees
|
|
$
|
7,417
|
|
|
$
|
5,827
|
|
Audit-Related Fees
|
|
|
1,628
|
|
|
|
—
|
|
Tax Fees
|
|
|
1,023
|
|
|
|
1,146
|
|
All Other Fees
|
|
|
4
|
|
|
|
2
|
|
TOTAL
|
|
$
|
10,072
|
|
|
$
|
6,975
|
|
Executive Compensation (page 26)
We strive to create a compensation
program for our associates, including our executives, that provides a compelling and engaging opportunity to attract, retain and
motivate the best talent. We believe this results in performance-driven leadership that is aligned to achieve our financial and
strategic objectives with the intention to deliver superior long-term returns to our stockholders. Our compensation program includes
the following key features:
|
We link rewards to performance and foster a team-based
approach by setting clear objectives that, if achieved, we believe will contribute to our overall success;
|
|
We emphasize long-term stockholder value creation by using stock
options and performance-based restricted stock units, in combination with a stock ownership policy, to deliver long-term compensation
incentives while minimizing risk-taking behaviors that could negatively affect long-term results;
|
|
We set Annual Incentive Plan operational and financial performance
targets based on the results of our Board’s strategic planning process and corporate budget, and provide payouts that
vary significantly from year-to-year based on the achievement of those targets; and
|
|
We believe the design of our overall compensation program, as
well as our internal controls and policies, serve to limit excessive risk-taking behavior, as described further on page 37.
|
Say-on-Pay: Advisory Vote to Approve the Compensation
of our Named Executive Officers (page 52)
We are asking our stockholders
to approve on an advisory basis the compensation of our named executive officers. We believe our compensation programs and practices
are appropriate and effective in implementing our compensation philosophy, and our focus remains on linking compensation to performance
while aligning the interests of management with those of our stockholders.
Proxy Statement for Annual Meeting of Stockholders
2020 Annual Meeting
We are furnishing this Proxy
Statement (the “Proxy Statement”) in connection with the solicitation by the Board of Directors (the “Board”)
of Colfax Corporation (hereinafter, “Colfax,” “we,” “us” and the “Company”) of
proxies for use at the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Thursday, May 21,
2020, at 3:00 p.m. local time, and at any adjournments or postponements thereof. The Board has made this Proxy Statement and the
accompanying Notice of Annual Meeting available on the Internet. We first made these materials available to the Company’s
stockholders entitled to vote at the Annual Meeting on or about April 9, 2020.
|
- 2020 Proxy Statement
|
9
|
|
|
|
About Colfax Corporation
Colfax Corporation is a
leading diversified technology company that provides orthopedic and fabrication technology products and services to customers
around the world principally under the DJO and ESAB brands. Our business has been built through a series of acquisitions, as well
as organic growth, since its founding in 1995.
Our January 2012 acquisition
of Charter International plc transformed Colfax from a fluid handling business into a diversified industrial enterprise with a
broad global footprint that encompassed fabrication technology (operating primarily under the ESAB brand name), fluid handling
products, and air & gas handling products (operating principally under the Howden brand name). In the years following
that acquisition, we completed 24 acquisitions to grow and strengthen our business across our three major business lines.
In December 2017, we completed the divestiture of our fluid handling business. This represented a strategic milestone in the development
and transformation of our business portfolio and strengthened our balance sheet, providing more flexibility to execute our strategic
growth strategy. In November 2018, we entered into a definitive agreement to acquire DJO Global Inc. (“DJO”) for $3.2
billion in cash and this acquisition was completed in February 2019. DJO is a global leader in orthopedic solutions, providing
orthopedic devices, reconstructive implants, software and services spanning the full continuum of patient care, from injury prevention
to rehabilitation. The acquisition is expected to evolve the Company to higher margins, faster growth, and lower cyclicality,
while providing opportunities for significant bolt-on and adjacent acquisitions over time. In May 2019, we signed a purchase agreement
to sell our Air & Gas Handling business for an attractive valuation. We completed the divestiture in September 2019 and
used the proceeds to pay-down our debt and position us to pursue strategic bolt-on acquisitions for our remaining businesses.
As discussed in our annual
report on Form 10-K, we seek to build an enduring premier global enterprise by applying the Colfax Business System (“CBS”)
to pursue growth in revenues and improvements in profit and cash flow. CBS is our business management system. It is a repeatable,
teachable process that we use to create superior value for our customers, stockholders, and associates. Rooted in our core values,
it is our culture. CBS provides the tools and techniques to ensure that we are continuously improving our ability to meet or exceed
customer requirements on a consistent basis.
Our principal executive
office is located at 420 National Business Parkway, 5th Floor, Annapolis Junction, MD, 20701. Our telephone number
is (301) 323-9000 and our website is located at www.colfaxcorp.com. Our common stock trades on the New York Stock Exchange
(NYSE) under the symbol CFX.
|
- 2020 Proxy Statement
|
10
|
|
|
|
Proposal 1 Election
of Directors
Ten director nominees will
be elected at the Annual Meeting, each to serve until the next annual meeting of the Company and until his or her successor is
duly elected and qualified. At the recommendation of the Nominating and Corporate Governance Committee, the Board has nominated
the following persons to serve as directors for the term beginning at the Annual Meeting on May 21, 2020: Mitchell P. Rales, Matthew
L. Trerotola, Patrick W. Allender, Thomas S. Gayner, Rhonda L. Jordan, Liam J. Kelly, A. Clayton Perfall, Didier Teirlinck, Rajiv
Vinnakota, and Sharon Wienbar. All nominees are currently serving on the Board.
Director Qualifications
Nominating Committee Criteria for Board Members
The Nominating and Corporate
Governance Committee considers, among other things, the following criteria in selecting and reviewing director nominees:
|
personal and professional integrity;
|
|
skills, business experience and industry knowledge useful to the oversight of the Company based on the perceived needs of the Company and the Board at any given time;
|
|
the ability and willingness to devote the required amount of time to the Company’s affairs, including attendance at Board and committee meetings;
|
|
the interest, capacity and willingness to serve the long-term interests of the Company and its stockholders; and
|
|
the lack of any personal or professional relationships that would adversely affect a candidate’s ability to serve the best interests of the Company and its stockholders.
|
Pursuant to its charter,
the Nominating and Corporate Governance Committee also reviews, among other qualifications, the perspective, broad business judgment
and leadership, business creativity and vision, and diversity of potential directors, all in the context of the needs of the Board
at that time. We believe that Board membership should reflect diversity in its broadest sense, including persons diverse in geography,
gender, and ethnicity, and we seek independent directors who represent a mix of backgrounds and experiences that will enhance the
quality of the Board’s deliberations and decisions.
The charter of the Nominating
and Corporate Governance Committee affirmatively recognizes diversity as one of the criteria for consideration in the selection
of director nominees, and in its deliberations and discussions concerning potential director appointments the Nominating and Corporate
Governance Committee has paid particular attention to diversity together with all other qualifying attributes. In addition, the
Nominating and Corporate Governance Committee annually considers its effectiveness in achieving these objectives as a part of its
assessment of the overall composition of the Board and as part of the annual Board evaluation process described further below,
which includes a director skills matrix to identify areas of director knowledge and experience that may benefit the Board in the
future. That information is used as a part of the director search and nomination process. The Nominating and Corporate Governance
Committee looks for candidates with the expertise, skills, knowledge and experience that, when taken together with that of other
members of the Board, will lead to a Board that is effective, collegial and responsive to the needs of the Company. As further
discussed below, certain members of our Board have experience with the business systems that are an integral part of our Company
culture. In addition, we feel that the familiarity of certain Board members with our business system from their work experiences
at Danaher Corporation and at our Company, combined with strong input from varied and sophisticated business backgrounds, provides
us with a Board that is both functional and collegial while able to draw on a broad range of expertise in the consideration of
complex issues.
Board Member Service
The biographies of each of
the nominees below contain information regarding the experiences, qualifications, attributes or skills that the Nominating and
Corporate Governance Committee and the Board considered in determining that the person should serve as a director of the Company.
The Board has been informed that all of the nominees listed below are willing to serve as directors, but if any of them should
decline or be unable to act as a director, the individuals named in the proxies may vote for a substitute designated by the Board.
The Company has no reason to believe that any nominee will be unable or unwilling to serve.
In determining to nominate
Mr. Gayner for re-election, the Nominating and Corporate Governance Committee and the Board carefully evaluated and took into account
that Mr. Gayner serves as an executive officer at Markel Corporation and serves on the boards of Markel Corporation, Graham Holdings
Co. and Cable One Inc. (which was a wholly-owned subsidiary of Graham Holdings
|
- 2020 Proxy Statement
|
11
|
|
|
|
until July 2015). The Nominating and Corporate
Governance Committee determined, and the Board concurred, that Mr. Gayner is a valuable, productive and fully engaged director
who should be re-elected to the Board. In reaching this conclusion, the Nominating and Corporate Governance Committee took note
of Mr. Gayner’s valuable role on the Board and stellar attendance record. As a result of his experience as an executive officer
at Markel Corporation, Mr. Gayner provides the Board with substantial knowledge regarding business operations strategy, as
well as valuable financial and investment expertise. Moreover, Mr. Gayner has continued to be an active participant in all Colfax
Board matters and is well-prepared for Board and Committee meetings, and played an important role in the Audit Committee’s
discussions and decision-making regarding Colfax’s acquisition of DJO and sale of the Air & Gas Handling business.
During the last three years, Mr. Gayner has attended all of the meetings of the Board and the Committees on which he served, except
for one Board of Directors meeting and one Audit Committee meeting. Based on these factors, Mr. Gayner was unanimously recommended
and re-nominated for election to our Board of Directors.
Nominees for Director
The names of the nominees
for director, their ages as of April 9, 2020, principal occupations, employment and other public company board service during at
least the last five years, periods of service as a director of the Company, and the experiences, qualifications, attributes and
skills of each nominee are set forth below:
MITCHELL P. RALES
|
Age 63
Director
since: 1995
CHAIRMAN
OF THE BOARD
Committees:
• None
|
Mitchell
P. Rales is a co-founder of Colfax and has served as a director of the Company since its founding in 1995.
He is the Chairman of our Board of Directors. Mr.
Rales is a co-founder and has served as a member of the board of directors
of Danaher Corporation, a global science and technology company, since 1983 and as Chairman of Danaher’s Executive
Committee since 1984, and is also a member of the Fortive Corporation board of directors, which is a diversified
industrial growth company that was spun-off from Danaher in 2016. He has been a principal in a number of private
business entities with interests in manufacturing companies and publicly traded securities for over 25 years. Mr.
Rales was instrumental in the founding of our Company and has played a key leadership role on our Board since that
time. He helped create the Danaher Business System, on which the Colfax Business System is modeled, and has provided
critical strategic guidance to the Company during its development and growth. In addition, as a result of Mr. Rales’
substantial ownership stake in our Company, he is well-positioned to understand, articulate and advocate for the
rights and interests of the Company’s stockholders.
|
MATTHEW L. TREROTOLA
|
Age 52
Director
since: 2015
Committees:
• None
|
Matthew
L. Trerotola has been our President and Chief Executive Office and has served as a director of the Company
since July 2015. Prior to joining Colfax, Mr. Trerotola
was an Executive Vice President and a member of DuPont’s Office of
the Chief Executive, responsible for DuPont’s Electronics & Communications and Safety & Protection
segments. Mr. Trerotola also had corporate
responsibility for DuPont’s Asia-Pacific business. Many of Mr. Trerotola’s roles at DuPont,
a global chemical company that is now part of DowDupont, involved applying innovation to improve margins and
accelerate organic growth in global businesses. Prior to rejoining DuPont in 2013, Mr. Trerotola had served in leadership
roles at Danaher since 2007, and was most recently Vice President and Group Executive for Life Sciences. Previously,
Mr. Trerotola was Group Executive for Product Identification from 2009 to 2012, and President of the Videojet
business from 2007 to 2009. While at McKinsey & Company from 1995 to 1999, Mr. Trerotola focused primarily
on helping industrial companies accelerate growth. Mr. Trerotola’s day-to-day leadership of Colfax, combined
with his significant international business experience
and familiarity with the Danaher Business System, gives the Board
an invaluable Company-focused perspective supplemented by his global operational expertise.
|
PATRICK W. ALLENDER
|
Age 73
Director
since: 2008
INDEPENDENT
Committees:
• Audit
• Nominating
and Corporate Governance
(Chair)
|
Patrick
W. Allender has served as a director of the Company since May 13, 2008. He is the former Executive Vice
President and Chief Financial Officer of Danaher Corporation,
where he served from 1987 until his retirement in 2007. Prior
to joining Danaher, Mr. Allender was an audit partner with a large international accounting firm. Mr. Allender is
a director of Brady Corporation, where he is a member of the audit and corporate governance committees and the
chairman of the finance committee, and a director of Diebold Nixdorf, Inc., where he is a member of the board finance
committee and chairman of the audit committee. Mr. Allender’s prior experience as the Chief Financial Officer
of a publicly traded company provides him with substantial
expertise in financial reporting and risk management. In addition,
his familiarity with the Danaher Business System provides targeted insight on the nature of the Company’s operations
to the Board.
|
|
- 2020 Proxy Statement
|
12
|
|
|
|
THOMAS S. GAYNER
|
Age 58
Director
since: 2008
INDEPENDENT
Committees:
• Audit
|
Thomas
S. Gayner has served as a director of the Company since May 13, 2008. He is Co-Chief Executive Officer
of Markel Corporation, a financial holding company
whose principal business markets and underwrites specialty insurance
products. Since 1990, Mr. Gayner has served as President of Markel Gayner Asset Management, Inc. Mr.
Gayner has served as a director of Markel Corporation since August 2016 and previously served on the Markel Corporation
board from 1998 to 2003. Mr. Gayner also currently serves on the board of directors of Graham Holdings Company
and Cable One, Inc., as well as a director of The Davis Series Funds. Through his experience and investment knowledge
with the Markel Corporation as well as his service on the boards and committees of other publicly traded companies,
Mr. Gayner brings extensive leadership, financial acumen and public company expertise to our Board.
|
RHONDA L. JORDAN
|
Age 62
Director
since: 2009
INDEPENDENT
Committees:
• Nominating
and Corporate Governance
• Compensation
(Chair)
|
Rhonda
L. Jordan has served as a director of the Company since February 17, 2009. She served as President,
Global Health & Wellness, and Sustainability
for Kraft Foods Inc. until 2012 and in that role led the development of
Kraft’s health & wellness and sustainability strategies and plans for the company, including marketing, product
development, technology, alliances and acquisitions. Prior to being named President, Health & Wellness in 2010,
she was the President of the Cheese and Dairy business
unit of Kraft. From 2006 to 2008 she served as the President
of the Grocery business unit of Kraft and from 2004 to 2005 she was the Senior Vice President, Global Marketing
of Kraft Cheese and Dairy. Ms. Jordan is a director of Ingredion Incorporated, where she is chair of the compensation
committee, and the private companies Bush Brothers & Company and G&L Holdings. Ms. Jordan’s management
and operations experience within a large, global corporation gives her an important strategic voice in
Board deliberations, and her knowledge and decision making with respect to business unit development and sustainable
top-line performance makes her a valued member of our Board.
|
LIAM J. KELLY
|
Age 53
Director
since: 2020
INDEPENDENT
Committees:
• None
|
Liam
J. Kelly has served as a director of the Company since January 1, 2020. Mr. Kelly has served as the President
and Chief Executive Officer of Teleflex Incorporated,
a global provider of medical technology products, since January 1,
2018. Since joining Teleflex in 2009, Mr. Kelly has held a variety of senior leadership roles. From May 2016 to December
2017, Mr. Kelly served as Teleflex’s President and Chief Operating Officer and from April 2015 to April 2016,
he served as Executive Vice President and Chief Operating Officer. Prior to joining Teleflex, Mr. Kelly held various
senior level positions with Hill-Rom Holdings, Inc., a medical device company, from October 2002 to April 2009,
serving as its Vice President of International Marketing and R&D from August 2006 to February 2009. As a result
of his significant experience in the medical technology industry, Mr. Kelly brings a valuable perspective to our Board,
particularly in light of our acquisition of DJO.
|
A. CLAYTON PERFALL
|
Age 61
Director
since: 2010
INDEPENDENT
Committees:
• Audit
(Chair)
|
A.
Clayton Perfall has served as a director of the Company since September 21, 2010. He is currently an Operating
Executive of Tailwind Capital, a private equity fund
manager focused on growing middle market companies in the Healthcare,
Business Services and Industrial services sectors. He previously served as the Chairman and Chief Executive
Officer of Archway Marketing Services, Inc., a provider of marketing logistics and fulfillment services, from 2008
through 2013. From 2001 until 2008 Mr. Perfall served as the Chief Executive Officer and as a member of the
board of directors of AHL Services, Inc. Mr. Perfall also served as the Chief Executive Officer of Union Street
Acquisition Corp. from 2006 until 2008. He served
as the Chief Financial Officer of Snyder Communications, Inc. from
1996 until 2000 and was previously a partner with a large international accounting firm. Mr. Perfall currently serves
on the board of directors of the private company Distinct Holdings Group, LLC and previously served on the boards
of directors of Comstock Holding Companies, Inc. from 2004 to 2018, Tailwind Premier Holdings, LLC from 2015
until 2019, Archway Marketing Services, Inc. from 2008 until 2013, RT Acquisition Corp. from 2012 until 2015 and
inVentiv Health, Inc. from 1999 to 2010. He served as the audit committee chairman for Comstock Holding Companies,
Inc. and InVentiv Health during his time on those boards. Mr. Perfall’s significant financial expertise and
experience as an audit committee chairman and public
company Chief Financial Officer, combined with his substantial executive
leadership background, are assets to both our Board and our Audit Committee.
|
|
- 2020 Proxy Statement
|
13
|
|
|
|
DIDIER TEIRLINCK
|
Age 63
Director
since: 2017
INDEPENDENT
Committees:
• Audit
|
Didier
Teirlinck has served as a director of the Company since September 18, 2017. He retired from Ingersoll Rand,
a diversified industrial manufacturing company, in
September 2018. He has been a strategic advisor to the CEO of Ingersoll
Rand since 2017, and previously served from November 2013 as executive vice president for Ingersoll Rand’s
Climate segment, overseeing climate businesses around the world and enhancing competitive position and market
share. After joining Ingersoll Rand in 2005, Mr. Teirlinck served as president of Climate Control in Europe before
becoming President of the global Climate Solutions sector in 2009. Before joining Ingersoll Rand, he was President
of Volvo Construction Equipment’s Compact Business Line worldwide and was previously general manager of
DANISCO Flexible Group for southern Europe. Mr. Teirlinck’s international operating history and wealth of knowledge
in the climate sector brings key geographic and market experience to our Board.
|
RAJIV VINNAKOTA
|
Age 49
Director
since: 2008
INDEPENDENT
Committees:
• Nominating
and Corporate Governance
• Compensation
|
Rajiv
Vinnakota has served as a director of the Company since May 13, 2008. He currently serves as the President
of the Woodrow Wilson National Fellowship Foundation,
a non-profit foundation that administers programs that support
leadership development, a position he has held since July 2019. From 2015 to September 2018 he was an
Executive Vice-President at the Aspen Institute, leading a division focused on youth and engagement. Prior to this
role, Mr. Vinnakota was the Co-Founder and Chief Executive
Officer of The SEED Foundation, a non-profit educational organization,
at which he served from 1997 to 2015. Mr. Vinnakota was the chairman of The SEED Foundation board from
1997 until 2006. Prior to co-founding SEED, Mr. Vinnakota was an associate at Mercer Management Consulting. He
was also a trustee of Princeton University from 2004 until 2007 and a member of the Executive Committee of the
Princeton University board of directors from 2006 to 2007, and he served as the national chairman of Annual Giving
at Princeton from 2007 until 2009. Mr. Vinnakota’s management experience, combined with his experience in
the non-profit sector, brings a valuable perspective to our Board.
|
SHARON WIENBAR
|
Age 58
Director
since: 2016
INDEPENDENT
Committees:
• Compensation
|
Sharon
Wienbar has served as a director of the Company since June 15, 2016. She was previously with Scale
Venture Partners, a venture capital firm, from 2001 to
2018, where she led investments in technology companies and
served on the board of numerous portfolio businesses. She was also a strategy consultant to Capella Education Company
after it acquired Hackbright Academy, a leading software engineering training company for women, where she
was the CEO from 2015 to 2016. Ms. Wienbar currently serves on the boards of Resideo Technology, a New York
Stock Exchange-listed public company, and True Anthem, a privately held software provider. She previously served
on other public and private boards, including the board of Everyday Health, Inc., a New York Stock Exchange-listed public company,
until its acquisition in December 2016. Prior to her venture capital career, Ms. Wienbar was
an executive in several software companies and a consultant at Bain & Company. Ms. Wienbar’s leadership
of technology investments, deep understanding of innovation
drivers, and business acumen bring an important perspective
to our Board.
|
Vote Required
The affirmative vote of the
holders of a majority of the votes cast is required for election of each director.
Board Recommendation
The
Board unanimously recommends that stockholders vote “FOR”
the election of each of the nominees
for director listed above.
|
|
- 2020 Proxy Statement
|
14
|
|
|
|
|
CORPORATE GOVERNANCE
|
Director Independence
Our Corporate Governance
Guidelines require that a majority of our Board members be “independent” under the NYSE’s listing standards.
In addition, the respective charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee
require that each member of these committees be “independent” under the NYSE’s listing standards and, with respect
to the Audit Committee, under the applicable SEC rules. In order for a director to qualify as “independent,” our Board
must affirmatively determine that the director has no material relationship with the Company that would impair the director’s
independence. Our Board undertook its annual review of director independence in February 2020. The Board has determined that Mr.
Allender, Mr. Gayner, Ms. Jordan, Mr. Kelly, Mr. Perfall, Mr. Teirlinck, Mr. Vinnakota, and Ms. Wienbar each qualify as “independent”
under the NYSE’s listing standards. In reaching a determination on these directors’ independence, the Board considered
that during fiscal 2019, Mr. Kelly was the chief executive officer of Teleflex, which does business with Colfax. The amount received
by Colfax or Teleflex in each of the last three fiscal years did not exceed the greater of $1 million or 1% of either Colfax’s
or Teleflex’s consolidated gross revenues. None of the other independent directors nor their immediate family members have
within the past three years had any direct or indirect business or professional relationships with the Company other than in their
capacity as directors.
The independent members of
our Board must hold at least two “executive session” meetings each year without the presence of management. If the
Chair of the Board is not an independent director, the independent directors select an independent director to serve as Chairperson
for each executive session. In general, the meetings of independent directors are intended to be used as a forum to discuss such
topics as they deem necessary or appropriate. Mr. Allender serves as the presiding director of the independent director executive
sessions and as such leads the independent directors during these sessions.
Board of Directors and its Committees
The Board and its committees
meet regularly throughout the year, and may also hold special meetings and act by written consent from time to time. The Board
held a total of five meetings during the year ended December 31, 2019. In aggregate, during this time our directors attended over
95% of our Board meetings and meetings of the committees of the Board on which such directors served. During 2019, no director
attended fewer than 75% of the total number of meetings of the Board and committees of the Board on which such director served.
Our Corporate Governance Guidelines request Board members to make every effort to attend our annual meeting of stockholders. Eight
of the nine directors then serving attended our annual meeting of stockholders in 2019.
The Board has a standing
Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. The charters for the Audit Committee,
Compensation Committee, and Nominating and Corporate Governance Committee are available on the Company’s website at www.colfaxcorp.com
on the Investors page under the Corporate Governance tab. These materials also are available in print to any stockholder upon request
to: Corporate Secretary, Colfax Corporation, 420 National Business Parkway, 5th Floor, Annapolis Junction, Maryland
20701. The Board committees review their respective charters on an annual basis. The Nominating and Corporate Governance Committee
oversees an annual evaluation of the Board and each committee’s operations and performance.
|
|
Audit
|
|
Nominating and Corporate
|
|
Compensation
|
Name
|
|
Committee
|
|
Governance Committee
|
|
Committee
|
Mitchell P. Rales
|
|
|
|
|
|
|
Matthew L. Trerotola
|
|
|
|
|
|
|
Patrick W. Allender
|
|
|
|
|
|
|
Thomas S. Gayner
|
|
|
|
|
|
|
Rhonda L. Jordan
|
|
|
|
|
|
|
Llam J. Kelly
|
|
|
|
|
|
|
A. Clayton Perfall
|
|
|
|
|
|
|
Didier Teirlinck
|
|
|
|
|
|
|
Rajiv Vinnakota
|
|
|
|
|
|
|
Sharon Wienbar
|
|
|
|
|
|
|
|
Chair
|
|
Member
|
|
- 2020 Proxy Statement
|
15
|
|
|
|
Audit Committee
Our Audit Committee met 13
times during the year ended December 31, 2019. The Audit Committee is responsible, among its other duties and responsibilities,
for overseeing our accounting and financial reporting processes, the audits of our financial statements, the qualifications of
our independent registered public accounting firm, and the performance of our internal audit function and independent registered
public accounting firm. The Audit Committee reviews and assesses the qualitative aspects of our financial reporting, our processes
to manage business and financial risks, and our compliance with significant applicable legal, ethical and regulatory requirements.
The Audit Committee is directly responsible for the appointment, compensation, retention and oversight of our independent registered
public accounting firm. The members of our Audit Committee are Mr. Perfall, Chair, Mr. Allender, Mr. Gayner, and Mr. Teirlinck.
The Board has determined that each of Mr. Perfall and Mr. Allender qualify as an “audit committee financial expert,”
as that term is defined under the SEC rules. The Board has determined that each member of our Audit Committee is independent and
financially literate under the NYSE’s listing standards and that each member of our Audit Committee is independent under
the standards of Rule 10A-3 under the Securities Exchange Act of 1934 (the “Exchange Act”).
Nominating and Corporate Governance Committee
Our Nominating and Corporate
Governance Committee met six times during the year ended December 31, 2019. The Nominating and Corporate Governance Committee is
responsible for recommending candidates for election to the Board. In making its recommendations, the committee will review a candidate’s
qualifications and any potential conflicts of interest and assess contributions of current directors in connection with his or
her renomination. The committee is also responsible, among its other duties and responsibilities, for making recommendations to
the Board or otherwise acting with respect to corporate governance policies and practices, including Board size and membership
qualifications, new director orientation, committee structure and membership, related person transactions, and communications with
stockholders and other interested parties. The Nominating and Corporate Governance Committee is also responsible for reviewing
the Company’s undertakings with respect to environmental, social, and governance matters, including the Company’s role
as a corporate citizen and the Company’s policies and programs relating to health, safety and sustainability matters. The
members of our Nominating and Corporate Governance Committee are Mr. Allender, Chair, Ms. Jordan and Mr. Vinnakota. The Board has
determined that each member of our Nominating and Corporate Governance Committee is independent under the NYSE’s listing
standards.
Compensation Committee
Our Compensation Committee
met six times during the year ended December 31, 2019. The Compensation Committee is responsible, among its other duties and responsibilities,
for determining and approving the compensation and benefits of our Chief Executive Officer and other executive officers, monitoring
compensation arrangements applicable to our Chief Executive Officer and other executive officers in light of their performance,
effectiveness and other relevant considerations and adopting and administering our equity and incentive plans. The members of our
Compensation Committee are Ms. Jordan, Chair, Mr. Vinnakota, and Ms. Wienbar. The Board has determined that each member of our
Compensation Committee is a “non-employee director” within the meaning of SEC Rule 16b-3, and is independent under
the NYSE’s listing standards for directors and compensation committee members.
The Compensation Committee
annually reviews and approves the corporate goals and objectives relevant to the compensation of our Chief Executive Officer, evaluates
his performance in light of those goals and objectives, and determines his compensation level based on that analysis. The Compensation
Committee also annually reviews and approves all elements of the compensation of our other executive officers. Our Chief Executive
Officer plays a significant role in developing and assessing achievement against the goals and objectives for other executive officers
and makes compensation recommendations to the Compensation Committee based on these evaluations. The Compensation Committee also
administers all of the Company’s incentive compensation plans and equity-based compensation plans. The Compensation Committee
makes recommendations to the Board regarding compensation of all executive officer hires, all elements of director compensation,
and the adoption of certain amendments to incentive or equity-based compensation plans. The Compensation Committee also assists
the Board in its oversight of risk related to the Company’s compensation policies and practices applicable to all Colfax
associates. Additionally, the Compensation Committee periodically reviews the Company’s strategies and policies related to
human capital management, including with respect to matters such as diversity, inclusion, pay equity, corporate culture, talent
development and retention. For further information on our compensation practices, including a description of our processes and
procedures for determining compensation, the scope of the Compensation Committee’s authority and management’s role
in compensation determinations, please see the Compensation Discussion and Analysis section of this Proxy Statement, which begins
on page 26.
Since April 2009, our Compensation
Committee has engaged Frederic W. Cook & Co. as its independent compensation consultant to, among other things, formulate
an appropriate peer group to be used by the Compensation Committee and to provide competitive comparison data and for other compensation
consulting services as requested by the Compensation Committee. Additional information on the nature of the information and services
provided by this independent compensation consultant can be found below in the Compensation Discussion and Analysis.
|
- 2020 Proxy Statement
|
16
|
|
|
|
Compensation Committee Interlocks and Insider
Participation
No member of the Compensation
Committee is or has ever been an officer or an employee of the Company or any of its subsidiaries, and no Compensation Committee
member has any interlocking or insider relationship with the Company which is required to be reported under the rules of the SEC.
Identification of Director Candidates and
Director Nomination Process
The Nominating and Corporate
Governance Committee considers candidates for Board membership suggested by its members and other Board members, as well as by
management and stockholders. The Nominating and Corporate Governance Committee may also use outside consultants to assist in identifying
candidates and during 2019 used third-party recruiters to identify and provide background information on possible candidates. Mr.
Kelly was first recommended to the Nominating and Corporate Governance Committee by a third-party recruiter. The Nominating and
Corporate Governance Committee is responsible for assessing whether a candidate may qualify as an independent director. Each possible
candidate is discussed and evaluated in detail before being recommended to the Board. The Nominating and Corporate Governance Committee
utilizes the same criteria for evaluating candidates regardless of the source of the referral.
The Nominating and Corporate
Governance Committee recommends, and the Board nominates, candidates to stand for election as directors. Stockholders may nominate
persons to be elected as directors and, as noted above, may suggest candidates for consideration by the Nominating and Corporate
Governance Committee. If a stockholder wishes to suggest a person to the Nominating and Corporate Governance Committee for consideration
as a director candidate, he or she must provide the same information as required of a stockholder who intends to nominate a director
pursuant to the procedures contained in Section 3.3 of our Bylaws, in accordance with the same deadlines applicable to director
nominations, as described below under “General Matters—Stockholder Proposals and Nominations.”
Board Leadership Structure
Our Corporate Governance
Guidelines specify that the positions of Chairman of the Board and Chief Executive Officer shall be held by separate persons. We
believe that this structure is appropriate given the differences between the two roles in our current management structure. Our
Chief Executive Officer, among other duties, is responsible for setting the strategic direction for the Company and the day-to-day
leadership and performance of the Company, while the Chairman of our Board, among other responsibilities, provides guidance to
the Chief Executive Officer, takes an active role in setting the agenda for Board meetings and presides over meetings of the full
Board. Our current Chairman, Mr. Rales, is not an independent director and, as noted above in “Director Independence,”
Mr. Allender serves as the presiding director for independent director executive sessions and as such leads the independent directors
during these sessions.
Board Evaluation Process
The Board and its Committees
conduct self-assessments annually at their February meetings. The Chair of the Nominating and Governance Committee oversees the
process. The annual evaluation procedure is summarized below.
Action and Timeframe
|
Description
|
Preparation – November/December
|
Each director receives draft materials for the annual evaluation of (i) the Board’s performance and (ii) the performance of his or her committee(s). The materials include the Board and committee self-assessment questionnaires. In advance of the assessment, questions are revised and supplemented based on the input received from the Board members and, prior to distribution, the Chair of the Nominating Committee leads a final review in the December Board and committee meetings.
|
Assessment – December/January
|
Each director is asked to consider a list of questions to assist with the evaluation of the Board and its committees, covering topics such as Board composition, the conduct and effectiveness of meetings, quality of discussions, roles and responsibilities, quality and quantity of information provided, and other opportunities for improvement.
|
Review and Discussion – February
|
The Board and the committees thereof receive a report summarizing the annual evaluations as well as a year-over-year comparison. The reports are distributed for consideration in advance of and discussed at the February Board meeting. The committee chairs report to the Board on their respective committee evaluations, noting any actionable items. Past evaluations have addressed a wide range of topics such as Board materials, director education and on-boarding, and allocation of meeting times.
|
Actionable Items and Follow-Up – Ongoing
|
The Board and committees address any actionable items throughout the year, including a mid-year check-in and end of year assessment against the actionable items identified in February.
|
|
- 2020 Proxy Statement
|
17
|
|
|
|
Board’s Role in Risk Oversight
The Board maintains responsibility
for oversight of risks that may affect the Company. The Board discharges this duty primarily through its standing committees and
also considers risk in its strategic planning for the Company and in its consideration of acquisitions. The Board engages in discussions
about risk at each quarterly meeting, where it receives reports from its committees, as applicable, about the risk oversight activities
within their respective areas of responsibility. Specifically, the Audit Committee (i) receives reports from and discusses with
management, our internal audit team, and our independent registered public accounting firm all major risk exposures (whether financial,
operating or otherwise), (ii) reviews the Company’s policies with respect to risk assessment and enterprise risk management,
including with respect to cybersecurity risks, and (iii) oversees compliance with legal and regulatory requirements and our ethics
program, including our Code of Business Conduct and Ethics. In addition, the Nominating and Corporate Governance Committee oversees
the corporate governance principles and governance structures that contribute to successful risk oversight and management. The
Compensation Committee oversees certain risks associated with compensation policies and practices, as discussed below.
The Audit, Nominating and
Corporate Governance and Compensation Committees each make full reports to the Board of Directors at each regularly scheduled meeting
regarding each committee’s considerations and actions, and risk considerations are presented to and discussed with the Board
by management as part of strategic planning sessions and when considering potential acquisitions.
Standards of Conduct
Corporate Governance Guidelines and Pledging
The Board has adopted Corporate
Governance Guidelines, which set forth a framework to assist the Board in the exercise of its responsibilities. The Corporate Governance
Guidelines cover, among other things, the composition and certain functions of the Board and its committees, executive sessions,
Board responsibilities, expectations for directors, director orientation and continuing education, and our policy prohibiting pledging.
In February 2014, the Board
amended the Corporate Governance Guidelines to prohibit any future pledging of Colfax’s common stock as security under any
obligation by our directors and executive officers. The Board excepted from the policy shares of Colfax common stock that were
already pledged at the time the policy was adopted, but any additional share pledges are prohibited. Pledged shares of Colfax common
stock do not count toward our stock ownership requirements.
Certain shares of common
stock owned by Mitchell Rales, Chairman of our Board, that were pledged at the time that the policy was adopted were grandfathered
from the policy. Notwithstanding that the existing pledge was grandfathered under our policy, as part of its risk oversight function
the Audit Committee of the Board reviews Mr. Rales’ share pledges on a quarterly basis to assess whether such pledging poses
an undue risk to the Company. In evaluating Mr. Rales’ pledge of Colfax shares, the Audit Committee considered that Mr. Rales
acquired these shares with his own funds in connection with founding the Company and did not receive them as compensation from
Colfax; that, as a founder of Colfax and dedicated long-term stockholder, he has (as with many institutional stockholders) pledged
a portion of his shares instead of selling shares for liquidity; and that Mr. Rales, as a founder or significant investor in other
public companies (including Danaher Corporation and Fortive Corporation), has significant personal assets. In addition to taking
into account the number of shares and percentage of outstanding shares pledged, the Audit Committee has also considered the degree
of overcollateralization (the amount by which the market value of the shares pledged as collateral exceeds the amount of secured
indebtedness), as the Committee believes this is a key factor in assessing the degree of risk posed by the pledging arrangements.
Based on its evaluation, the Committee has concluded that the existing pledge arrangements do not pose an undue risk to the Company.
The Audit Committee will continue to periodically review the shares pledged as part of its risk oversight function.
Code of Business Conduct and Ethics
As part of our system of
corporate governance, the Board has also adopted a Code of Business Conduct and Ethics (the “Code of Ethics”), which
was updated in 2019, that is applicable to all directors, officers and employees of the Company. The Code of Ethics sets forth
Company policies, expectations and procedures on a number of topics, including but not limited to conflicts of interest, compliance
with laws, rules and regulations (including insider trading laws), honesty and ethical conduct, and quality. The Code of Ethics
also sets forth procedures for reporting violations of the Code and investigations thereof. If the Board grants any waivers from
our Code of Ethics to any of our directors or executive officers, or if we amend our Code of Ethics, we will, if required, disclose
these matters through our website within four business days following such waiver or amendment.
|
- 2020 Proxy Statement
|
18
|
|
|
|
Policies on Insider Trading, Hedging and Stock
Ownership
The Company has a Policy
on Insider Trading and Compliance which, in addition to mandating compliance with insider trading laws, prohibits any director,
officer or employee of the Company from engaging in short sales, transactions in derivative securities (including put and call
options), or other forms of hedging and monetization transactions, such as zero-cost collars, equity swaps, exchange funds and
forward sale contracts, that allow the holder to limit or eliminate the risk of a decrease in the value of the Company’s
securities. Further, we have stock ownership policies applicable to our directors and executives to promote alignment of interests
between our stockholders, directors and management.
Where to Find Our Key Governance Policies
The Corporate Governance
Guidelines and Code of Ethics are available on the Company’s website at www.colfaxcorp.com on the Investors page
under the Corporate Governance tab. These materials also are available in print to any stockholder upon request to: Corporate
Secretary, Colfax Corporation, 420 National Business Parkway, 5th Floor, Annapolis Junction, Maryland 20701.
Certain Relationships and Related Person Transactions
Policies and Procedures for Related Person Transactions
We have adopted a written
Policy Regarding Related Person Transactions pursuant to which our Nominating and Corporate Governance Committee or a majority
of the disinterested members of our Board generally must approve related person transactions in advance. The policy applies to
any transaction or series of similar transactions involving more than $120,000 in which the Company is a participant and in which
a “related person” has a direct or indirect material interest. “Related persons” include the Company’s
directors, nominees for director, executive officers, and greater than 5% stockholders, as well as the immediate family members
of the foregoing. In approving or rejecting the proposed transaction, our Nominating and Corporate Governance Committee takes into
account, among other factors it deems appropriate, whether the proposed related person transaction is on terms no less favorable
than terms generally available to an unaffiliated third party under the same or similar circumstances, the extent of the person’s
interest in the transaction and, if applicable, the impact on a director’s independence. Under the policy, if we discover
related person transactions that have not been approved, the Nominating and Corporate Governance Committee is to be notified and
will determine the appropriate action, including ratification, rescission or amendment of the transaction.
Related Person Transactions
Set forth below is a summary
of certain transactions since January 1, 2019 in which (i) the Company was or is a participant, (ii) any of our directors, executive
officers, beneficial owners of more than 5% of our common stock, or the immediate family members of any of the foregoing had or
will have a direct or indirect material interest and (iii) the amount involved exceeds or will exceed $120,000:
Transactions with Fortive
Corporation
Certain of our subsidiaries
purchase products from and sell products to Fortive Corporation (“Fortive”) from time to time in the ordinary course
of business and on an arms’-length basis. Such transactions are pre-approved under our Policy Regarding Related Person Transactions.
In 2019, our subsidiaries purchased approximately $243,000 of products from, and sold approximately $81,000 of products to, Fortive,
which is less than 0.01% of our, and of Fortive’s, gross revenues for 2019. Our subsidiaries intend to purchase products
from and sell products to Fortive in the future in the ordinary course of their businesses and on an arms’-length basis.
Mitchell P. Rales and Steven M. Rales are each members of Fortive’s Board of Directors, and both are the beneficial owners
of at least 5% of Fortive’s outstanding common stock and our outstanding common stock.
Issuance and Sale of
Tangible Equity Units
As previously reported, on
January 11, 2019, we issued $460 million in 5.75% tangible equity units. Each unit is comprised of (i) a prepaid stock purchase
contract issued by us to purchase a number of shares of the Company’s common stock equal to a specified settlement rate and
(ii) a senior amortizing note due January 15, 2022. For additional information relating to the terms of the units, please refer
to the “Description of
|
- 2020 Proxy Statement
|
19
|
|
|
|
Securities registered under
Section 12 of the Exchange Act” included as an exhibit to our Annual Report on Form 10-K filed with the Securities and Exchange
Commission on February 24, 2020. As part of this transaction, one or more entities affiliated with Mitchell P. Rales, Chairman
of our Board and a beneficial owner of at least 5% of our outstanding common stock, purchased an aggregate of 400,000 5.75% tangible
equity units for an aggregate purchase price of $40.0 million and one or more entities affiliated with Steven M. Rales, a beneficial
owner of at least 5% of our outstanding common stock, purchased an aggregate of 100,000 5.75% tangible equity units for an aggregate
purchase price of $10.0 million.
Contacting the Board of Directors
The Board of Directors has
established a process for stockholders and interested parties to communicate with the Board and to report complaints or concerns
relating to our accounting, internal accounting controls or auditing matters. Stockholders and interested parties wishing to communicate
with our Board may do so by writing to any of the members of the Board, the Chairman of the Board, or the non-management members
of the Board as a group, at:
Colfax Corporation
420 National Business Parkway, 5th Floor
Annapolis Junction, Maryland 20701
Attn: Corporate Secretary
Complaints or concerns relating
to our accounting, internal accounting controls or auditing matters will be referred to members of the Audit Committee. Other correspondence
will be referred to the relevant director or group of directors. Our Policy on Stockholder and Interested Party Communications
with the Board of Directors (the “Board Communications Policy”) requires that any stockholder communication to members
of the Board prominently display the legend “Board Communication” in order to indicate to the Corporate Secretary that
it is communication subject to our policy and will be received and processed by the Corporate Secretary’s office. Each communication
received by the Corporate Secretary is copied for our files and promptly forwarded to the addressee. In our Board Communications
Policy, the Board has requested that certain items not related to the Board’s duties and responsibilities be excluded from
forwarded communications, such as mass mailings and business advertisements. In addition, the Corporate Secretary is not required
to forward any communication that the Corporate Secretary, in good faith, determines to be frivolous, unduly hostile, threatening,
illegal or similarly unsuitable. However, the Corporate Secretary maintains a list of each communication subject to this policy
that is not forwarded, and on a quarterly basis delivers the list to the Chairman of the Board. In addition, each communication
subject to this policy that is not forwarded because it was determined by the Secretary to be frivolous, commercial advertising,
irrelevant or similarly unsuitable is nevertheless retained in our files and made available at the request of any member of the
Board to whom such communication was addressed.
|
- 2020 Proxy Statement
|
20
|
|
|
|
|
DIRECTOR COMPENSATION
|
Our Board, at the recommendation
of our Compensation Committee, sets the compensation program for non-employee directors. The Compensation Committee reviews this
program on an episodic basis and recommends director compensation levels based on its evaluation of competitive levels for director
compensation, utilizing data drawn from our current list of peer companies and its reasoned business judgment. See “Role
of Compensation Consultants and Peer Data Review” on page 36. The compensation program was last revised in 2019.
Our non-employee Board members
receive the following:
|
an annual cash retainer of $85,000;
|
|
an annual equity award valued at $130,000, calculated under
the same valuation approach applied in determining our annual equity grants as described in “Compensation Discussion
and Analysis—Additional Compensation Information—Equity Grant Practice,” and awarded in connection with
our annual meeting of stockholders, which consists of 50% director restricted stock units that vest after one year of service
on the Board and 50% director stock options, which are fully vested upon grant and exercisable for a seven-year term;
|
|
a $20,000 annual retainer for service as the Chair of our
Audit Committee and a $15,000 annual retainer for service as Chair of the Compensation Committee or of the Nominating and
Corporate Governance Committee; and
|
As part of the changes made
in 2019, Directors no longer receive an initial equity grant, but instead receive a pro-rated portion of the annual equity award.
Our non-executive Chairman
of the Board is entitled to receive an annual cash retainer of $1 and does not receive any other cash fees or the initial or annual
equity awards described above.
The Board has also
approved a stock ownership policy for our directors. Each director is required to own shares of our common stock (including shares
issuable upon exercise of stock options and shares underlying restricted stock units) with a value equal to five times the annual
cash retainer within five years of joining the Board. All of our directors except for Mr. Teirlinck and Mr. Kelly, who were appointed
during 2017 and 2020, respectively, have achieved these ownership targets as of the date of this Proxy Statement.
Further, our Board has adopted
a policy prohibiting any director (or executive officer) from pledging as security under any obligation any shares of Colfax common
stock that he or she directly or indirectly owns and controls (other than shares already pledged as of February 17, 2014), and
providing that pledged shares of Colfax common stock do not count toward our stock ownership requirements.
The Board has adopted a Director
Deferred Compensation Plan which permits non-employee directors to receive, at their discretion, deferred stock units, or DSUs,
in lieu of their annual cash retainers and committee chairperson retainers. A director who elects to receive DSUs receives a number
of units determined by dividing the cash fees earned during, and deferred for, the quarter by the closing price of our common stock
on the date of the grant, which is the last trading day of the quarter. A non-employee director also may convert director restricted
stock unit grants to DSUs under the plan. DSUs granted to our directors convert to shares of our common stock after termination
of service from the Board, based upon a schedule elected by the director in advance. In the event that a director elects to receive
DSUs, the director will receive dividend equivalent rights on such DSUs to the extent dividends are issued on our common stock.
Dividend equivalents are deemed reinvested in additional DSUs (or fractions thereof) at the dividend payment date.
We also reimburse all directors
for travel and other necessary business expenses incurred in the performance of their services on our Board and the committees
thereof and extend coverage to them under our directors’ and officers’ indemnity insurance policies.
|
- 2020 Proxy Statement
|
21
|
|
|
|
The following table sets
forth information regarding compensation paid to our non-employee directors during 2019:
DIRECTOR COMPENSATION
FOR 2019
Name(1)
|
|
Fees Earned or
Paid
in Cash
($)
|
|
|
Stock
Awards
($)
|
(3)
|
|
Option
Awards
($)
|
(5)
|
|
Total
($)
|
|
Mitchell P. Rales
|
|
|
1
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1
|
|
Patrick W. Allender
|
|
|
98,173
|
(2)
|
|
|
65,010
|
(4)
|
|
|
65,009
|
|
|
|
228,192
|
|
Thomas S. Gayner
|
|
|
83,173
|
(2)
|
|
|
65,010
|
(4)
|
|
|
65,009
|
|
|
|
213,192
|
|
Rhonda L. Jordan
|
|
|
98,173
|
|
|
|
65,010
|
(4)
|
|
|
65,009
|
|
|
|
228,192
|
|
A. Clayton Perfall
|
|
|
103,173
|
(2)
|
|
|
65,010
|
(4)
|
|
|
65,009
|
|
|
|
233,192
|
|
Didier Teirlinck
|
|
|
83,173
|
(2)
|
|
|
65,010
|
(4)
|
|
|
65,009
|
|
|
|
213,192
|
|
Rajiv Vinnakota
|
|
|
83,173
|
|
|
|
65,010
|
|
|
|
65,009
|
|
|
|
213,192
|
|
Sharon Wienbar
|
|
|
83,173
|
(2)
|
|
|
65,010
|
(4)
|
|
|
65,009
|
|
|
|
213,192
|
|
(1)
|
Mr. Kelly was appointed
to our Board on January 1, 2020. Accordingly, he did not receive any compensation for 2019.
|
(2)
|
Messrs. Allender,
Gayner, Perfall, Teirlinck and Ms. Wienbar elected to receive DSUs in lieu of their annual cash retainers and committee chairperson
retainers. DSUs convert to shares of our common stock after termination of service from the Board, based upon a schedule elected
by the director in advance. During 2019, the amount of DSUs received in lieu of annual cash retainers and committee chairperson
retainers by these directors was as follows: Mr. Allender— 3,222, Mr. Gayner— 2,729, Mr. Perfall— 3,385,
Mr. Teirlinck— 2,729, and Ms. Wienbar— 2,729. DSUs received for these cash retainers are considered “vested”
and thus are not reflected in the table below.
|
(3)
|
Amounts shown in the
“Stock Awards” column represent the grant date fair value for stock awards granted to each director during 2019,
as computed pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”)
Topic 718 (“FASB ASC Topic 718”). See Note 14 to our consolidated financial statements for the year ended December
31, 2019, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 24, 2020.
The amounts reflect the grant date fair value of the 2019 annual grant of 2,213 restricted stock units made to each director
in connection with the 2019 annual meeting of stockholders, which vest in full on May 13, 2020.
|
(4)
|
2,213 restricted stock
units granted to each of these directors, which were awarded in connection with the 2019 annual meeting of stockholders, were
converted into DSUs at the election of each director. DSUs convert to shares of our common stock after termination of service
on the Board, based upon a schedule selected by each director in advance. These DSUs will vest in full on May 13, 2020 in
accordance with the vesting schedule applicable to the underlying restricted stock units.
|
(5)
|
Amounts represent
the aggregate grant date fair value for options to purchase 6,938 shares of our common stock granted to each director in connection
with the 2019 annual meeting of stockholders, as computed pursuant to FASB ASC Topic 718. See Note 14 to our consolidated
financial statements for the year ended December 31, 2019, included in our Annual Report on Form 10-K filed with the Securities
and Exchange Commission on February 24, 2020. The director stock options are fully vested upon grant and exercisable for a
seven-year term.
|
As of December 31, 2019,
the aggregate number of unvested stock awards and unexercised options outstanding held by each of our non-employee directors was
as follows:
Name
|
|
Restricted
Stock Units
|
|
|
Stock
Options
|
|
Mitchell P. Rales
|
|
—
|
|
|
—
|
|
Patrick W. Allender
|
|
|
2,213
|
|
|
|
27,903
|
|
Thomas S. Gayner
|
|
|
2,213
|
|
|
|
27,903
|
|
Rhonda L. Jordan
|
|
|
2,213
|
|
|
|
27,903
|
|
A. Clayton Perfall
|
|
|
2,213
|
|
|
|
27,903
|
|
Didier Teirlinck
|
|
|
4,065
|
|
|
|
12,240
|
|
Rajiv Vinnakota
|
|
|
2,213
|
|
|
|
27,903
|
|
Sharon Wienbar
|
|
|
2,213
|
|
|
|
16,478
|
|
|
- 2020 Proxy Statement
|
22
|
|
|
|
Proposal 2
|
Ratification of Selection of Independent Registered Public Accounting
Firm
|
We are asking our stockholders
to ratify the Audit Committee’s selection of Ernst & Young LLP as our independent registered public accounting firm for
the fiscal year ending December 31, 2020. The Audit Committee is directly responsible for the appointment, compensation, retention,
and oversight of our independent auditors. Ernst & Young LLP has served as our independent auditor since its appointment in
2002. Although stockholder ratification is not required, the appointment of Ernst & Young LLP is being submitted for ratification
as a matter of good corporate practice with a view towards soliciting stockholders’ opinions which the Audit Committee will
take into consideration in future deliberations. If the selection is not ratified, the Audit Committee will consider whether it
is appropriate to select another registered public accounting firm. Even if the selection is ratified, the Audit Committee in its
discretion may select a different registered public accounting firm at any time during the year if it determines that such a change
would be in the best interests of the Company and our stockholders. The Board of Directors and the Audit Committee believe that
the retention of Ernst & Young LLP as the Company’s independent auditor is in the best interests of the Company and its
stockholders.
Representatives for Ernst & Young LLP are expected to be present at the Annual Meeting, will have the opportunity to make a statement if they desire
to do so and are expected to be available to respond to appropriate questions.
Independent Registered
Public Accounting Firm Fees and Services
The following table sets
forth the aggregate fees for services rendered by Ernst & Young LLP for the Company for the fiscal years ended December 31,
2019 and 2018:
Fee Category (fees in thousands)
|
|
2019
|
|
|
2018
|
|
Audit Fees
|
|
$
|
7,417
|
|
|
$
|
5,827
|
|
Audit-Related Fees
|
|
|
1,628
|
|
|
|
—
|
|
Tax Fees
|
|
|
1,023
|
|
|
|
1,146
|
|
All Other Fees
|
|
|
4
|
|
|
|
2
|
|
TOTAL
|
|
$
|
10,072
|
|
|
$
|
6,975
|
|
Audit Fees
This category of the table
above includes fees for the fiscal years ended December 31, 2019 and 2018 that were for professional services rendered (including
reimbursement for out-of-pocket expenses) for the integrated audits of our annual consolidated financial statements, for reviews
of the financial statements included in our Quarterly Reports on Form 10-Q, and for statutory audits.
Audit-Related Fees
This category of the table
above includes the fees billed for assurance and related services that are reasonably related to the performance of the audit or
review of our financial statements and are not reported under “Audit Fees.” For 2019, Audit-Related Fees included fees
related to services rendered in connection with audited carve-out financial statements of our Air & Gas Handling business in
connection with the disposition of that business in September 2019 and services rendered in connection with the acquisition of
DJO. There were no Audit-Related Fees incurred for 2018.
Tax Fees
This category of the table
above includes fees billed for tax compliance, tax preparation, tax planning and other tax services. For 2019, Tax Fees included
approximately $1,004,038 for tax compliance and tax preparation and approximately $19,000 for tax planning and other tax services.
For 2018, Tax Fees included approximately $910,555 for tax compliance and tax preparation and approximately $234,920 for tax planning
and other tax services.
All Other Fees
This category of the table
above includes fees billed for products and services other than those described above under Audit Fees, Audit-Related Fees and
Tax Fees. For 2019 and 2018, these included fees incurred for Ernst & Young LLP’s online accounting information tool.
The Audit Committee has considered
whether the services rendered by the independent registered public accounting firm with respect to the fees described above are
compatible with maintaining the independent registered public accounting firm’s independence and has concluded that such
services do not impair its independence.
|
- 2020 Proxy Statement
|
23
|
|
|
|
Audit Committee’s Pre-Approval
Policies and Procedures
Pursuant to its charter,
the Audit Committee must pre-approve all auditing services, review and attest services, internal control related services and non-audit
services provided to the Company by the independent registered public accounting firm and all fees payable by the Company to the
independent registered public accounting firm for such services. The Audit Committee also is responsible for overseeing the audit
fee negotiations associated with the retention of Ernst & Young LLP for the audit of our financial statements. The Audit Committee
has adopted a pre-approval policy to promote compliance with the NYSE’s listing standards and the applicable SEC rules and
regulations relating to auditor independence. In accordance with the Audit Committee charter and the pre-approval policy, the Audit
Committee reviews with Ernst & Young LLP and management the plan and scope of Ernst & Young LLP’s proposed annual
financial audit and quarterly reviews, including the procedures to be utilized and Ernst & Young LLP’s compensation,
and pre-approves all auditing services, review and attest services, internal control related services and permitted non-audit services
(including the fees and terms thereof) to be performed for us by Ernst & Young LLP. The Audit Committee may delegate pre-approval
authority to one or more members of the Audit Committee consistent with the pre-approval policy, provided that the decisions of
such Audit Committee member or members must be presented to the full Audit Committee at its next scheduled meeting. Pre-approval
of permitted non-audit services can only be approved by the full Audit Committee.
Vote Required
The affirmative vote of the
holders of a majority of shares present in person or represented by proxy at the Annual Meeting and entitled to vote is required
to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2020.
Board Recommendation
The Board unanimously
recommends that stockholders vote “FOR” the
ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting
firm for 2020.
|
|
- 2020 Proxy Statement
|
24
|
|
|
|
|
AUDIT COMMITTEE REPORT
|
The Audit Committee
consists of A. Clayton Perfall, Patrick Allender, Thomas Gayner, and Didier Teirlinck, who are all non-management directors. The
members of the Audit Committee meet the independence and financial literacy requirements of the NYSE and the additional, heightened
independence criteria applicable to members of the Audit Committee under SEC and NYSE rules. In 2019, the Audit Committee held
13 meetings. The Audit Committee operates pursuant to a written charter adopted by the Board of Directors, which it annually reviews.
The charter, which complies with all current regulatory requirements, is available on the Company’s website at www.colfaxcorp.com
on the Investors page under the Corporate Governance tab. During 2019, at each of its regularly scheduled meetings, the Audit
Committee met with senior members of the Company’s finance team. Additionally, the Audit Committee has separate private
sessions, during its regularly scheduled meetings, with the Company’s independent registered public accounting firm and
head of internal audit, respectively. The Audit Committee is updated periodically on management’s process to assess the
adequacy of the Company’s system of internal control over financial reporting, the framework used to make the assessment,
and management’s conclusions on the effectiveness of the Company’s internal control over financial reporting. The
Audit Committee has also discussed with the independent registered public accounting firm, their evaluation of the Company’s
system of internal control over financial reporting.
The Audit Committee evaluates
the performance of the Company’s independent registered public accounting firm each year and determines whether to reengage
the current independent registered accounting firm or consider other independent registered accounting firms. In doing so, the
Audit Committee considers the quality and efficiency of the services provided by the independent registered accounting firm, the
firm’s global capabilities, and the firm’s technical expertise, tenure as the Company’s independent registered
accounting firm and knowledge of the Company’s global operations and businesses. In connection with the applicable audit
partner rotation requirements, the Audit Committee also is involved in considering the selection of the auditors’ lead engagement
partner when rotation is required. Based on this evaluation, the Audit Committee decided to engage Ernst & Young LLP as our
independent registered accounting firm for the year ended December 31, 2020. The Audit Committee reviews with the independent registered
accounting firm and management the overall audit scope and plans, as well as the results of internal and external audit examinations
and evaluations by management and the independent registered accounting firm of the Company’s internal controls over financial
reporting and the quality of the Company’s financial reporting. Although the Audit Committee has the sole authority to appoint
the independent registered public accounting firm, the Audit Committee recommends that the Board ask stockholders, at the Company’s
annual meeting, to ratify the appointment of the independent registered accounting firm (see Proposal 2 beginning on page 23).
The Audit Committee has reviewed
and discussed the Company’s audited financial statements for the fiscal year ended December 31, 2019 with management and
with the Company’s independent registered public accounting firm, including a discussion of the quality and suitability of
the accounting principles, the reasonableness of significant accounting judgments and estimates, and the clarity of disclosures
in the financial statements. In addressing the quality of management’s accounting judgments, members of the Audit Committee
are apprised of certifications prepared by the Chief Executive Officer and the Chief Financial Officer that the unaudited quarterly
and audited annual consolidated financial statements of the Company fairly present, in all material respects, the financial condition,
results of operations and cash flows of the Company.
In performing all of these
functions, the Audit Committee acts in an oversight capacity. The Audit Committee reviews the Company’s quarterly and annual
reports on Form 10-Q and Form 10-K prior to filing with the SEC. In its oversight role, the Audit Committee relies on the work
and assurances of the Company’s management, which has the primary responsibility for establishing and maintaining adequate
internal control over financial reporting and for preparing the financial statements, and other reports, and of the independent
registered public accounting firm, which is engaged to review the quarterly consolidated financial statements of the Company, and
audit and report on the annual consolidated financial statements of the Company and the effectiveness of the Company’s internal
control over financial reporting as of the Company’s year-end.
The Audit
Committee discussed with the independent registered public accounting firm the matters required to be discussed by the
applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and SEC. The Audit Committee
has received from the independent registered public accounting firm the written disclosures and the letter required by the
applicable requirements of the PCAOB regarding the independent registered public accounting firm’s communications with
the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm its
independence. On the basis of the reviews and discussions referenced above, the Audit Committee recommended to the Board of
Directors that the audited financial statements for the fiscal year ended December 31, 2019 be included in the
Company’s Annual Report on Form 10-K for filing with the Securities and Exchange Commission.
Audit Committee of the
Board of Directors
A. Clayton Perfall, Audit Committee Chair
Patrick Allender
Thomas Gayner
Didier Teirlinck
|
- 2020 Proxy Statement
|
25
|
|
|
|
|
COMPENSATION DISCUSSION AND ANALYSIS
|
The following discussion
and analysis of compensation arrangements of our named executive officers for 2019 should be read together with the compensation
tables and related disclosures set forth under the section heading “Executive Compensation.”
Executive Summary
Named Executive Officers
The following discussion
provides details regarding our executive compensation program and the compensation of our named executive officers in 2019. Our
named executive officers (“NEOs”) for 2019 are:
Name
|
Title
|
Matthew
Trerotola
|
President and Chief Executive Officer
|
Christopher
Hix
|
EVP, Finance, Chief Financial Officer
|
Daniel
Pryor
|
EVP, Strategy and Business Development
|
Shyam
Kambeyanda
|
EVP, Colfax, President and CEO of ESAB
|
Brady
Shirley
|
Chief Executive Officer of DJO
|
Ian
Brander(1)
|
Former SVP, Colfax, Howden President
|
(1)
|
Mr. Brander stepped down from his position effective as of September
30, 2019, in connection with the completion of the sale of the Air & Gas Handling business.
|
Our
Compensation Philosophy and Guiding Principles
Our executive compensation
approach links compensation to Company and individual performance while aligning the long-term interests of management and stockholders.
We strive to create a compensation program for our associates, including our executives, that provides a compelling and engaging
opportunity to attract, retain and motivate the best talent. We believe that our compensation programs motivate performance-driven
leadership that is aligned to achieve our financial and strategic objectives with the intention to deliver superior long-term returns
to our stockholders. Utilizing this philosophy, our executive compensation program has been designed to:
Link rewards to performance and foster a team-based approach
|
|
Each executive has clear performance expectations and must contribute to our overall success rather than solely to objectives within his or her primary area of responsibility.
|
Align the performance responsibilities of executives with the long-term interests of stockholders
|
|
Our program emphasizes long-term stockholder value creation by using stock options and performance-based restricted stock units, in combination with a stock ownership policy, to deliver long-term compensation incentives while minimizing risk-taking behaviors that could negatively affect long-term results.
|
Provide transparency through simplicity of design and practices
|
|
We provide three main elements in our compensation program–base salary, annual incentive cash bonuses, and long-term incentives–with an appropriate blend of purposes and incentives linked to easily understood objectives, as described further on page 29.
|
Fiscal 2019 Pay for Performance
Alignment and Compensation Overview
Fiscal 2019 was a transformational
year for Colfax, as we completed significant transactions that marked a strategic shift to diversify end-market exposure, reduce
cyclicality, and increase profitability and cash flow, positioning us for continued growth. In February 2019, we completed the
acquisition of DJO Global, Inc. (“DJO”) and related financing. DJO is a global leader in orthopedic solutions, providing
orthopedic devices, reconstructive implants, software and services spanning the full continuum of patient care, from injury prevention
to rehabilitation. DJO has approximately 5,000 employees across 18 locations around the world. The acquisition is expected to evolve
the Company to higher margins, faster growth, and lower cyclicality, while providing opportunities for significant bolt-on and
adjacent acquisitions over time.
|
- 2020 Proxy Statement
|
26
|
|
|
|
In May 2019, we signed a
purchase agreement to sell our Air & Gas Handling business for an attractive valuation. We completed the divestiture in September
2019 and used the proceeds to pay-down our debt and position us to pursue strategic bolt-on acquisitions for our remaining businesses.
The divestiture reduced our exposure to cyclical end markets and improved our profit margin and cash generation profile.
Our strong operational performance
in 2019 reflected improvements in our Fabrication Technology business that enabled it to increase its market share while sharply
improving margins. DJO rapidly returned to healthy growth levels following investments and improvements in its operating and innovation
capabilities. Consolidated net sales of over $3.3 billion reflected only 10 months of DJO results, and Colfax delivered full year
organic growth despite dynamic industrial markets. Excluding costs associated with portfolio changes, exiting certain pension obligations,
and restructuring charges primarily related to DJO, our core operating metric, adjusted EBITA, and adjusted earnings per share
(“EPS”) showed strong growth.
We achieved and exceeded
many of our internal corporate financial and operational goals, leading to an overall corporate bonus achievement under our Annual
Incentive Plan (“AIP”) of 100% for Messrs. Trerotola, Hix, and Pryor.
In 2019, Fabrication Technology
net sales increased 2.5%, including the successful integration of businesses acquired in 2018. Fabrication Technology achieved
organic growth in 2019 at rates higher than the growth rates of competitors, increasing its market share. Overall, the business
improved its cost position and achieved its commercial objectives, but the business was below threshold achievement on its working
capital metric. These results were reflected in a company-wide/business specific achievement under our AIP with an 88% blended
company factor (weighted 30% Colfax corporate and 70% ESAB) for Mr. Kambeyanda.
For the 10-month period in
2019 since being acquired by Colfax in February 2019, DJO achieved net sales of $1.1 billion, with $333.7 million in the fourth
quarter of 2019. Since we acquired DJO, we have made significant investments to support operating improvements throughout the business
and completed many of the transformational projects that had been started in 2017, enabling the business to better serve its customers.
Organic growth improved throughout the year, delivering strong year-on-year organic growth in the fourth quarter of fiscal 2019,
and revenue for 2019 came in above target while EBITDA was below threshold. These results were reflected in a company-wide/business
specific achievement under our AIP with an 83% blended company factor (weighted 30% Colfax corporate and 70% DJO) for Mr. Shirley.
Further, the Compensation
Committee took the following actions during 2019:
|
The Compensation Committee redesigned our performance-based
restricted stock units (“PRSUs”) in 2019 and transitioned from using an operational improvement metric (adjusted
operating margin) and an investor return benchmark (relative total stockholder return (“TSR”) vs. the S&P
MidCap 400 Industrials Index), each of which was equally weighted and measured over a three-year period, to solely using relative
TSR vs. the S&P MidCap 400 Industrials Index, measured over a three-year period. The Compensation Committee believes that
using a single investor return benchmark is more appropriate for the Company at this time due to the highly acquisitive nature
of our business, which makes it difficult to set meaningful three-year operational improvement metrics.
|
|
|
|
Each of Messrs. Trerotola’s and Pryor’s annual
equity awards consisted of approximately equal parts of (i) stock options that vest in equal installments over a three-year
period following their grant date, and (ii) PRSUs that cliff vest in three years based on relative TSR performance over a
three-year performance period. Mr. Trerotola did not receive annual equity grants in 2018 and 2017 due to his new hire grant
in 2015 and his special equity grant that was made in January 2016.
|
|
|
|
Due to outstanding performance related to the portfolio
changes in fiscal 2019, the Compensation Committee approved a promotional increase to Mr. Hix’s base salary and to Mr.
Kambeyanda’s base salary and long-term incentive awards. For their performance throughout the transactions noted above,
the Committee also approved in December 2019 a one-time grant of RSUs for Messrs. Hix and Kambeyanda that vest ratably over
a three-year period. Both gentlemen also received their annual equity award, which consisted of (i) stock options that vest
in equal installments over a three-year period following their grant date and (ii) PRSUs that cliff vest in three years based
on relative TSR performance over a three-year performance period.
|
|
|
|
Mr. Shirley’s annual equity award consisted of (i)
stock options that vest in equal installments over a three-year period following their grant date, (ii) PRSUs that become
earned subject to achieving adjusted EBITDA targets at DJO (the “DJO PRSUs”) over a two-year performance period,
with potential 50% vesting on the second anniversary of the grant date and 50% vesting on the third anniversary of the grant
date, and (iii) RSUs that cliff vest two years following the grant. With respect to the DJO PRSUs, the Compensation Committee
awarded a larger grant of PRSUs than normally provided annually to incentivize Mr. Shirley to achieve deal related targets
that would represent significant progress toward the achievement of the Company’s long-term growth objectives with respect
to DJO. Additionally, the Compensation Committee believes Mr. Shirley’s award will help align the new DJO platform with
Colfax’s long-term growth objectives.
|
|
|
|
In light of the strategic review undertaken with respect
to the Air & Gas Handling business, and its ultimate sale completed in September 2019, the Compensation Committee determined
it was appropriate that Mr. Brander receive a deal related bonus of $3,152,585 for his performance during the transaction.
Mr. Brander’s annual equity award consisted solely of stock options that were scheduled to vest in equal installments
over a three-year period following their grant date; however, these options were forfeited in connection with the sale of
the Air & Gas Handling business.
|
|
- 2020 Proxy Statement
|
27
|
|
|
|
2019 Say-On-Pay Vote
At our 2019 Annual Meeting,
approximately 99% of the stockholder votes cast on our advisory proposal to approve the compensation of our NEOs were voted in
favor of our executive compensation proposal. Our Compensation Committee considered the outcome of this vote in the context of
our prior and on-going engagement with stockholders and accordingly did not make any additional changes to our executive compensation
policies and program elements (other than the redesign of our PRSUs described above). The Compensation Committee has determined
to provide for an annual “say-on-pay” proposal and will continue to carefully evaluate the feedback received from our
stockholders in connection with the voting on that proposal.
Our Executive Compensation
Program
Our executive compensation
program includes elements designed to align executive pay with Company objectives and long-term stockholder returns, including
the PRSU grants entirely based on relative Total Shareholder Return as discussed above.
For 2019, the Compensation
Committee established the following target compensation program for our CEO:
2019 CEO Incentive Compensation
Structure
87% of CEO compensation “at risk” and aligned with company and shareholder success
|
With respect to our other
NEOs, for 2019, the Compensation Committee established the following target compensation program:
2019 Incentive Compensation
Structure for Other NEOs (Average)*
78% of compensation for other NEOs “at risk” and aligned with company and shareholder success
|
*
|
This does not include the one-time promotional grants of RSUs to Messrs. Hix and
Kambeyanda discussed above and the grant of RSUs provided to Mr. Shirley in connection with his joining the Company and does
not include Mr. Brander’s compensation, as his compensation was approved in connection with the strategic review and
potential sale of our Air & Gas Handling business and is not representative of our incentive compensation structure.
|
**
|
This reflects performance goals under the plan for corporate-level
executives; weightings and performance goals differ for business unit executives as discussed below.
|
|
- 2020 Proxy Statement
|
28
|
|
|
|
Our 2019 executive compensation
structure consists of three core compensation elements–base salary, an annual cash bonus, and long-term incentives. The Compensation
Committee reviewed each element individually while also considering the total compensation package provided to create an appropriate
mix designed to attract, incentivize, and retain our executives. The following table summarizes the core elements of our 2019 executive
compensation program:
Element
of Compensation
|
Purpose/Description
|
Form/Timing
of Payout
|
Base Salary
|
Established at a competitive
level to attract and retain our executive talent. Provides a base level of compensation that is not at risk to avoid fluctuations
in compensation that could distract executives from the performance of their responsibilities.
|
Paid in cash throughout
the year
|
Annual Incentive Plan (“AIP”)
|
Variable compensation
that rewards our executive officers for achievement of critical annual operational and financial performance goals by the
Company and, if applicable, respective business units, and recognizes the executive’s individual performance during
the year.
|
Paid in cash after the
year has ended and performance has been measured. See page 31 for further detail.
|
Long-Term
Incentive Plan
|
Variable
compensation that aligns the rewards of executives with the interests of stockholders to encourage actions and long-term
prioritization that we believe will increase stockholder value by generating sustained and superior operational and financial
performance over an extended period of time.
|
See
page 34 for further detail.
|
The framework of our executive
compensation program includes the governance features and other specific elements discussed below:
What we do
|
|
What we don’t do
|
|
Pay for performance focus – Our AIP compensation is
linked to pre-established financial and operational goals that are intended to
drive performance over the annual performance plan period. Options and PRSUs
are linked with longer-term performance, our stock price, and, for PRSUs, relative
TSR performance, which we believe incentivizes long-term Company success and stockholder
value creation.
|
|
|
No gross-up payments to cover excise taxes or perquisites –
We do not provide tax gross-ups to our executives in connection with
severance benefits or executive perquisites other than relocation.
|
|
Varying performance metrics under short-term and longer-term incentive
plans – In balancing compensation objectives linked to short-term
and long-term time horizons, the Company seeks to align compensation with several
performance metrics that are critical to achievement of sustained growth and stockholder
value creation.
|
|
|
No pledging or hedging of Company stock – We prohibit our executives
and directors from hedging Colfax stock and from entering into new pledge arrangements
or derivative agreements using Colfax stock.
|
|
Caps on Annual Incentive Plan payouts – Executive bonus payments
are capped under our AIP, as approved by our stockholders, in part to
discourage excessive risk taking. The Compensation Committee is prohibited from
increasing the results with respect to each financial and operational performance
metric once established, but retains the discretion to reduce or eliminate compensation
under our AIP even if performance goals are attained.
|
|
|
No repricing or buyout of underwater stock options – We do not
permit the repricing of underwater stock options without the express
approval of our stockholders.
|
|
Double trigger provisions for change in control – Severance payable
upon a change in control is only received upon executive’s employment termination
without cause or resignation for good reason within two years following the change
in control. This approach is commonly referred to as “double trigger.”
|
|
|
No excessive change in control payments – No severance upon a
change in control in excess of two times salary and target bonus.
|
|
Clawback Policy and Insider Trading Policy – We have a comprehensive
compensation clawback policy that is triggered by a material restatement of the
Company’s financial statements and applies to all of our executive officers,
and enforce a strict insider trading policy and blackout periods for executives
and directors.
|
|
|
No short-term vesting – We do not award any long-term incentives
with a vesting period shorter than one year.
|
|
Stock Ownership Policy – We have a robust stock ownership policy
to further align the long-term financial interests of Company executives with those
of our stockholders.
|
|
|
No compensation programs or policies that reward for material or
excessive risk taking – We annually review the Company’s
compensation policies and practices in relation to our risk management
practice and any potential risk-taking incentives. Our most recent assessment concluded
that the risks arising from our compensation policies and practices are not reasonably
likely to have a material adverse effect on the Company.
|
|
Independent Compensation Committee and Consultant – Our Compensation
Committee is comprised solely of independent directors. The compensation consultant
to the Compensation Committee during 2019, FW Cook (i) is, based on the Compensation
Committee’s assessment, independent and without any conflicts of interest
with the Company and (ii) has never provided any services to the Company other than
the compensation-related services provided to the Compensation Committee.
See page 37 for further details.
|
|
|
No pension plan – We do not maintain a defined benefit pension
plan for any senior executives, other than a frozen foreign plan that we acquired
via acquisition which is limited to a small number of historical participants.
|
|
- 2020 Proxy Statement
|
29
|
|
|
|
Determination of Executive
Compensation and Performance Criteria
Our executive compensation
program is based on the philosophy and design outlined above with a focus on exceptional performance and continuous improvement
from our management team. Within this framework, the Compensation Committee exercises its reasoned business judgment in making
executive compensation decisions and takes into account recommendations by our Chief Executive Officer with respect to the compensation
of each executive officer, other than himself (see “CEO Recommendations” on page 36). Some of the factors that
generally are referenced when making executive compensation decisions, none of which is assigned a particular weight, are as follows:
|
The nature of the executive’s position
|
|
The Compensation Committee’s assessment of pay levels
and practices for executives with the skills and experience our executives possess (see “Role of Compensation Consultants
and Peer Data Review” on page 36)
|
|
The performance record of the executive
|
|
The Company’s operational and financial performance
|
|
The executive’s leadership potential
|
|
The retention value of our compensation program over time
|
Further, a substantial percentage
of compensation under our Annual Incentive Plan is determined solely by the achievement of annual performance criteria based on
Board-approved financial and operational goals for the fiscal year. These goals are then incorporated into the metrics set for
our Annual Incentive Plan and approved by the Compensation Committee, as further discussed under “Bonus Calculation and Payment
- Financial and Operational Metrics and 2019 Performance Results” on page 32. We believe that this link to our Board-established
corporate and business goals reinforces alignment and incents breakthrough results both at the business-unit level and Company-wide.
Elements of Our 2019 Executive
Compensation Program
Base Salary
Base salaries are designed
to provide compensation that is market competitive so that we can attract the best qualified individuals and retain our senior
management. Base salaries are established at an executive’s hire and generally reviewed annually for potential increases.
In February 2019, the Compensation Committee set the salary levels for each of our NEOs based on the Compensation Committee’s
assessment of the relative roles and responsibilities of management and the results of their individual performance assessments,
combined with perspective from competitive compensation data prepared by FW Cook and the Compensation Committee’s reasoned
business judgment. Mr. Shirley’s base salary was approved by the Compensation Committee in connection with the DJO acquisition
and based upon his historical compensation and a review of competitive compensation data prepared by FW Cook. In December 2019
the Compensation Committee approved promotional increases for Messrs. Hix and Kambeyanda in light of their continuing strong performance,
in particular their performance related to the transition of the portfolio, and to maintain market competitiveness. As a result,
Mr. Hix’s salary was increased from the base salary of $595,000 set in February 2019 to $650,000, and Mr. Kambeyanda’s
salary was increased from the base salary of $550,000 set in February 2019 to $625,000, in each case effective as of December 9,
2019. Messrs. Trerotola and Pryor received modest base salary increases in 2019 primarily reflecting our continued operational
improvements and the Compensation Committee’s competitive marketplace review. Mr. Brander’s base salary increase was,
in part, based on his engaged and focused leadership while the Company undertook a strategic review of the Air & Gas Handling
business, which was first publicly announced in November 2018. A comparison of base salary levels as of December 31, 2019 (or September
30, 2019 for Mr. Brander) and 2018 is set forth below:
|
|
2018 Annual
|
|
|
2019 Annual
|
|
|
Percentage
|
Named Executive Officer
|
|
Base Salary
|
|
|
Base Salary
|
|
|
Increase
|
Mr. Trerotola
|
|
$
|
1,056,000
|
|
|
$
|
1,077,000
|
|
|
|
2.0
|
%
|
Mr. Hix
|
|
$
|
575,000
|
|
|
$
|
650,000
|
(1)
|
|
|
13.0
|
%
|
Mr. Pryor
|
|
$
|
550,000
|
|
|
$
|
565,000
|
|
|
|
2.7
|
%
|
Mr. Kambeyanda
|
|
$
|
510,000
|
|
|
$
|
625,000
|
(1)
|
|
|
22.6
|
%
|
Mr. Shirley
|
|
|
—
|
|
|
$
|
850,000
|
|
|
|
—
|
|
Mr. Brander
|
|
£
|
320,000
|
|
|
£
|
385,000
|
|
|
|
13.0
|
%
|
(1)
|
Reflects promotional increase approved by the Board in December
2019, as noted in discussion above.
|
|
- 2020 Proxy Statement
|
30
|
|
|
|
Annual Incentive Plan
The goal of our AIP is to
reward our executives for achievement in key areas of Company operational and financial performance as well as each executive’s
individual contributions to Company success. Our NEOs are eligible to receive a cash incentive payment that is expressed as a
percentage of the executive’s base salary (i.e., “target bonus”) under our Annual Incentive Plan. Performance
measures include corporate and individual performance against pre-determined financial and operational metrics approved by the
Compensation Committee at the beginning of the fiscal year.
These performance metrics
established by the Compensation Committee for business leaders reflect both Company-wide and business-specific performance targets
resulting in a company performance factor (“CPF”). The CPF for Messrs. Kambeyanda and Shirley is a weighted average
consisting of 70% segment performance and 30% Colfax corporate performance. The amount payable under the AIP can be adjusted upward
or downward based on the individual performance factor (“IPF”), which is linked to specific, individualized business
goals. Actual bonus amounts are determined following completion of the performance year and are based on performance relative
to these pre-established business and individual goals using the following formulas:
As shown in the payout curve
that follows, executives can achieve a payout percentage of their target bonus ranging from zero for below-threshold performance
to a threshold of 50% to a maximum of 200%, with 100% target goal achievement resulting in 100% payout of the individual’s
target bonus for that performance metric, based on the extent to which objective pre-established financial and operational performance
goals are achieved; and
The total amount earned
is subject to adjustment based on individual achievement as measured by an IPF. The IPF is a multiplier that ranges from 0 to
1.5 (subject to an overall payout cap of 250% of the target bonus). For 2019, IPFs for our NEOs ranged from 1.0 to 1.35. The IPF
rating is based on individual performance against pre-established objectives and the embodiment of our Company’s core values
and behaviors. The IPF and key performance indicators include both financial and non-financial Company objectives over which the
executive has primary control.
2019 Annual Incentive Plan Payout to Performance
*
|
Working
capital turns (WCT) threshold and maximum set within bounds based on management assessment of WCT performance expectations.
|
|
- 2020 Proxy Statement
|
31
|
|
|
|
Detail regarding the individual components of
these formulas for fiscal year 2019, including a calculation of the payout percentages and description of the IPF component, follows
the NEO bonus payout tables below.
Key Executive Team Achievements
|
Successful completion of the DJO acquisition and sale of the Air &
Gas Handling business, furthering the strategic shift of our portfolio to diversify end-market exposure, reduce cyclicality,
and increase profitability
|
|
|
|
Integration of DJO into existing operations, with certain members of the executive team undertaking
oversight responsibilities with respect to our new medical device platform
|
|
|
|
Successful integration of two fiscal 2018 acquisitions completed in our Fabrication Technology
segment
|
|
|
|
Very strong margin improvement in our Fabrication Technology segment
|
|
|
|
Acceleration of quarter over quarter growth in our Medical Technology segment and strong
growth in the Reconstructive and Prevention and Rehabilitiation product lines
|
|
|
|
Introduction of 84 new products into the market, outpacing competitors and contributing to
market share gains in our Fabrication Technology segment
|
Bonus Calculation and Payment – Financial
and Operational Metrics and 2019 Performance Results
For corporate executives, the Company performance
factors (CPF) consisted of financial targets based on net sales (as adjusted), adjusted EBITA, working capital turns (as adjusted),
and adjusted EPS. In 2019, we transitioned from using a financial target based on operating profit (as adjusted) to the financial
target based on adjusted EBITA. This was intended to better align with how Colfax management evaluates the business and the Company’s
financial reporting practices. The pre-established targets were based upon Board-approved operational and financial goals for
2019. These targets represented significant progress in each category toward the achievement of the Company’s long-term
growth objectives and aligned with the Board-approved corporate budget.
For Mr. Shirley, the “target goals”
included adjusted EBITDA for the DJO segment, which was pre-established by the Compensation Committee in connection with the acquisition
of DJO. His goals were set at levels that would represent significant progress in each category toward the achievement of the
Company’s long-term growth objectives with respect to DJO and align with the Board-approved corporate budget.
For Messrs. Kambeyanda and Shirley, Colfax corporate
measures constituted 30% of the potential payout factor with their business unit goals consisting of 70% of the total target.
These weightings are intended to drive accountability for business operational results while also encouraging thoughtful work
and cooperation across the organization.
The financial and operational performance measures
and corresponding weightings of these metrics for 2019 were as follows:
Measure
|
Corporate
|
ESAB
|
DJO
|
Net sales (as adjusted)(1)
|
25%
|
30%
|
40%
|
Adjusted EBITA(2)
|
40%
|
50%
|
N/A
|
Working Capital Turns (as adjusted)(3)
|
20%
|
20%
|
N/A
|
Adjusted EPS(4)
|
15%
|
N/A
|
N/A
|
DJO Adjusted EBITDA(5)
|
N/A
|
N/A
|
60%
|
(1)
|
Net sales measured by U.S. GAAP sales excluding any sales from unbudgeted
2019 acquisitions, compared to 2019 budgeted sales at actual FX rates.
|
(2)
|
Adjusted EBITA is defined as net income from continuing operations excluding restructuring
and other related charges, acquisition-related amortization and other non-cash charges, and strategic transaction costs, as
well as provision (benefit) for income taxes, loss on short-term investments, interest expense, net and pension settlement
loss.
|
(3)
|
Working capital turns measured by the weighted average of the quarterly turns for the
fiscal year, computed by dividing annualized quarterly sales by the average ending working capital for each quarter. Working
capital is defined as the sum of accounts receivable, other receivables, promissory notes, inventory, accounts payable, and
nonrecurring items that the Compensation Committee considers unusual and not representative of the underlying economic performance
of the Company.
|
(4)
|
Adjusted EPS is defined as net income adjusted for the after-tax impact of discontinued
operations, the cumulative effect of accounting changes, restructuring costs, non-cash asset impairments, including goodwill
and intangibles, costs related to acquisitions in excess of budgeted amounts, financial asset impacts (due to unusual economic
circumstances or devaluation by a governing body), as further adjusted for the impact of foreign currency exchange gains or
losses arising from the initial recognition of a highly inflationary currency, early extinguishment of debt costs, or other
unplanned or nonrecurring items that the Compensation Committee considers unusual and not representative of the underlying
economic performance of the Company, divided by the weighted average of diluted shares outstanding.
|
(5)
|
DJO Adjusted EBITDA is defined as net income adjusted for business unit entities divested
in 2019, including related gain/loss on disposition, restructuring costs, non-cash asset impairments, including goodwill and
intangibles, costs related to acquisitions and divestitures in excess of budgeted amounts, the impact of foreign currency
exchange gains or losses arising from the initial recognition of a highly inflationary currency, pension curtailment costs,
the cumulative effect of accounting changes, and other unplanned or nonrecurring items that the Compensation Committee considers
unusual and not representative of the underlying economic performance of the Company, as well as a provision (benefit) for
income taxes, interest expense, net, and depreciation and acquisition-related amortization and inventory step-up charges.
|
|
- 2020 Proxy Statement
|
32
|
|
|
|
Bonuses were calculated using the aforementioned
formula as shown in the following table. These bonuses are also reflected in the “Non-Equity Incentive Plan Compensation”
column of the Summary Compensation Table below on page 40.
|
|
|
|
|
|
|
|
Bonus
|
Individual
|
|
Executive
|
|
|
|
Target Bonus
|
|
Target
|
|
|
before IPF
|
Performance
|
|
Bonus
|
NEO
|
Base Salary
|
|
Percentage
|
|
Bonus
|
|
CPF
|
application
|
Factor (IPF)
|
|
Payment
|
Mr. Trerotola
|
$
|
1,077,000
|
X
|
125%
|
=
|
$
|
1,346,250
|
X
|
100%
|
1,346,250
|
110%
|
=
|
$
|
1,480,600
|
Mr. Hix
|
$
|
595,000
|
X
|
80%
|
=
|
$
|
476,000
|
X
|
100%
|
476,000
|
100%
|
=
|
$
|
476,000
|
Mr. Pryor
|
$
|
565,000
|
X
|
80%
|
=
|
$
|
452,000
|
X
|
100%
|
452,000
|
110%
|
=
|
$
|
497,200
|
Mr. Kambeyanda*
|
$
|
550,000
|
X
|
80%
|
=
|
$
|
440,000
|
X
|
88%
|
387,200
|
135%
|
=
|
$
|
522,720
|
Mr.
Shirley*
|
$
|
850,000
|
X
|
100%
|
=
|
$
|
850,000
|
X
|
83%
|
702,100
|
100%
|
=
|
$
|
702,100
|
*
|
The business payout percentage is a weighted average consisting of
70% business segment and 30% Colfax corporate.
|
In light of Mr. Brander’s execution and
effort with respect to the sale of our Air & Gas Handling business, which strengthened our balance sheet and provides more
flexibility for our growth strategy, Mr. Brander received a bonus for 2019 of $3,152,585, which is reflected in the “Bonus”
column of the Summary Compensation Table below on page 40. The bonus was based upon the performance of the Air & Gas Handling
business and his performance through the closing of the transaction.
Bonus Calculation – Target Bonus
The Compensation Committee annually reviews and
approves AIP target bonus percentages for each executive officer in alignment with our compensation philosophy and taking into
consideration the Compensation Committee’s competitive marketplace review. Targets as a percentage of base salary did not
change from prior-year targets, except for Mr. Kambeyanda, whose AIP target increased from 75% to 80% to better align with the
Compensation Committee’s evaluation of the competitive market.
In connection with the DJO acquisition, the Compensation
Committee set Mr. Shirley’s target bonus at 100% based upon his historical compensation and the Compensation Committee’s
competitive marketplace review.
The 2019 corporate performance goals and achievement
for each are set forth below. As shown in the table, the weighted average performance result for 2019 corporate metrics was 100%
of plan, compared to 121% of plan for 2018 and 83% of plan for 2017.
Measure
|
Weighting
|
Target Goal
|
Threshold Goal
|
Maximum Goal
|
Achieved
|
Company
Performance
Factor (CPF)
|
Net Sales
(as adjusted)
|
25%
|
$
|
4,839 billion
|
$
|
4,355 billion
|
$
|
5,323 billion
|
$
|
4,788 billion
|
95%
|
Adjusted EBITA
|
40%
|
$
|
666 million
|
$
|
533 million
|
$
|
799 million
|
$
|
680 million
|
110%
|
Working Capital Turns
(as adjusted)
|
20%
|
4.7
|
4.5
|
4.9
|
4.6
|
67%
|
Adjusted
EPS
|
15%
|
$
|
2.62/share
|
$
|
2.10/share
|
$
|
3.14/share
|
$
|
2.74/share
|
123%
|
The table below summarizes the 2019 achievement
of business goals for Messrs. Kambeyanda and Shirley, which when aggregated with the corporate goal results as shown above, determine
their AIP financial and operational performance factor:
Company Performance
Factor – DJO and ESAB Segments
|
ESAB*
|
DJO*
|
Sales (as adjusted)
(30% for ESAB and 40% DJO)
|
80%
|
100%
|
Adjusted EBITA/EBITDA
(50% for ESAB and 60% DJO)
|
117%
|
65%
|
Working
Capital Turns (as adjusted) (20% ESAB)
|
0%
|
—
|
Business
Achievement (before weighted average with Colfax corporate)*
|
83%
|
79%
|
*
|
The respective business
unit metrics constituted 70% of each executive’s potential AIP performance payout, in aggregate, and the corporate metrics
constituted 30% of the potential payout.
|
We do not disclose the specific target goals
or achievement applicable to our business segments as they are highly confidential to our businesses. We believe that disclosure
of this information would be competitively harmful to us, as it would provide our competitors with strategic information specific
to certain businesses, thus providing our competitors insight into our plans and projections for such businesses. As evidenced
by our performance this year, these target levels are designed to be difficult to accomplish and are not certain to be met.
Bonus Calculation – Individual Performance
Factor
In addition to the target bonus percentages and
financial and operational metrics discussed above, the third and final factor under our AIP is the IPF, as described above. The
individual performance factors for each executive were determined after evaluating each NEO’s performance, including the
collective achievements detailed on page 32 above. For 2019, IPFs for our NEOs ranged from 1.0 to 1.35, as shown above.
|
- 2020 Proxy Statement
|
33
|
|
|
|
Long-Term Incentives
The goal of our long-term incentive plan is to
align the compensation of executives with the interests of stockholders by encouraging sustained long-term improvement in operational
and financial performance and long-term increase in stockholder value. Long-term incentives also serve as retention instruments
and provide equity-building opportunities for executives. In recent years, we have granted stock options and PRSUs as our primary
forms of equity awards, with service-based RSUs being granted principally as recruitment or promotion awards at the time of hire
or promotion. The Compensation Committee redesigned our PRSUs in 2019 and transitioned from using an operational improvement metric
(adjusted operating margin) and an investor return benchmark (relative TSR vs. the S&P MidCap 400 Industrials Index), each
of which was equally weighted and measured over a three-year period, to solely using relative TSR vs. the S&P MidCap 400 Industrials
Index, measured over a three-year period. The Compensation Committee believes that using a single investor return benchmark is
more appropriate for the Company at this time due to the highly acquisitive nature of our business, which makes it difficult to
set meaningful three-year operational improvement metrics. Once vested, at least 50% of the shares delivered pursuant to the PRSUs
(net of shares withheld or sold for taxes) must be held for an additional one-year period.
In connection with the acquisition of DJO, Mr.
Shirley received an annual equity award consisting of (i) DJO PRSUs, (ii) RSUs that cliff vest after two years and (iii) stock
options. The DJO PRSUs are subject to achieving certain adjusted EBITDA targets at DJO, measured over a two-year period, with
50% vesting on the second anniversary of the grant date and 50% vesting on the third anniversary of the grant date. The DJO PRSUs
further provided that 50% of the PRSUs may be earned (but not vest) if a specified adjusted EBITDA target was achieved during
2019. However, this target was not achieved during 2019 and such DJO PRSUs remain eligible to vest following completion of the
two-year performance period. The award is intended to align Mr. Shirley’s compensation with the interests of stockholders
and incentivize the achievement of certain strategic objectives relating to the acquisition and integration of DJO.
2019 Performance Vesting of Outstanding PRSUs
None of the outstanding PRSUs held by the NEOs
were earned in 2019. In 2017, we transitioned to using a full three-year performance period for measuring PRSUs. Prior to that,
PRSUs were subject to achieving certain performance targets over any four consecutive quarters during a three-year period.
Annual Grants under Omnibus Incentive Plan
On February 25, 2019, the Compensation Committee
granted annual awards under the 2016 Omnibus Incentive Plan with a target aggregate value as set forth in the table below. Messrs.
Trerotola, Hix, Pryor and Kambeyanda received 50% of their annual grant in the form of PRSUs and 50% in the form of stock options.
As discussed further above, on December 13, 2019, the Compensation Committee also granted Messrs. Hix and Kambeyanda RSUs with
a grant date fair value of approximately $1,000,000 and $500,000, respectively, in recognition for their contributions to the
portfolio changes that occurred in 2019. Mr. Shirley received DJO PRSUs with a target grant date fair value of $2,000,000,
stock options with a grant date fair value of approximately $500,000, and RSUs with a grant date fair value of $500,000. Mr. Brander’s award
consisted solely of stock options with a grant date fair value of approximately $400,000.
|
Total Aggregate
|
|
|
Value of Grant
|
|
Annual Grant Recipient
|
($)
|
|
Mr. Trerotola
|
5,450,000
|
|
Mr. Hix
|
3,000,000
|
(1)
|
Mr. Pryor
|
1,850,000
|
|
Mr. Kambeyanda
|
1,800,000
|
(1)
|
Mr. Shirley
|
3,000,000
|
|
Mr. Brander
|
400,000
|
|
(1)
|
Messrs. Hix’s and
Kambeyanda’s annual grants under the 2016 Omnibus Incentive Plan include an additional grant in recognition of their
work related to the portfolio changes in 2019 of RSUs with grant date fair values of approximately $1,000,000 and $500,000,
respectively.
|
Stock options vest in three equal annual installments
beginning on the first anniversary of the grant date and PRSUs cliff vest at the end of the three-year measurement period to the
extent of achievement of the relative TSR performance metric based on the following payout scale:
|
|
Resulting
|
|
3-Year TSR
|
Shares Earned
|
|
Percentile Rank*
|
(% of target)
|
Below Threshold
|
<30th
|
0%
|
Threshold
|
30th
|
50%
|
Target
|
55th
|
100%
|
Maximum
|
80th
|
200%
|
*
|
Linear interpolation
between achievement points.
|
As shown in the table above, the target payout
is subject to achieving the relative TSR performance metric at the 55th percentile, which underscores the Company’s
commitment to delivering and incentivizing above-median performance and returns to stockholders.
|
- 2020 Proxy Statement
|
34
|
|
|
|
The DJO PRSUs vest in two equal installments
beginning on the second anniversary of the grant date, to the extent of achievement of the DJO adjusted EBITDA target based on
the payout scale below.
|
|
Resulting
|
|
DJO Adjusted EBITDA
|
Shares Earned
|
|
(% of target)*
|
(% of target)
|
Below Threshold
|
<90%
|
0%
|
Threshold
|
90%
|
50%
|
Target
|
100%
|
100%
|
Maximum
|
120%
|
200%
|
*
|
Linear interpolation
between achievement points.
|
Additional Compensation Information
Other Elements
of Compensation–Non-Qualified Deferred Compensation and Perquisites
The Company does not maintain an active pension
plan and instead makes matching contributions to a tax-qualified 401(k) plan and Non-Qualified Deferred Compensation Plan. We
established the Non-Qualified Deferred Compensation Plan, which provides participants the opportunity to defer a percentage of
their compensation without regard to the compensation limits imposed by the Internal Revenue Code under our 401(k) plan, to allow
our senior-level executives to contribute toward retirement on a tax-effective basis in a manner that is consistent with other
Colfax employees who are not limited by the Internal Revenue Code limits. For additional details concerning the Non-Qualified
Deferred Compensation Plan, please see the Non-Qualified Deferred Compensation Table and the accompanying narrative disclosure.
With respect to Mr. Brander, who is based in the U.K., as discussed below in the footnotes to the Summary Compensation Table,
for 2019 Howden made contributions to the Howden Retirement Plan, a defined contribution plan, on his behalf. In addition, as
discussed following the Pension Benefits table below, Mr. Brander maintains a balance in the Howden Group Pension Plan, a frozen
defined benefit pension plan. Mr. Brander’s benefits under the Howden Group Pension Plan were frozen in 2006 and he
did not accrue any additional benefits after this date. We retained liability with respect to the Howden Group Pension Plan in
connection with the sale of our Air & Gas Handling business. Additionally, the Company also maintains the DJO Global Executive
Deferred Compensation Plan (the “DJO Nonqualified Plan”), which was acquired in connection with the acquisition of
DJO. The DJO Nonqualified Plan was frozen to new participants and future deferrals on December 31, 2019. Mr. Shirley holds
an account balance in this plan.
Aside from the benefits provided to Mr. Trerotola
at the time of his hire, which include (i) an automobile allowance of $20,000 per year and (ii) personal use of a private aircraft
chartered by the Company and/or personal financial planning services (or any combination thereof) in an aggregate amount not to
exceed $100,000 in compensation income (i.e., imputed income under tax rules) for any calendar year, we provide minimal perquisites
to our executives, including up to $10,000 in financial and tax planning services for senior executives, business-related items
such as relocation assistance, which may be grossed up consistent with competitive market recruitment practices, and benefits
provided in non-U.S. locations in accordance with local practice.
Employment & Service Agreements
Messrs. Trerotola and Pryor are party to the
same form of employment agreement. These agreements provide for a two-year initial term, or in the case of Mr. Trerotola, a three-year
initial term, with automatic one-year term extensions thereafter, unless our Board or the executive provides written notice in
advance to terminate the automatic extension provision. Each executive’s base salary may not be reduced below the amount
previously in effect without the written agreement of the executive. In addition, as set forth in their current employment agreements,
each of Messrs. Trerotola and Pryor is entitled to participate in our Annual Incentive Plan with a target bonus amount no less
than 120% and 50%, respectively, of his base salary then in effect. The employment agreements provide severance benefits and provide
change in control benefits only if a termination for “good reason” or other than for “cause” occurs within
two years following the change in control (i.e., “double trigger” provisions).
Mr. Hix’s letter agreement entered into
upon his hire provides for severance and change in control benefits primarily commensurate with those provided in our employment
agreements. Mr. Kambeyanda is party to a letter agreement with the Company that specifies his starting annual salary and
a target bonus of at least 70% under the AIP. This agreement also provides for a transition bonus made in connection with his
hire that is to be paid in installments over his first five years of employment (with $330,000 payable in each of 2017 and 2018,
and $130,000 payable in each of 2019 and 2020). This letter agreement also provides that Mr. Kambeyanda is subject to our Executive
Officer Severance Plan.
Mr. Shirley is party to a service agreement with
DJO, which he entered into prior to our acquisition of the DJO business in 2019 and which was assumed as part of the purchase.
The agreement provides for a four-year initial term, with automatic one-year term extensions commencing November 14, 2020, unless
we or Mr. Shirley provides written notice in advance to terminate the automatic extension provision. The agreement provides that
Mr. Shirley’s base salary is a specified amount and that he is entitled to such increases as determined by the Board. In
addition, Mr. Shirley is entitled to receive an annual bonus of 100% of his base salary. The employment agreement also provides
severance benefits, but does not provide enhanced change in control benefits.
|
- 2020 Proxy Statement
|
35
|
|
|
|
Mr. Brander’s employment with Colfax was
terminated in connection with the completion of the sale of the Air & Gas Handling business. Prior to this, Mr. Brander’s
employment agreement was amended on May 7, 2019, in contemplation of such sale. The amended agreement provided that Mr. Brander
was eligible to receive a retention bonus upon closing of such sale, subject to his continued employment through closing. The
agreement also provided that, in its discretion, the Company could increase the retention bonus based on its assessment of the
performance of the Air & Gas Handling business and Mr. Brander through closing. Mr. Brander was awarded a $3,152,585 payment
consistent with these arrangements.
Additional details regarding the material terms
of these agreements are summarized under “Employment Agreements and Executive Officer Severance Plan” on page 44 and
“Potential Payments Upon Termination or Change in Control” on page 47 and a summary of the material terms and eligibility
requirements for the Executive Officer Severance Plan is provided under “Potential Payments Upon Termination or Change in
Control.”
Stock Ownership Policy and Stock Holding Requirements
Our stock ownership policy further aligns the
long-term financial interests of Company executives with those of our stockholders while also serving as a risk mitigation tool.
Each executive at a vice president level or higher must retain at least one-half of vested equity awards, less shares withheld
or sold for tax withholding obligations, until the executive has accumulated shares of our common stock or other qualifying forms
of equity having the value described below. The ownership value thresholds are as follows:
Leadership Position
|
Value of Shares
|
President and CEO
|
6x base salary
|
EVP/SVP
|
3x base salary
|
VP
|
1x base salary
|
All of the Company’s NEOs currently employed
with the Company have achieved these ownership targets as of the date of this Proxy Statement.
CEO Recommendations
During 2019, Mr. Trerotola provided recommendations
to the Compensation Committee with respect to the compensation levels for our executive officers, other than for himself. These
recommendations were based on his assessment of the executive officer’s relative experience, overall performance, and impact
on the achievement of our financial and operational goals and strategic objectives, combined with perspective from the competitive
review data. While the Compensation Committee took these recommendations under advisement, it independently evaluated the pay
recommendations for each executive officer and made all final compensation decisions in accordance with its responsibilities as
set forth in the Compensation Committee Charter.
Role of Compensation Consultants and Peer
Data Review
Our Compensation Committee also obtains perspective
from competitive data reviewed by FW Cook, the independent advisor to the Compensation Committee on matters of executive compensation.
The Compensation Committee annually reviews the list of peer companies previously recommended by FW Cook to confirm that such
continues to reflect the peers used by financial analysts and governance advisors covering Colfax and to represent our growth
trajectory, revenue, market capitalization and overall scope and nature of operations. In light of the DJO acquisition, the peer
group was revised to include certain companies in the medical device industry to reflect our current business portfolio. The peer
group referenced in 2019 was as follows:
Colfax
Peer Group
|
|
|
AMETEK, Inc.
|
IDEX Corporation
|
STERIS plc
|
The Cooper Companies, Inc.
|
ITT Inc.
|
Teleflex Incorporated
|
Crane Co.
|
Kennametal Inc.
|
The Timken Company
|
Dover Corporation
|
Lincoln Electric Holdings, Inc.
|
Varian Medical Systems
|
Flowserve Corporation
|
Pentair plc
|
Xylem Inc.
|
Haemonetics Corporation
|
Regal Beloit Corporation
|
Zimmer Biomet Holdings, Inc.
|
Hill-Rom Holdings, Inc.
|
Rexnord Corporation
|
|
Hubbell Incorporated
|
Snap-on Incorporated
|
|
Competitive review data drawn from this group
was utilized by the Compensation Committee as one of many reference points to assist in its compensation decisions, and for certain
NEOs, competitive review data drawn from this group was used to “benchmark” the amount of compensation paid to such
NEOs.
|
- 2020 Proxy Statement
|
36
|
|
|
|
Independence of Compensation Consultant
In April 2020, the Compensation Committee considered
the independence of FW Cook in light of the SEC rules regarding conflicts of interest involving compensation consultants and NYSE
listing standards regarding compensation consultant independence. The Compensation Committee requested and received a letter from
FW Cook addressing conflicts of interest and independence, including specific factors enumerated in both relevant SEC rules and
NYSE listing standards. The Compensation Committee discussed and considered these factors, and other factors it deemed relevant,
and concluded that FW Cook is independent and that its work during 2019 did not raise any conflict of interest.
Compensation Program and Risk
As part of our continued appraisal of our compensation
program, management, with oversight from the Compensation Committee, annually reviews our compensation policies and practices
and the design of our overall compensation program in relation to our risk management practices and any potential risk-taking
incentives. This assessment includes a review of the primary elements of our compensation program in light of potential risks:
Compensation
Program Risk Considerations
|
Pay Mix
|
■
|
Compensation program includes an appropriate mix of short- and long-term
incentives, which mitigate the risk of undue focus on short-term targets while rewarding
performance in areas that are key to our long-term success.
|
|
■
|
Base salaries are set at competitive levels to promote stability and provide a component
of compensation that is not at risk.
|
Performance Metrics and Goals
|
■
|
Distinct performance metrics are used in both our short-term (AIP) and long-term incentive
plans. Effective for the 2019 fiscal year, the long term performance metrics no longer
include a margin goal.
|
|
■
|
Our Annual Incentive Plan is designed with a payout scale (including a maximum cap) that
supports our pay-for-performance philosophy, as set forth on page 31.
|
Long-Term Incentives
|
■
|
The equity grant portion of our compensation program, combined with our stock ownership
guidelines and stock holding requirements, is designed to align the long-term interests of our
executives with those of our stockholders.
|
We have controls and other policies in place
that serve to limit excessive risk-taking behavior within our compensation program, including, but not limited to, the following:
Compensation
Risk Mitigation Components
|
Compliance Risk Mitigation
|
■
|
Oversight of our compensation process and procedures by the Compensation
Committee, each member of which has been determined by the Board to be independent under
applicable SEC rules and NYSE listing standards;
|
|
■
|
Internal controls over our financial reporting, which are maintained by management and reviewed
as a part of our internal audit process and further reviewed and tested by our external auditors, as overseen
by the Audit Committee; and
|
|
■
|
Audit Committee oversight and review of financial results and non-GAAP metrics used in certain
components of our AIP and long-term incentives.
|
Personnel Risk Mitigation
|
■
|
Implementation of and training on Company-wide standards of conduct, as described on page
18 under “Standards of Conduct”.
|
Risk Mitigation Policies
|
■
|
Provisions in the Company’s insider trading policy prohibiting hedging transactions
that would allow the holder to limit or eliminate the risk of a decrease in the value
of the Company’s securities;
|
|
■
|
A policy prohibiting pledging of Company shares after February 17, 2014; and
|
|
■
|
A
clawback policy applicable to all executive officers.
|
The Compensation Committee reviews with management
the results of its assessment annually. Based on its most recent review, the Compensation Committee concluded that the risks arising
from Company compensation policies and practices for our employees are not reasonably likely to have a material adverse effect
on the Company.
Additionally, the Compensation Committee also
reviews the Company’s strategies and policies related to human capital management, including with respect to matters such
as diversity, inclusion, pay equity, corporate culture, talent development and retention.
Hedging Ban
Any director, officer or employee of the Company
is prohibited from engaging in short sales, transactions in derivative securities (including put and call options), or other forms
of hedging and monetization transactions, such as zero-cost collars, equity swaps, exchange funds and forward sale contracts,
that allow the holder to limit or eliminate the risk of a decrease in the value of the Company’s securities.
|
- 2020 Proxy Statement
|
37
|
|
|
|
Pledging Policy
Our Board has adopted a policy that prohibits
any director or executive officer from pledging as security under any obligation any shares of Colfax common stock that he or
she directly or indirectly owns and controls (other than shares already pledged as of February 17, 2014). Any shares of Colfax
common stock that were pledged prior to February 17, 2014 do not count toward meeting our stock ownership requirements.
Clawback Policy
The Compensation Committee has adopted a clawback
policy applicable to our executive officers. Under the policy, in the event the Company is required to restate its financial results
due to material non-compliance with any financial reporting requirement under the securities laws as generally applied, the Board
will review all bonus payments made, including all bonus payments under our Annual Incentive Plan, and all performance-based equity
compensation that was earned or vested on the basis of having met or exceeded financial results during the three years prior to
the date that the Company determines such restatement is required.
If the Board determines that such payments or
the amount of awards earned/vested would have been lower had they been determined or calculated based on such restated results,
the Board will, to the extent permitted by governing law, seek to recoup for the benefit of the Company the value of such excess
payments made to and/or equity awards earned by executive officers. The Board maintains discretion, to the extent permitted under
applicable law, not to seek such recoupments if the Board determines, in the exercise of its fiduciary duties, that under the
specific circumstances it would not be appropriate to seek to recover such amounts. The Company may effect such recoupment by
requiring executive officers to pay such amount(s) to the Company, by set-off, by reducing future compensation, or by such other
means or combination of means as the Board determines to be appropriate.
Equity Grant Practice
The Compensation Committee has the authority
to grant equity awards. The Company does not time the grant of equity awards around material, non-public information. Grant dates
are determined either as of the date of Compensation Committee approval or on the date of a specific event, such as the date of
hire or promotion, for certain executive officers. The target grant value is translated into a number of shares underlying each
grant using a valuation formula that, for PRSUs and RSUs, incorporates a 20-day average closing price up to and including the
grant date, to avoid the potential volatility impact of using a single-day closing price.
The Compensation Committee has delegated authority
to our CEO and Chief Human Resources Officer for grants of equity awards to associates who are non-executive officers. The aggregate
grant date value of such equity awards may not exceed $4,000,000 during the fiscal year period. Such awards are subject to further
restrictions on individual size, and awards must be made pursuant to the terms of award agreement forms previously approved by
the Board or the Compensation Committee. The effective grant date of these awards is on the first trading day on or after the
date of hire or promotion for newly hired employees following review and approval by the CEO or Chief Human Resources Officer,
as applicable. The Compensation Committee receives a report of any grants made pursuant to this delegated authority at each regularly
scheduled meeting.
Rule 10b5-1 Trading Plans by Executive Officers
Certain of our executive officers have adopted
written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our insider trading policy. A Rule 10b5-1
Trading Plan is a written document that pre-establishes the amount (or ratio), prices, and dates (or range of possible dates)
of future purchases or sales of our common stock. These plans are entered into during an open window period in accordance with
the terms of our insider trading policy. From time to time, certain NEOs have entered into such plans (i) to sell the percentage
of vested shares necessary to satisfy applicable tax withholding obligations upon the vesting and delivery of PRSUs, or (ii) to
exercise options that are approaching the end of their term.
Changes to Compensation Program for 2020
As noted above, in recent years, we have granted
stock options and PRSUs as our primary forms of annual equity awards, with service-based RSUs being granted principally as recruitment
or promotion awards at the time of hire or promotion. Beginning in 2020, annual equity awards will generally consist of 50% PRSUs,
25% stock options, and 25% time vesting RSUs. The Compensation Committee believes this will further align the long-term interests
of management and stockholders and promote increased equity ownership among our executive officers.
In April 2020, the Compensation Committee and
Board adopted amendments to our Annual Incentive Plan to (i) eliminate language that was no longer necessary due to the repeal
of Section 162(m) of the Internal Revenue Code’s exemption from the deduction limit for certain “performance-based”
compensation and (ii) add provisions that provide for certain payments of annual awards in the event of death, disability or retirement,
as defined in the Annual Incentive Plan.
|
- 2020 Proxy Statement
|
38
|
|
|
|
|
COMPENSATION COMMITTEE REPORT
|
The Compensation Committee participated in the
preparation of the Compensation Discussion and Analysis, reviewing successive drafts and discussing the drafts with management.
Based on its review and discussions with management, the Compensation Committee recommended to the Board of Directors that the
Compensation Discussion and Analysis be included in the Company’s 2020 Proxy Statement and in the Company’s Annual
Report on Form 10-K for 2019 by reference to the Proxy Statement.
Compensation Committee of the Board of Directors
Rhonda Jordan, Compensation Committee Chair
Rajiv
Vinnakota
Sharon Wienbar
|
- 2020 Proxy Statement
|
39
|
|
|
|
|
EXECUTIVE COMPENSATION
|
Summary Compensation Table
Name and
Principal Position
|
|
Year
|
|
Salary
($)
|
|
Bonus
($)(1)
|
|
Stock
Awards
($)(2)
|
|
Option
Awards
($)(3)
|
|
Non-Equity
Incentive Plan
Compensation
($)(4)
|
|
Change
in
Pension
Value and
Nonqualified
Deferred
Compensation
Earnings(5)
|
|
All Other
Compen-
sation
($)(6)
|
|
Total
($)
|
|
Matthew Trerotola
President and Chief Executive Officer
|
|
2019
|
|
1,071,346
|
|
—
|
|
2,724,996
|
|
2,724,996
|
|
1,480,600
|
|
—
|
|
428,088
|
|
8,430,026
|
|
|
2018
|
|
1,049,000
|
|
—
|
|
—
|
|
—
|
|
1,676,000
|
|
—
|
|
422,927
|
|
3,147,927
|
|
|
2017
|
|
1,021,932
|
|
1,000,000
|
|
—
|
|
—
|
|
881,000
|
|
—
|
|
374,184
|
|
3,277,107
|
|
Christopher Hix
Executive Vice President, Finance and
Chief Financial Officer
|
|
2019
|
|
591,731
|
|
—
|
|
1,999,987
|
|
999,998
|
|
476,000
|
|
—
|
|
81,442
|
|
4,149,158
|
|
|
2018
|
|
570,962
|
|
—
|
|
999,987
|
|
1,000,002
|
|
640,000
|
|
—
|
|
29,260
|
|
3,240,211
|
|
|
2017
|
|
557,308
|
|
—
|
|
850,002
|
|
849,999
|
|
319,000
|
|
—
|
|
52,953
|
|
2,629,262
|
|
Daniel Pryor
Executive Vice President, Strategy and
Business Development
|
|
2019
|
|
560,962
|
|
—
|
|
924,995
|
|
924,999
|
|
497,200
|
|
—
|
|
68,578
|
|
2,976,734
|
|
|
2018
|
|
544,615
|
|
—
|
|
1,874,996
|
|
1,875,004
|
|
532,000
|
|
—
|
|
64,249
|
|
4,890,864
|
|
|
2017
|
|
525,962
|
|
500,000
|
|
874,983
|
|
874,997
|
|
382,000
|
|
—
|
|
52,078
|
|
3,210,019
|
|
Shyam Kambeyanda
Executive Vice President, President and
CEO of ESAB
|
|
2019
|
|
544,688
|
|
130,000
|
|
1,149,998
|
|
650,001
|
|
522,720
|
|
—
|
|
58,644
|
|
3,056,051
|
|
|
2018
|
|
505,000
|
|
330,000
|
|
599,992
|
|
599,999
|
|
460,000
|
|
—
|
|
96,121
|
|
2,591,112
|
|
|
2017
|
|
485,000
|
|
330,000
|
|
499,985
|
|
500,000
|
|
340,000
|
|
—
|
|
296,938
|
|
2,451,923
|
|
Brady Shirley
Chief Executive Officer of DJO
|
|
2019
|
|
719,231
|
|
—
|
|
2,499,995
|
|
500,003
|
|
702,100
|
|
—
|
|
22,027
|
|
4,443,356
|
|
Ian Brander
Former Senior Vice President, Colfax
and Howden President
|
|
2019
|
|
378,652
|
(7)
|
3,152,585
|
|
—
|
|
400,000
|
|
—
|
|
195,391
|
|
58,300
|
|
4,184,928
|
|
|
2018
|
|
398,000
|
|
—
|
|
650,012
|
|
349,999
|
|
355,000
|
|
—
|
|
82,198
|
|
1,835,209
|
|
|
2017
|
|
414,462
|
|
—
|
|
499,985
|
|
500,000
|
|
137,981
|
|
90,634
|
|
66,995
|
|
1,710,056
|
|
(1)
|
For Mr. Trerotola, the amounts in this column
for 2017 represent the final payment of the three installment payments of his cash signing bonus agreed to in 2015 when he
joined the company. See “2015 CEO Succession” on pages 16-17 of our 2016 Proxy Statement as filed with the SEC
on April 1, 2016. For Mr. Pryor the amount represents a performance-related bonus for 2017 in recognition of his contributions
to the successful completion of the Colfax Fluid Handling sale. For Mr. Kambeyanda, the amounts represent for 2019, 2018 and
2017 the second, third and fourth of five installment payments of his cash signing bonus. For Mr. Brander the amount represents
a performance-related bonus for 2019 in recognition of his contributions to the successful completion of the sale of the Air &
Gas Handling business.
|
(2)
|
Amounts represent the aggregate grant date fair value of grants
made to each NEO, as computed in accordance with FASB ASC Topic 718. See Note 14 to our consolidated financial statements
for the year ended December 31, 2019, included in our Annual Report on Form 10-K filed with the SEC on February 24, 2020.
See “Long-Term Incentives” above on page 34. Assuming the maximum achievement of the performance goals applicable
to the PRSUs, the grant date value of the PRSUs granted to the NEOs in 2019 would have been $5,449,992, $2,000,007, $1,849,990,
$1,300,012 and $4,000,014 for Messrs. Trerotola, Hix, Pryor, Kambeyanda, and Shirley, respectively.
|
(3)
|
Amounts represent the aggregate grant date fair value of grants
made to each NEO, as computed in accordance with FASB ASC Topic 718. See Note 14 to our consolidated financial statements
for the year ended December 31, 2019, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission
on February 24, 2020. For 2019 grants, options were valued by the Black Scholes-based option value based on the closing
price of our common stock on the date of grant. The exercise price for stock option awards equals the closing price of our
common stock on the date of grant. See “Long-Term Incentives” above on page 34.
|
(4)
|
Amounts represent the payouts pursuant to our Annual Incentive
Plan. For a discussion of the performance metrics on which the 2019 Annual Incentive Plan was based, including the weighting
for each performance metric and the actual percentage achievement of the financial performance targets, see “Annual
Incentive Plan” above on page 31.
|
(5)
|
For 2019, amount represents £149,000 or $195,391 in
U.S. dollars, calculated based on the exchange rate in effect on December 31, 2019. This amount is the aggregate change in
the actuarial present value of Mr. Brander’s accumulated benefit under a closed pension benefit plan from the pension
plan measurement date used for financial statement reporting purposes in fiscal 2018 as compared to fiscal 2019. For additional
details regarding this plan, see the Pension Benefits table and narrative that follows such table below.
|
|
- 2020 Proxy Statement
|
40
|
|
|
|
(6)
|
Amounts set forth in this column for 2019 consist
of the following:
|
|
Name
|
|
Company
401(k)/Deferred
Compensation
Plan
Match and
Contribution
($)(a)
|
|
Auto
Allowance
($)(b)
|
|
Financial
Services
($)(c)
|
|
Aircraft
Usage
($)(d)
|
|
Supplemental
Long-Term
Disability
Premiums
($)(e)
|
|
Accident
Insurance
($)(f)
|
|
Howden
Retirement
Plan
Company
Contribution
($)(g)
|
|
Medical
Care
Supplement
($)(h)
|
|
Total
($)
|
|
|
Mr. Trerotola
|
|
164,841
|
|
20,000
|
|
12,380
|
|
230,867
|
|
—
|
|
—
|
|
—
|
|
—
|
|
428,088
|
|
|
Mr. Hix
|
|
73,904
|
|
—
|
|
7,538
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
81,442
|
|
|
Mr. Pryor
|
|
65,578
|
|
—
|
|
3,000
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
68,578
|
|
|
Mr. Kambeyanda
|
|
54,144
|
|
—
|
|
4,500
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
58,644
|
|
|
Mr. Shirley
|
|
22,027
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
22,027
|
|
|
Mr. Brander
|
|
—
|
|
11,802
|
|
—
|
|
—
|
|
5,547
|
|
191
|
|
37,865
|
|
2,894
|
|
58,300
|
|
|
(a)
|
Amounts represent the aggregate Company match and Company
contribution made by Colfax during 2019 to such NEO’s 401(k) plan account and Non-Qualified Deferred Compensation Plan
account. See the Nonqualified Deferred Compensation table and accompanying narrative for additional information on the Non-Qualified
Deferred Compensation Plan.
|
|
(b)
|
For Mr. Trerotola, amount represents an annual cash allowance for
car-related expenses pursuant to his employment contract. For Mr. Brander, the amount represents an annual cash allowance
for car-related expenses pursuant to his service contract in the amount of £9,000 or $11,802 in U.S. dollars, calculated
based on the exchange rate in effect on December 31, 2019.
|
|
(c)
|
Amount represents amounts for financial planning services as reimbursed
by the Company during 2019.
|
|
(d)
|
Amount represents Company expenses incurred for private plane usage
in 2019. The Company is billed directly for the charter flight services used for Mr. Trerotola’s personal travel. The
imputed income to Mr. Trerotola for these flights as calculated under the tax rules was $31,596, based on the SIFL rates promulgated
by the Internal Revenue Service. The Company does not gross-up or make whole Mr. Trerotola for the income imputed to his use
of chartered flights.
|
|
(e)
|
Amount represents £4,230, or $5,547 in U.S. dollars, calculated
based on the exchange rate in effect on December 31, 2019.
|
|
(f)
|
Amount represents £146, or $191 in U.S. dollars, calculated
based on the exchange rate in effect on December 31, 2019.
|
|
(g)
|
Amount represents the annual employer contribution of £28,875,
or $37,865 in U.S. dollars, calculated based on the exchange rate in effect on December 31, 2019. Howden contributed 10% of
Mr. Brander’s annual salary if Mr. Brander contributed 5% of his annual salary to the retirement plan (as he did in
2019). There is no guaranteed distribution amount based on service years or age. Amounts contributed to the retirement plan
are at risk and are invested via direction from Mr. Brander to the plan provider.
|
|
(h)
|
Amount represents a private medical insurance premium and executive
physical of £2,207 in aggregate, or $2,894 in U.S. dollars, calculated based on the exchange rate in effect on December
31, 2019.
|
(7)
|
For Mr. Brander, amount represents £288,750 or
$378,652 in U.S. dollars, calculated based on the exchange rate in effect on December 31, 2019.
|
|
- 2020 Proxy Statement
|
41
|
|
|
|
Grants of Plan-Based Awards for 2019
The following table sets
forth information with respect to grants of plan-based awards to our named executive officers during 2019:
|
|
|
|
|
|
Estimated
Possible Payouts Under
Non-Equity Incentive
Plan Awards(1)
|
|
Estimated
Future Payouts
Under Equity Incentive
Plan Awards(2)
|
|
All Other
Stock
Awards:
Number of
shares of
stock
|
|
All Other
Option
Awards:
Number of
Securities
Underlying
|
|
Exercise
or Base
Price of
Option
|
|
Grant
Date
Fair Value
of Stock
and
|
|
Name
|
|
Award Type
|
|
Grant Date
|
|
Threshold
($)
|
|
Target
($)
|
|
Maximum
($)
|
|
Threshold
(#)
|
|
Target
(#)
|
|
Maximum
(#)
|
|
or units
(#)(3)
|
|
Options
(#)(4)
|
|
Awards
($/Sh)
|
|
Option
Awards ($)(5)
|
|
Matthew L. Trerotola
|
|
Annual Incentive Plan
|
|
—
|
|
673,125
|
|
1,346,250
|
|
3,365,625
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
PRSUs
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
53,531
|
|
107,062
|
|
214,124
|
|
|
|
|
|
|
|
2,724,996
|
|
|
Stock Options
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
310,364
|
|
26.88
|
|
2,724,996
|
|
Christopher M. Hix
|
|
Annual Incentive Plan
|
|
|
|
238,000
|
|
476,000
|
|
1,190,000
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
PRSUs
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
19,645
|
|
39,289
|
|
78,578
|
|
—
|
|
—
|
|
—
|
|
1,000,003
|
|
|
RSUs(6)
|
|
12/13/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
29,394
|
|
|
|
|
|
999,984
|
|
|
Stock Options
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
113,895
|
|
26.88
|
|
999,998
|
|
Daniel A. Pryor
|
|
Annual Incentive Plan
|
|
—
|
|
226,000
|
|
452,000
|
|
1,130,000
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
PRSUs
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
18,171
|
|
36,342
|
|
72,684
|
|
—
|
|
—
|
|
—
|
|
924,995
|
|
|
Stock Options
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
105,353
|
|
26.88
|
|
924,999
|
|
Shyam Kambeyanda
|
|
Annual Incentive Plan
|
|
—
|
|
220,000
|
|
440,000
|
|
1,100,000
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
|
|
PRSUs
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
12,769
|
|
25,538
|
|
51,076
|
|
—
|
|
—
|
|
—
|
|
650,006
|
|
|
RSUs(6)
|
|
12/13/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
14,697
|
|
—
|
|
—
|
|
499,992
|
|
|
Stock Options
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
74,032
|
|
26.88
|
|
650,001
|
|
Brady Shirley
|
|
Annual Incentive Plan
|
|
—
|
|
425,000
|
|
850,000
|
|
2,125,000
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
|
|
DJO PRSUs
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
39,289
|
|
78,578
|
|
157,156
|
|
—
|
|
—
|
|
—
|
|
2,000,007
|
|
|
RSUs
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
19,644
|
|
—
|
|
—
|
|
499,989
|
|
|
Stock Options
|
|
2/25/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
56,948
|
|
26.88
|
|
500,003
|
|
Ian Brander
|
|
Stock Options(7)
|
|
3/1/2019
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
45,977
|
|
26.52
|
|
400,000
|
|
(1)
|
Amounts represent the possible payouts under our
Annual Incentive Plan. Threshold estimated possible payouts incorporate a 0.5 IPF, target estimated possible payouts incorporate
a 1.0 IPF and maximum estimated possible payouts incorporate the 250% maximum payout cap under the Annual Incentive Plan.
For a discussion of the performance metrics and actual results and payouts under the plan for fiscal 2019 see the Compensation
Discussion and Analysis and the “Non-Equity Incentive Plan Compensation” column of the Summary Compensation Table
above, respectively.
|
(2)
|
Amounts represent potential shares issued under performance-based
restricted stock unit awards. The PRSUs may be earned at the end of the performance period upon certification by the Compensation
Committee of the performance level that has been met. For Messrs. Trerotola, Hix, Pryor and Kambeyanda the PRSUs cliff vest
at the end of the three-year performance period, if earned. Once vested, at least 50% of the shares delivered pursuant to
the PRSUs (net of shares withheld or sold for taxes) must be held for an additional one-year period. For Mr. Shirley, the
PRSUs are subject to a two-year performance period, with 50% vesting on the second anniversary of the grant date and 50% vesting
on the third anniversary of the grant date, if earned.
|
(3)
|
Amounts represent restricted stock units. For Messrs. Hix
and Kambeyanda, the RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. For
Mr. Shirley, the RSUs cliff vest after two years.
|
(4)
|
Amounts represent stock option awards that vest ratably over
three years, beginning on the first anniversary of the grant date, based on continued service.
|
(5)
|
The amounts shown in this column represent the full grant
date fair value of grants made to each NEO, as computed in accordance with FASB ASC Topic 718. PRSUs are valued based upon
the probable outcome of the performance conditions associated with these awards as of the grant date and such calculation
is consistent with the estimate of aggregate compensation cost recognized over the service period determined as of the grant
date under FASB ASC Topic 718, excluding the effect of estimated forfeitures.
|
(6)
|
The Compensation Committee approved a one-time promotional
grant of RSUs for each of Messrs. Hix and Kambeyanda.
|
(7)
|
These options were forfeited in connection with the sale of
the Air & Gas Handling Business.
|
|
- 2020 Proxy Statement
|
42
|
|
|
|
Outstanding Equity Awards at 2019 Fiscal Year-End
The following table shows,
as of December 31, 2019, the number of outstanding stock options, performance-based restricted stock unit awards and restricted
stock unit awards held by the named executive officers:
|
|
Option Awards
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
Equity Incentive Plan Awards
|
Name
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
|
Option
Exercise
Price
($)
|
|
Option
Expiration
Date(1)
|
|
Number
of Shares
or Units of
Stock That
Have Not
Vested
(#)(2)
|
|
Market Value
of Shares or
Units of Stock
That Have Not
Vested
($)(3)
|
|
Number of
Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
(#)(4)
|
|
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)(5)
|
Matthew L. Trerotola
|
|
359,066
|
|
179,534
|
|
39.54
|
|
7/23/2022
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
186,521
|
|
373,042
|
|
23.74
|
|
1/3/2023
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
310,364
|
|
26.88
|
|
2/24/2026
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
123,774
|
|
4,502,898
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
107,062
|
|
3,894,916
|
Christopher M. Hix
|
|
124,611
|
|
—
|
|
26.56
|
|
6/30/2023
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
47,739
|
|
23,870
|
|
40.47
|
|
2/12/2024
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
32,237
|
|
64,475
|
|
33.41
|
|
3/7/2025
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
113,895
|
|
26.88
|
|
2/24/2026
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
42,607
|
|
1,550,043
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
68,774
|
|
2,501,998
|
Daniel A. Pryor
|
|
23,669
|
|
—
|
|
42.25
|
|
2/17/2020
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
144,648
|
|
—
|
|
52.79
|
|
7/28/2020
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
78,673
|
|
39,337
|
|
52.02
|
|
2/15/2022
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
114,613
|
|
—
|
|
26.51
|
|
11/15/2022
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
49,143
|
|
24,572
|
|
40.47
|
|
2/12/2024
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
60,444
|
|
120,891
|
|
33.41
|
|
3/7/2025
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
105,353
|
|
26.88
|
|
2/24/2026
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
91,627
|
|
3,333,390
|
Shyam Kambeyanda
|
|
24,644
|
|
—
|
|
24.96
|
|
5/12/2023
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
28,081
|
|
14,042
|
|
40.47
|
|
2/12/2024
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
19,342
|
|
38,685
|
|
33.41
|
|
3/7/2025
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
74,032
|
|
26.88
|
|
2/24/2026
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
45,334
|
|
1,649,251
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
43,229
|
|
1,572,671
|
Brady Shirley
|
|
—
|
|
56,948
|
|
26.88
|
|
2/24/2026
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
19,644
|
|
714,649
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
78,578
|
|
2,858,668
|
Ian Brander
|
|
14,793
|
|
—
|
|
42.25
|
|
1/29/2020
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
15,024
|
|
—
|
|
68.23
|
|
1/29/2020
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
54,087
|
|
—
|
|
52.02
|
|
1/29/2020
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
28,081
|
|
—
|
|
40.47
|
|
1/29/2020
|
|
—
|
|
—
|
|
—
|
|
—
|
(1)
|
The vesting date of unvested stock option awards
is set forth beside each option expiration date in the following chart. Note that the vesting date provided reflects when
the options fully vest. Stock option awards vest ratably over three years beginning on the first anniversary of the grant
date except as follows: For Mr. Trerotola, options granted on July 24, 2015 and January 4, 2016 vest in equal amounts on the
third, fourth and fifth anniversaries of the grant date. For Mr. Pryor, the options granted on February 16, 2015 vest in equal
amounts on the third, fourth and fifth anniversaries of the grant date.
|
|
- 2020 Proxy Statement
|
43
|
|
|
|
|
Option
Grant Date
|
Option
Expiration Date
|
Option
Full Vesting Date (options vest over
three year period except as noted above)
|
|
2/16/2015
|
2/15/2022
|
2/16/2020
|
|
7/24/2015
|
7/23/2022
|
7/24/2020
|
|
11/16/2015
|
11/15/2022
|
11/16/2018
|
|
1/4/2016
|
1/3/2023
|
1/4/2021
|
|
5/13/2016
|
5/12/2023
|
5/13/2019
|
|
7/1/2016
|
6/30/2023
|
7/1/2019
|
|
2/14/2017
|
2/12/2024
|
2/13/2020
|
|
3/8/2018
|
3/7/2025
|
3/8/2021
|
|
2/25/2019
|
2/24/2026
|
2/25/2022
|
(2)
|
For Mr. Trerotola, the amounts represent (i) 37,937
PRSUs that were earned upon certification by the Compensation Committee that the performance metric for these awards had been
met and that vest on July 24, 2020 pending continued service with the Company, and (ii) 85,837 PRSUs that were earned upon
certification by the Compensation Committee that the performance metric for these awards had been met, of which 42,918 vested
on January 4, 2020 and 42,919 will vest on January 4, 2021, pending continued service with the Company.
|
|
For Mr. Hix, the amounts represent (i) 6,006 restricted stock
units that are the remaining portion of the RSU portion of his 2016 signing bonus, which vests July 1, 2020, (ii) 29,394 restricted
stock units granted to Mr. Hix as part of the promotional award discussed above that vest ratably over three years, beginning
on December 13, 2020, and (iii) 7,207 PRSUs that were earned upon certification by the Compensation Committee that the performance
metric for these awards had been met and that vest on July 1, 2020 pending continued service with the Company.
|
|
For Mr. Kambeyanda, the amounts represent (i) 22,759 RSUs
that vest on May 13, 2020, which is the outstanding restricted stock unit award portions of his 2016 signing bonus, (ii) 14,697
restricted stock units granted to Mr. Kambeyanda as part of the promotional award discussed above that vest ratably over three
years, beginning on December 13, 2020, and (iii) 7,878 PRSUs from his initial long-term incentive award that were earned upon
certification by the Compensation Committee that the performance metric for these awards had been met and that vest on May
13, 2020 pending continued service with the Company.
|
|
For Mr. Shirley, the amounts represent 19,644 RSUs that vest
on February 25, 2021.
|
(3)
|
The amounts shown in this column represent the market value
of the unvested PRSUs or restricted stock units, as applicable, based on the closing price of the Company’s common stock
on December 31, 2019, which was $36.38 per share, multiplied by the number of units, respectively, for each unvested award.
|
(4)
|
The amounts shown in this column reflect unearned PRSUs as
of December 31, 2019. If earned, these PRSUs are then subject to an additional service-based vesting period.
|
|
The amounts shown in this column reflect awards made in 2018
and 2019 and show the target amount of PRSUs that may be earned at the end of the performance period upon certification by
the Compensation Committee. For Messrs. Trerotola, Hix, Kambeyanda and Pryor, the amounts would cliff vest at the end of the
three-year performance period, if earned. Once vested, at least 50% of the shares delivered pursuant to the PRSUs (net of
shares withheld or sold for taxes) must be held for an additional one-year period. For Mr. Shirley, the PRSUs are subject
to a two-year performance period, with 50% vesting on the second anniversary of the grant date and 50% vesting on the third
anniversary of the grant date, if earned. For 2019, these amounts are reflected in the “Grants of Plan-Based Awards
for 2019” table above under the column “Estimated Future Payouts Under Equity Incentive Plan Awards” and
for 2018 are reflected in the “Grants of Plan-Based Awards for 2018” table in the Proxy Statement for the 2019
Annual Meeting.
|
|
PRSU grants made to Messrs. Hix, Pryor and Kambeyanda in February
2017 were cancelled without any shares being issued following the end of their performance period, which concluded as of the
end of the fiscal year, and are not reflected in this table.
|
(5)
|
The amounts shown in this column represent the market value
of the unearned PRSUs based on the closing price of the Company’s common stock on December 31, 2019, which was $36.38
per share, multiplied by the threshold number of units, respectively, for each unvested and unearned performance stock award.
|
Employment Agreements and Executive Officer Severance
Plan
Messrs. Trerotola and Pryor
are party to our current form of employment agreement for executive officers, which was adopted by the Company on September 15,
2010.
Mr. Hix’s letter agreement,
entered into upon his hire, provides for severance and change in control benefits primarily commensurate with those provided under
our employment agreements. Mr. Kambeyanda is party to a letter agreement that specifies his starting annual salary and minimum
target bonus. Mr. Shirley is party to a service agreement with DJO, which he entered into prior to our acquisition of the DJO
business in 2019. The agreement provides for a four-year initial term, with automatic one-year term extensions commencing November
14, 2020, unless we or Mr. Shirley provides written notice in advance to terminate the automatic extension provision. The agreement
provides that Mr. Shirley’s base salary is a specified amount and that he is entitled to such increases as determined by
the Board. In addition, Mr. Shirley is entitled to receive an annual bonus of 100% of his base salary. The employment agreement
also provides severance benefits, but does not provide change in control benefits.
Mr. Brander’s employment
with Colfax was terminated in connection with the completion of the sale of the Air & Gas Handling business. Prior to
this, Mr. Brander’s employment agreement was amended on May 7, 2019, in contemplation of such sale. The amended agreement
provided that Mr. Brander was eligible to receive a retention bonus upon closing of such sale, subject to his continued employment
through closing. The agreement also provided that, in its discretion, the Company could increase the retention bonus based on
its assessment of the performance of the Air & Gas Handling business and Mr. Brander through closing.
We also maintain an Executive
Officer Severance Plan, which provides for severance benefits upon a termination without cause or a resignation for good reason
for executive officers who are not otherwise contractually entitled to severance compensation. The Executive Officer Severance
Plan does not provide for change in control benefits. Mr. Kambeyanda is the only NEO subject to this plan.
Form of Employment Agreement
On September 15, 2010, the
Company adopted a new form of employment agreement for executive officers. Messrs. Trerotola and Pryor are each parties to employment
agreements based on this form, which, except for Mr. Trerotola (who has a three-
|
- 2020 Proxy Statement
|
44
|
|
|
|
year term), currently has
a two-year term that is automatically extended unless the Board or the executive provides written notice to terminate the automatic
extension provision. In addition, in the event we undergo a “change in control” (as described below under “Potential
Payments Upon Termination or Change in Control”) during the term of the employment agreements, the agreements will be automatically
extended to the second anniversary of the change in control. Each officer’s base salary may not be reduced below the amount
previously in effect without the written agreement of the executive.
With respect to the
benefits payable to each executive under these agreements upon a change in control of Colfax, the benefits are only paid upon
a “double trigger,” meaning a change in control event must occur and the executive must either be terminated
without cause by Colfax (or its successor) or the executive must resign for good reason. In entering into these arrangements,
the Company wanted to ensure the continued dedication of these executive officers, notwithstanding the possibility of a
change in control, and to retain such officers in our employ after any such transaction. We believe that, should the
possibility of a change in control arise, Colfax should be able to receive and rely upon our officers’ advice as to the
best interests of the Company and without the concern that such officer might be distracted by the personal uncertainties and
risks created by the potential change in control. In the event, however, that such officer is actually terminated during the
period beginning three months prior to a change in control event or within a certain period of time following the change in
control (or prior to the end of the term of the applicable employment agreement should the change of control not be
consummated), which termination may be out of their control (i.e., by the successor company or management), we believe that
the officers should be compensated for their efforts in positioning Colfax for the possibility of an acquisition event.
Further, any bonus payment paid in conjunction with the termination of a NEO will be based upon the performance of the
Company, as stipulated in the Company’s Annual Incentive Plan. Additional information on certain benefits
provided under the form of employment agreement in certain terminations or in connection with a change of control is
discussed below under “Potential Payments Upon Termination or Change in Control.”
Option Exercises and Stock Vested
The following table provides
information regarding (i) the vesting of earned PRSUs for Messrs. Trerotola, Hix, Pryor, and Kambeyanda, (ii) the vesting of new
hire RSU awards for Messrs. Hix and Kambeyanda, (iii) the vesting of RSUs granted to Mr. Brander in contemplation of the strategic
review for the Air & Gas Handling business and (iv) Mr. Brander’s option exercises during 2019. The number of shares
acquired upon exercise or vesting and the value realized before payment of any taxes and broker commissions is reflected below.
Value realized represents the product of the number of shares received upon exercise or vesting and the closing market price of
our common stock on the exercise or vesting date, less the exercise price for options. Mr. Shirley did not exercise any Company
options nor did any of his Company stock awards vest in 2019.
Option Exercises and Stock Vested During Fiscal
2019
|
|
Option Awards
|
|
Stock Awards
|
Name
|
|
Number of Shares
Acquired on Exercise
(#)
|
|
Value Realized
on Exercise
($)
|
|
Number of Shares
Acquired on Vesting
(#)
|
|
Value Realized
on Vesting
($)
|
Matthew Trerotola
|
|
N/A
|
|
N/A
|
|
80,854
|
|
2,013,171
|
Chris Hix
|
|
N/A
|
|
N/A
|
|
13,213
|
|
364,811
|
Daniel Pryor
|
|
N/A
|
|
N/A
|
|
14,373
|
|
482,070
|
Shyam Kambeyanda
|
|
N/A
|
|
N/A
|
|
30,637
|
|
811,881
|
Ian Brander
|
|
68,589
|
|
407,052
|
|
9,144
|
|
239,298
|
Nonqualified Deferred Compensation
Effective January 1, 2016,
we established the Colfax Corporation Nonqualified Deferred Compensation Plan (the “Nonqualified Plan”) to provide
certain select members of management and other highly compensated employees, including each of the NEOs, with an opportunity to
defer a stated percentage of their base compensation or their bonus compensation without regard to the compensation limits imposed
by the Internal Revenue Code for our 401(k) plan. We established the Nonqualified Plan to allow these individuals to contribute
toward retirement on a tax-effective basis in a manner that is consistent with other Colfax employees who are not limited by the
Internal Revenue Code limits. The plan is “unfunded,” meaning there are no assets segregated for the exclusive benefit
of plan participants.
The Nonqualified Plan allows
the NEOs to defer up to 50% of their base salaries and up to 75% of their bonus compensation. In addition, during 2017 we matched
up to 4% of all excess
|
- 2020 Proxy Statement
|
45
|
|
|
|
deferrals by the NEOs and
provided a 2% Company contribution. Our NEOs vest in these Company contributions to the Nonqualified Plan on the same terms as
under the Company’s 401(k) plan.
Deferrals under the Nonqualified
Plan are notionally invested among a number of different mutual funds, insurance company separate accounts, indexed rates or other
measurement funds, which are selected periodically by the plan administrator to best match the funds offered in the qualified
401(k) plan. Each participating NEO can allocate his deferrals among these notional fund investment options and may change elections
at any time by making a change of election with the plan administrator. Colfax notionally invests its match and contribution amounts
in the same investment options in the same amounts and allocations as the reference funds selected by the officer.
Simultaneously with the
executive’s election to defer amounts under the Nonqualified Plan, the executive must elect the time and form of payment
for the deferred amounts, which may generally be either a lump sum distribution or in quarterly installments payable over a period
of one to ten years following a specified date (that must be at least one year following the end of the year to which the officer’s
deferral election relates) or at least six months following the officer’s separation from service. Limited changes to deferral
elections are permitted in accordance with the terms of the Nonqualified Plan. If no election is made, the benefit will be paid
in a lump sum on the last day of the month which occurs six months after the executive’s separation from service. Deferred
amounts may alternatively be paid out in a lump sum in the event of an executive’s death or disability or in the event of
an unforeseeable financial emergency, Furthermore, in the event the executive’s account balance at the time of his or her
separation from service is less than $15,000, payment of the account balance will be made in a lump sum on or before the later
of (i) December 31 of the calendar year of separation, or (ii) the date 2.5 months after the executive’s separation from
service.
The Company also maintains
the Colfax Corporation Excess Benefit Plan (the “Excess Benefit Plan”) which was frozen to new participants and future
new deferrals on December 31, 2015. Like the Nonqualified Plan, the Excess Benefit Plan is an unfunded non-qualified deferred
compensation plan in which Mr. Pryor holds an account balance. Like the Nonqualified Plan, amounts deferred under the Excess Benefit
Plan are notionally invested in offered measurement funds as selected by the plan participant and will be distributed in accordance
with participant elections and the terms of the Excess Benefit Plan following a participant’s separation from service, death
or disability.
The Company also maintains
the DJO Global Executive Deferred Compensation Plan (the “DJO Nonqualified Plan”), which was acquired in connection
with the acquisition of DJO. The DJO Nonqualified Plan was frozen to new participants and future deferrals on December 31, 2019.
Like the Nonqualified Plan, the DJO Nonqualified Plan is an unfunded non-qualified deferred compensation plan. Mr. Shirley holds
an account balance in this plan. Like the Nonqualified Plan, amounts deferred under the DJO Nonqualified Plan are notionally invested
in offered measurement funds as selected by the plan participant and will be distributed in accordance with participant elections.
Deferred amounts may generally be paid out in either a lump sum distribution or in annual installments payable over a period of
two to ten years following a specified date or the officer’s separation from service (subject to any required 6-month delay).
Deferred amounts will alternatively be paid out in a lump sum in the event of an executive’s death.
Mr. Brander does not participate in either the
Nonqualified Plan or the Excess Benefit Plan.
Nonqualified Deferred Compensation
Name
|
|
Executive
Contributions
in Last FY
($)(1)
|
|
Registrant
Contributions
in Last FY
($)(2)
|
|
Aggregate
Earnings
in Last FY
($)
|
|
Aggregate
Withdrawals/
Distributions
($)
|
|
Aggregate
Balance at
Last FYE
($)
|
Matthew L. Trerotola
|
|
137,367
|
|
148,041
|
|
29,941
|
|
—
|
|
889,527
|
Christopher M. Hix
|
|
49,269
|
|
57,104
|
|
6,331
|
|
—
|
|
254,978
|
Daniel A. Pryor
|
|
65,578
|
|
48,778
|
|
26,311
|
|
—
|
|
935,670
|
Shyam Kambeyanda
|
|
27,234
|
|
37,344
|
|
11,326
|
|
—
|
|
353,327
|
Brady Shirley
|
|
—
|
|
—
|
|
4,091
|
|
—
|
|
62,637
|
(1)
|
With respect to each applicable NEO, amounts represent
deferred salary and deferred bonus amounts that are reported in the Summary Compensation Table above under the applicable
column.
|
(2)
|
All amounts reported in this column for each applicable NEO
are reported in the “All Other Compensation” column of the Summary Compensation Table above.
|
Pension Benefits- Mr. Brander
Mr. Brander previously
participated in a pension plan provided by Howden Group Ltd., the Howden Group Pension Plan. Members of the Howden Group Pension
Plan stopped accruing benefits on September 30, 2006. The pension amount available to each participant under the Howden Group
Pension Plan is based on the participant’s years of service and his or her “Final Pensionable Earnings.” For
purposes of the Howden Group Pension Plan, “Final Pensionable Earnings” means the participant’s base annual
salary as of the date accruals ceased under the Howden Group Pension Plan, plus an allowance for fluctuating earnings for overtime
and shift allowances, less an amount equal to 1.5 times the Lower Earnings Limit (a figure determined by the UK tax authorities).
|
- 2020 Proxy Statement
|
46
|
|
|
|
The pension formula under
the plan is one sixtieth of the Final Pensionable Earnings multiplied by the number years of pensionable service for each participant.
All pension amounts under
the Howden Group Pension Plan are paid monthly following retirement. We retained liability with respect to the Howden Group Pension
Plan in connection with the sale of our Air & Gas Handling business.
2019 Pension Benefits
Name
|
|
Plan Name
|
|
Number of Years
Credited Service
(#)(1)
|
|
Present Value of
Accumulated Benefit
($)(2)
|
|
Payments During
Last Fiscal Year
($)
|
Ian Brander
|
|
Howden Group Pension Plan
|
|
19.4
|
|
883,850
|
(3)
|
—
|
(1)
|
Represents the number of years of pensionable
service for Mr. Brander under the Howden Group Pension Plan. The number of years of pensionable service represents Mr. Brander’s
actual years of service with the company prior to the plan freeze date in 2006.
|
(2)
|
Amounts represent the actuarial present value of Mr. Brander’s
accumulated benefit under the plan, computed as of the date used for financial statement reporting purposes with respect to
our 2019 financial statements and assuming the normal plan retirement age of 65. The value quoted is the full Howden Group
Pension Plan transfer value that would be paid in full upon transfer to Mr. Brander.
|
(3)
|
Amount represents £674,000 or $883,850 in U.S. dollars,
calculated based on the exchange rate in effect on December 31, 2019.
|
Potential Payments Upon Termination or Change
in Control
The information below describes
relevant employment agreement, severance plan and equity plan provisions for payments upon termination or change in control and
sets forth the amount of compensation that could have been received by each of the NEOs in the event such executive’s employment
had terminated under the various applicable triggering events described below as of December 31, 2019. The benefits discussed
below are in addition to those generally available to all salaried employees, such as distributions under the 401(k) plan, Howden
Group Pension Plan, health care benefits and disability benefits or vested amounts payable under the Nonqualified Plan and Excess
Benefit Plan described above. In addition, these benefits do not take into account any arrangements that we may provide in connection
with an actual separation from service or a change in control. Due to the number of different factors that affect the nature and
amount of any benefits provided in connection with these events, actual amounts payable to any of the NEOs should a separation
from service or change-in-control occur during the year will likely differ, perhaps significantly, from the amounts reported below.
Factors that could affect such amounts include the timing during the year of the event, the Company’s stock price, and the
target amounts payable under annual and long-term incentive arrangements that are in place at the time of the event.
Employment Agreements
Pursuant to the terms of
the employment agreements with each of Messrs. Trerotola, Pryor and Shirley, each executive is entitled to the following severance
payments or benefits in the event his employment is terminated by us without “cause” or the executive resigns for
“good reason,” in the case of Messrs. Trerotola and Pryor, or as a result of a “constructive termination,”
in the case of Mr. Shirley (each as described below):
|
For Mr. Trerotola, the (i) payment
of his base salary then in effect for 24 months following termination, (ii) an amount equal to 200% of his target annual incentive
bonus for the year of termination paid in equal installments over the 24 months following termination, and (iii) COBRA coverage
for 24 months or until he becomes eligible for coverage by another company or is no longer eligible for COBRA;
|
|
For Mr. Pryor, a lump sum payment equal to one
times the executive’s base salary in effect and his target annual incentive compensation for the year of termination
(or, if greater, the average of the two highest actual annual incentive payments made to the executive during the last three
years);
|
|
For each of Messrs. Trerotola and Pryor, a lump
sum payment equal to the executive’s pro rata annual incentive compensation for the year of termination subject to the
performance criteria having been met for that year under the Annual Incentive Plan; and
|
|
For Mr. Shirley, (i) a lump sum payment equal
to one and a half times the sum of the executive’s base salary in effect and his target annual incentive compensation
for the year of termination and (ii) a pro rata portion of the executive’s annual bonus that would have been earned
for the year of termination.
|
In the event Messrs. Trerotola or Pryor terminate
employment without “cause” or for “good reason” within three months prior to a “change in control
event” (as described below), or two years after a “change in control”, each executive is entitled to the following
severance payments or benefits:
|
a lump sum payment equal to two times
the executive’s base salary in effect and his or her target annual incentive compensation for the year of termination
(or, if greater, the average of the two highest actual incentive payments made to the executive during the last three years);
|
|
a lump sum payment equal to the executive’s
pro rata annual incentive compensation for the year of termination subject to the performance criteria having been met for
that year under the Annual Incentive Plan; and
|
|
all equity awards will immediately vest, with
any performance objectives applicable to performance-based equity awards deemed to have been met at the greater of (i) the
target level at the date of termination, and (ii) actual performance at the date of termination.
|
Mr. Shirley’s agreement
does not provide for any additional payments or benefits in the event of a change in control or a termination in connection with
a change in control.
|
- 2020 Proxy Statement
|
47
|
|
|
|
In each case described above,
the executive’s right to the severance payments and benefits is conditioned on the executive’s execution of a waiver
and release agreement in favor of Colfax. In addition, each employment agreement contains standard confidentiality covenants,
non-disparagement covenants, non-competition covenants and non-solicitation covenants.
Under Mr. Trerotola’s
and Mr. Pryor’s agreements, in the event that any payment or benefit to the executives pursuant to the employment agreements
or otherwise constitute excess parachute payments under Section 280G of the Internal Revenue Code such that they would trigger
the excise tax provisions of the Internal Revenue Code, such payments are to be reduced so that the excise tax provisions are
not triggered, but only upon determination that the after-tax value of the termination benefits calculated with the restriction
described above exceed the value of those calculated without such restriction.
Mr. Trerotola’s and
Mr. Pryor’s agreements further provide that, in the event it is determined that the willful actions of the executive have
resulted in a material misstatement or omission in any report or statement filed by Colfax with the SEC, or material fraud against
Colfax, Colfax is entitled to recover all or any portion of any award or payment made to the executive.
For purposes of the employment
agreements, the following terms generally have the following meanings:
|
“cause”
means conviction of a felony or a crime involving moral turpitude, willful commission of any act of theft, fraud,
embezzlement or misappropriation against Colfax or its subsidiaries or willful and continued failure of the executive to
substantially perform his or her duties;
|
|
“change in
control” means:
|
|
–
|
a transaction or series of transactions
pursuant to which any person acquires beneficial ownership of more than 50% of the voting power of the common stock of Colfax
then outstanding;
|
|
–
|
during any two-year consecutive period, individuals
who at the beginning of the period constitute the Board (together with any new directors approved by at least two-thirds of
the directors at the beginning of the period or subsequently approved) cease to constitute a majority of the Board;
|
|
–
|
a merger, sale of all or substantially all of
the assets of Colfax or certain acquisitions of the assets or stock by Colfax of another entity in which there is a change
in control of Colfax; or
|
|
–
|
a liquidation or dissolution of Colfax.
|
|
“change in control
event” means the earlier to occur of a “change in control” or the execution of an agreement by Colfax
providing for a change in control.
|
|
“constructive
termination” means:
|
|
–
|
Colfax’s failure to pay or cause to be paid
the executive’s base salary or annual bonus, if any, when due;
|
|
–
|
a reduction in the executive’s base salary or target annual
bonus;
|
|
–
|
any diminution in the executive’s title or any substantial
and sustained diminution in the executive’s duties;
|
|
–
|
a relocation of the executive’s primary work location more
than 50 miles without the executive’s prior written consent; or
|
|
–
|
Colfax provides notice to the executive that it is electing not
to extend the executive’s employment term.
|
|
“good reason” means:
|
|
–
|
upon or following a change in control, the assignment
to the executive of duties materially inconsistent with his or her position or any alteration of an executive’s duties,
responsibilities and authorities, and then only if such adjustments or assignments are not the result of the conclusion by
a significantly larger successor entity and its board of directors that such executive’s role needs to be altered;
|
|
–
|
the requirement for the executive to relocate his or her principal
place of business at least 35 miles from his or her current place of business;
|
|
–
|
Colfax’s failure to obtain agreement from any successor
to fully assume its obligations to the executive under the terms of the agreement; or
|
|
–
|
any other failure by Colfax to perform its material obligations
under, or breach of Colfax of any material provision of, the employment agreement.
|
Trerotola Pro-Rata Vesting Provisions
In addition, for Mr. Trerotola
his CEO Performance Stock Unit Agreements provide that if he is terminated by the Company without “cause” (and not
on account of disability) or resigns for “good reason” his outstanding performance-based equity awards shall vest
pro-ratably only if the performance objectives are achieved as of the end of the performance period.
Hix Letter Agreement
Mr. Hix is subject
to a letter agreement entered into with the Company upon his hire. Pursuant to that letter agreement, severance in an amount equal
to the sum of his base salary and target bonus is to be provided in the event of a termination without “cause” or
for “good reason”, with severance of two times such amount to be provided in connection with such a termination within
three months prior to or two years after a “change in control”.
|
- 2020 Proxy Statement
|
48
|
|
|
|
Executive Officer Severance Plan
Mr. Kambeyanda is a
participant in our Executive Officer Severance Plan, which provides for severance benefits upon termination without cause or for
good reason for executive officers who are not otherwise contractually entitled to severance compensation pursuant to a separate
agreement with the Company. Severance provided in the event of termination without “cause” or for “good reason”
(each defined as in the form of employment agreement) is a lump sum payment equal to one times the executive’s base salary
in effect and a pro rata payment of his or her target annual incentive compensation for the year of termination. The Executive
Officer Severance Plan does not provide for any additional change in control benefits.
Equity Awards
The vesting of outstanding
equity awards, other than performance-based awards, accelerates in full upon the death or total and permanent disability of the
grantee or, unless assumed or substituted as discussed below, upon a “corporate transaction” (as defined below). The
vesting of the outstanding PRSUs accelerates in full upon the death or total and permanent disability of the grantee only if and
when the performance criteria for such award are achieved as of the end of the performance period upon certification of the same
by the Compensation Committee, or immediately if the performance period has already ended and the Compensation Committee has certified
that the performance criteria have been achieved. The outstanding PRSUs will terminate and cease to vest upon a “corporate
transaction,” unless prior to the corporate transaction the achievement of the performance criteria is certified by the
Compensation Committee, in which case the vesting for the award will accelerate in full unless assumed or substituted as discussed
below. While these benefits are available to all of our equity plan participants equally, pursuant to SEC requirements, we have
included these acceleration benefits in the table below. In addition, in the event of termination of service other than for death,
disability or cause, any stock option awards will remain exercisable to the extent vested for 90 days after termination of service.
A “corporate transaction”
under any outstanding equity awards is generally defined as:
|
the dissolution or liquidation of the Company or
a merger, consolidation, or reorganization of the Company with one or more other entities in which we are not the surviving
entity;
|
|
a sale of substantially all of our assets to another person or
entity; or
|
|
any transaction which results in any person or entity, other
than persons who are stockholders or affiliates immediately prior to the transaction, owning 50% or more of the combined voting
power of all classes of our stock.
|
Accelerated vesting upon
a “corporate transaction” will not occur to the extent that provision is made in writing in connection with the corporate
transaction for the assumption or continuation of the outstanding awards, or for the substitution of such outstanding awards for
similar awards relating to the stock of the successor entity, or a parent or subsidiary of the successor entity, with appropriate
adjustments to the number of shares of stock that would be delivered and the exercise price, grant price or purchase price relating
to any such award. If an award is assumed or substituted in connection with a corporate transaction and the holder is terminated
without cause within a year following a change in control, the award will fully vest and may be exercised in full, to the extent
applicable, beginning on the date of such termination and for the one-year period immediately following such termination or for
such longer period as the compensation committee shall determine.
Estimate of Payments
The following table provides
information related to compensation payable to each NEO assuming termination of such executive’s employment on December
31, 2019, or assuming a change of control or corporate transaction with corresponding qualifying termination occurred on December
31, 2019. Amounts also assume the price of our common stock was $36.38, the closing price on December 31, 2019, the last trading
day of the fiscal year.
|
- 2020 Proxy Statement
|
49
|
|
|
|
Potential Payments Upon Termination or Change
of Control
|
|
Matthew L.
|
|
Christopher
|
|
Daniel A.
|
|
Shyam
|
|
|
Executive
|
|
Trerotola
|
|
M. Hix
|
|
Pryor
|
|
Kambeyanda
|
|
Brady Shirley
|
Employment Agreement/Severance
Plan Benefits:
|
|
|
|
|
|
|
|
|
|
|
Termination without “cause” or “good reason”
(for all NEOs other than Mr. Shirley) or “constructive termination”
(for Mr. Shirley)
|
|
|
|
|
|
|
|
|
|
|
Payment Over 24 Months/18 Months//Lump Sum Payment(1)
|
|
4,846,500
|
|
1,170,000
|
|
1,017,000
|
|
625,000
|
|
2,550,000
|
Pro Rata Incentive Compensation(2)
|
|
1,346,250
|
|
—
|
|
452,000
|
|
440,000
|
|
850,000
|
Termination in connection
with a “change of control”
|
|
|
|
|
|
|
|
|
|
|
Lump Sum Payment
|
|
4,846,500
|
|
2,340,000
|
|
2,034,000
|
|
625,000
|
|
2,550,000
|
Pro Rata Incentive Compensation(2)
|
|
1,346,250
|
|
—
|
|
452,000
|
|
440,000
|
|
850,000
|
Accelerated Stock Options(3)
|
|
7,663,710
|
|
1,273,493
|
|
1,359,900
|
|
818,199
|
|
541,006
|
Accelerated PRSUs(4)
|
|
8,397,814
|
|
3,529,188
|
|
4,120,872
|
|
2,309,257
|
|
2,858,668
|
Accelerated RSUs(4)
|
|
—
|
|
1,287,852
|
|
—
|
|
1,362,649
|
|
714,649
|
NQDC Plans/Pension(5)
|
|
889,527
|
|
254,978
|
|
935,670
|
|
353,327
|
|
62,637
|
(1)
|
For
Messrs. Trerotola and Shirley, the amount is paid over the 24 months and 18 months, respectively, following termination. For
the other NEOs, the amount is paid as a lump sum.
|
(2)
|
Assumes
achievement at target.
|
(3)
|
In
addition to accelerated vesting pursuant to Messrs. Trerotola’s and Pryor’s employment agreements, stock options
accelerate upon death, total and permanent disability, and, unless assumed or substituted as discussed above, upon a “corporate
transaction” as defined above.
|
(4)
|
Under
Messrs. Trerotola’s and Pryor’s employment agreements, in the event of a termination in connection with a change
in control, the performance objectives applicable to PRSUs will be deemed to have been met at the greater of (i) the target
level at the date of termination, and (ii) actual performance at the date of termination. In addition to accelerated vesting
pursuant to the employment agreements, RSUs, and PRSUs for which the performance criteria have been certified as achieved,
accelerate upon death, total and permanent disability and, unless assumed or substituted as discussed above, upon a “corporate
transaction” as defined above.
|
(5)
|
Amounts
represent the aggregate balance of the NEO’s Excess Benefit Plan or Non-Qualified Deferred Compensation account as of
December 31, 2019. For more details on these plans, see “Nonqualified Deferred Compensation” above.
|
Payments Made to Mr.
Brander
As a result of the sale
of our Air & Gas Handling business, Mr. Brander’s employment with Colfax terminated at the close of the transaction
in September 2019. In light of the execution and effort with respect to the sale of our Air & Gas Handling business,
Mr. Brander received a bonus for 2019 of $3,152,585, which is reflected in the “Bonus” column of the Summary Compensation
Table above on page 40. The bonus consisted of a retention bonus pursuant to his amended employment agreement, with the remaining
amount based upon the performance of the Air & Gas Handling business and his performance through the closing of the transaction.
This bonus was paid in lieu of a bonus under our AIP for 2019. Mr. Brander’s outstanding unvested stock options and PRSUs
were forfeited in connection with the sale of our Air & Gas Handling business.
|
- 2020 Proxy Statement
|
50
|
|
|
|
|
CEO PAY RATIO DISCLOSURE
|
As required by Section 953(b)
of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u) of Regulation S-K, we are providing the following
information about the relationship of the annual total compensation of our median compensated associate and the annual total compensation
of Mr. Trerotola, our President & Chief Executive Officer. The pay ratio included in this section is a reasonable
estimate calculated in a matter consistent with Item 402(u) of Regulation S-K.
For 2019:
|
The annual total compensation of the median compensated of all of our employees (other than our CEO) was $23,146; and
|
|
The annual total compensation of Mr. Trerotola, as presented in the Summary Compensation Table, was $8,430,026.
|
Based on this information, for 2019 the ratio of the annual total compensation of Mr. Trerotola, our Chief Executive Officer, to the annual total compensation of our median compensated employee was 364 to one.
|
The SEC’s rules for
identifying the median compensated employee and calculating the pay ratio based on that employee’s annual total compensation
allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions
that reflect their employee populations and compensation practices. As a result, the pay ratio reported by other companies may
not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices
and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.
To identify our median-compensated
employee, as well as to determine the annual total compensation of this “median employee”:
|
We determined that, as of December 31, 2019, our employee population consisted of approximately 14,202 persons, of whom approximately 2,794 were employed in the United States and approximately 11,408 were employed outside the United States, based on our payroll records;
|
|
We selected December 31, 2019 as the date upon which we would identify the “median employee”;
|
|
We annualized the compensation of associates employed by us for less than a full fiscal year;
|
|
Based on payroll data for all employees aside from those noted as excluded above, we used annualized base salary or base pay rate to identify our median employee, who was a full-time, hourly associate in Mexico; and
|
|
Once the median employee was identified, we calculated the elements of this employee’s compensation for 2019 in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-X, resulting in annual total compensation of $23,146 based on the exchange rate in effect as of December 31, 2019.
|
|
- 2020 Proxy Statement
|
51
|
|
|
|
Proposal 3
|
Approval of Named Executive Officers’ Compensation, on a Non-Binding Advisory Basis (“Say-on-Pay”)
|
We are asking our stockholders
to cast an advisory vote at our Annual Meeting to approve the compensation of our named executive officers, as disclosed in this
Proxy Statement. Pursuant to Section 14A of the Exchange Act, we are asking that you vote on the following advisory resolution:
RESOLVED,
that the 2019 compensation paid to the Company’s named executive officers, as disclosed pursuant to the rules of the SEC,
including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.
Though the vote is non-binding,
the Compensation Committee and the Board of Directors value your opinion and will consider the outcome of the vote in establishing
our compensation philosophy and making future compensation decisions. At this time, we intend to seek stockholder approval of our
executive compensation program on an annual basis.
Why You Should Approve Our Executive Compensation
Program
As discussed in our Compensation
Discussion and Analysis, we believe our compensation programs and practices are appropriate and effective in implementing our compensation
philosophy, and our focus remains on linking compensation to performance while aligning the interests of management with those
of our stockholders.
Vote Required
The affirmative vote of the
holders of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote is required
to approve the advisory vote approving the compensation of our named executive officers.
Board Recommendation
The
Board unanimously recommends that you vote FOR Proposal
3, which is advisory approval of Colfax’s named executive compensation as disclosed in this Proxy Statement. We strongly
urge stockholders to review our entire Compensation Discussion and Analysis and the accompanying tables, which provides complete
information on the compensation awarded to the named executive officers and the reasoning supporting those awards.
|
|
- 2020 Proxy Statement
|
52
|
|
|
|
Proposal 4
|
Approval of Colfax Corporation 2020 Omnibus Incentive Plan
|
On April 3, 2020, the Board
of Directors, upon recommendation of the Compensation Committee, approved the adoption of the Colfax Corporation 2020 Omnibus Incentive
Plan (the “2020 Plan” or the “Plan”) subject to approval by the Company’s stockholders at the Annual
Meeting. We are asking stockholders to consider and vote upon a proposal to approve the 2020 Plan. Upon approval of the 2020 Plan,
awards will no longer be made under our existing Colfax Corporation 2016 Omnibus Incentive Plan (the “2016 Plan”),
and the 2020 Plan will become the primary plan used for equity grants to employees, officers and directors of the Company and its
affiliates going forward. If the 2020 Plan is not approved by the Company’s stockholders, the 2016 Plan will continue to
operate in accordance with its terms.
The Board recommends that
you vote for approval of the 2020 Plan in order to allow the Company to continue our equity-based, pay-for-performance compensation
philosophy. The number of shares of common stock that remain available for issuance under the 2016 Plan is insufficient to satisfy
our equity compensation needs for 2020 and beyond. Equity compensation aligns the compensation of our non-employee directors and
employees with the investment interests of our stockholders and promotes a focus on long-term value creation. As of February 28,
2020, approximately 225 of our regular, full-time employees held outstanding equity awards.
The affirmative vote of a
majority of our shares of common stock present, in person or represented by proxy, and entitled to vote at the Annual Meeting is
required to approve the 2020 Plan. Our executive officers and non-employee directors have an interest in this proposal by virtue
of their being eligible to receive equity awards under the 2020 Plan.
The material features and
provisions of the 2020 Plan are summarized below. The full text of the 2020 Plan is attached as Appendix A to this Proxy Statement.
The following description is not complete and is qualified in its entirety by reference to that exhibit.
Highlights of the 2020 Plan
The 2020 Plan authorizes
the Compensation Committee to provide equity-based compensation in the form of stock options, stock appreciation rights, restricted
stock, restricted stock units, performance-based stock, performance-based stock units, dividend equivalents, and unrestricted stock
awards for the purpose of providing our non-employee directors, officers and other employees (and those of our subsidiaries and
affiliates) with incentives and rewards for performance.
We believe our future success
depends in part on our ability to attract, motivate and retain high quality employees and non-employee directors and that the ability
to provide equity-based and incentive-based awards under the 2020 Plan is critical to achieving this success. We would be at a
competitive disadvantage if we could no longer use share-based awards to recruit and compensate our non-employee directors, officers
and other employees.
Some of the key features
of the 2020 Plan that reflect our commitment to effective management of equity and incentive compensation and our maintenance of
sound governance practices in granting awards include:
Performance-Based Awards
The 2020 Plan provides that
the payment of dividend equivalents with respect to performance-based awards will accumulate, be deferred and only paid contingent
upon the level of achievement of the applicable management performance goals.
Clawback
All amounts paid to a grantee
under the 2020 Plan are subject to recovery under any law, governmental regulation, stock exchange listing requirement or any policy
adopted by the Company and may be deducted or clawed back in accordance with such law, regulation or policy.
Minimum Vesting Period
The 2020 Plan requires that
nearly all awards granted under it be subject to a one-year minimum vesting period.
|
- 2020 Proxy Statement
|
53
|
|
|
|
Limitation on Awards to Outside Directors
The aggregate equity-based
and cash compensation granted under the Plan or otherwise to Outside Directors during any calendar year will not exceed $350,000,
except in the instance of a newly-elected or appointed director or a newly-designated lead director or chair, which limit is then
increased to $700,000.
No Discounted Options or Stock Appreciation Rights
The 2020 Plan prohibits the
grant of options or stock appreciation rights with an exercise price less than the fair market value of our shares of common stock
on the grant date.
No Repricing of Options or Stock Appreciation
Rights
The 2020 Plan prohibits the
repricing of options or stock appreciation rights (outside of certain corporate transactions or adjustment events described in
the 2020 Plan) without stockholder approval.
Independent Committee Administration
Awards to our named executive
officers under the 2020 Plan will be granted by a committee composed entirely of independent directors.
Term of the 2020 Plan
No awards may be granted
under the 2020 Plan more than ten years from the date of initial stockholder approval of the Plan.
Summary of Material Terms of the 2020 Plan
Shares of Common Stock Available
Subject to adjustment as
provided in the 2020 Plan and the approval of this Proposal 4 by stockholders at the Annual Meeting, the number of shares of common
stock that may be issued or transferred:
|
upon the exercise of options or stock appreciation rights;
|
|
as restricted shares released from substantial risks of forfeiture;
|
|
in payment of performance shares or performance units that have been earned;
|
|
in payment for restricted stock units;
|
|
in payment for other share-based awards; or
|
|
in payment of dividend equivalents paid with respect to awards made under the 2020 Plan
|
will not exceed, in the aggregate,
4,430,000 shares. Such shares may be shares of original issuance or treasury shares or a combination of both.
The share reserve under the
2020 Plan will be reduced on a one-for-one basis for shares covered by an award. Canceled, terminated, expired, forfeited or lapsed
Awards (in whole or in part) shall be added back to the aggregate number of shares of stock reserved and available for issuance
pursuant to awards granted under the Plan (“Total Available Shares”). Any stock-related award that is settled in cash
or other consideration shall be added back to the Total Available Shares reserve and available again for issuance. Shares of stock
withheld or deducted from an award by the Company to satisfy tax withholding requirements relating to options or stock appreciation
rights shall not be added back to the Total Available Shares reserve, but shares of stock withheld or deducted by the Company to
satisfy tax withholding requirements relating to full value awards shall be added back to the Total Available Shares reserve and
available again for issuance pursuant to awards granted under the Plan. Performance awards (other than an option or stock appreciation
right) where performance criteria were not met shall be added back to the Total Available Shares reserve and shall be available
again for issuance pursuant to awards granted under the 2020 Plan. Substitute awards granted will not count against the Total Available
Share reserve.
If the full number of shares
of stock subject to an option or a stock-settled stock appreciation right is not issued upon exercise of such option or stock appreciation
right for any reason, including by reason of a net settlement or net exercise, all such shares
|
- 2020 Proxy Statement
|
54
|
|
|
|
of stock that were covered
by the exercised option or stock appreciation right shall not be added back to the Total Available Shares reserve. If the exercise
price of an option is satisfied by the grantee delivering shares of stock to the Company (by either actual delivery or attestation),
such shares of stock shall not be added to the Total Available Shares reserve. Shares of stock repurchased on the open market with
the proceeds of an option exercise shall not be added to the Total Available Shares reserve. Any dividend equivalent denominated
in shares of stock shall be counted against the Total Available Shares in such amount and at such time as the dividend equivalent
first constitutes a commitment to issue shares of stock.
Limit on Awards
The following limits apply
to awards under the 2020 Plan (subject to limited permitted adjustments under the 2020 Plan):
|
With respect to Outside Directors, the aggregate equity-based and cash compensation granted (measured as of the grant date) under the Plan or otherwise to each Outside Director during any calendar year will not exceed $350,000, except in the instance of a newly-elected or appointed director or a newly-designated lead director or chair, which limit is then increased to $700,000.
|
|
The maximum number of shares of common stock that may be issued upon exercise of incentive stock options granted under the 2020 Plan is 4,430,000.
|
|
The maximum number of shares of common stock underlying awards to any grantee in any fiscal years is 1,000,000.
|
Minimum Vesting Requirement
The Compensation Committee
will not award more than 5% of the aggregate number of shares of common stock that become available for grant under the 2020 Plan
pursuant to awards that are solely subject to a vesting or performance condition that provides for full vesting or completion of
the performance period in less than one year following the grant date of the applicable award, subject to the authority of the
Compensation Committee to vest awards earlier, as the Committee deems appropriate, in the event of a Change in Control (as defined),
in the event of termination of employment or service or as otherwise permitted by the Plan.
Eligibility
Our officers and employees,
and those of our subsidiaries and affiliates (in total, approximately 317 people) and our non-employee directors (currently 8 people)
may be selected by the Board or Compensation Committee to receive benefits under the 2020 Plan. These individuals are referred
to as “Service Providers” in the 2020 Plan, and as participants or grantees in this summary description.
Administration
The Board has delegated to
the Compensation Committee the power and authority to administer and implement the Plan. The Compensation Committee has the authority
to interpret the terms and intent of the 2020 Plan, determine eligibility and terms of awards for participants and make all other
determinations necessary or advisable for the administration of the 2020 Plan. To the extent permitted by law, the Board or Compensation
Committee may delegate authority under the 2020 Plan to a member of the Board or officer of the Company, who may administer the
plan with respect to employees or other service providers of the Company who are not officers or directors.
Amendment or Suspension
The Board may amend, suspend
or terminate the 2020 Plan at any time with respect to any shares of common stock as to which awards have not been made. No such
action may amend the 2020 Plan without the approval of stockholders if the amendment is required to be submitted for stockholder
approval by applicable law, rule or regulation, including rules of the NYSE.
Effective Date and Term
The 2020 Plan will be effective
as of the date of stockholder approval and will expire on May 21, 2030 unless earlier terminated by our Board. In no event will
any award under the 2020 Plan be granted on or after the tenth anniversary of its effective date, and no award of incentive stock
options will be granted on or after April 3, 2030.
|
- 2020 Proxy Statement
|
55
|
|
|
|
Options
An option granted under the
Plan is the option to purchase one or more shares of common stock pursuant to the Plan. An option granted under the 2020 Plan will
be exercisable only to the extent that it is vested on the date of exercise. Exercisability of options may be subject to future
service requirements, to the achievement of one or more of the performance objectives of the Company or to such other terms and
conditions as the Compensation Committee, in its sole discretion, may impose. No option may be exercisable more than ten years
from the option grant date, and subject to limited exceptions, shall be subject to the minimum vesting requirement. The exercise
price per share under each option granted under the 2020 Plan may not be less than 100%, or 110% in the case of an incentive stock
option granted to a 10% stockholder, of the fair market value of the common stock on the option grant date. Payment of the option
price for shares purchased pursuant to the exercise of an option may be made in cash or in cash equivalents acceptable to us or
any other method permitted by law and approved by Compensation Committee. Promptly after payment , the grantee is entitled to issuance
of the shares of stock subject to the option. The 2020 Plan does not permit reloading of options and, except in connection with
recapitalization events, prohibits repricings without stockholder approval.
In the case of incentive
stock options, the aggregate fair market value of the common stock determined on the option grant date with respect to which such
options are exercisable for the first time during any calendar year may not exceed $100,000. Incentive stock options are non-transferable
during the optionee’s lifetime. Awards of non-qualified stock options are generally non-transferable, except for transfers
by will or the laws of descent and distribution. The Compensation Committee may, in its discretion, authorize in an Award Agreement
that an award of options, other than Incentive stock options, also may be transferred to family members by gift or other transfers
deemed not to be for value.
Stock Appreciation Rights (SAR)
A SAR confers on the grantee
the right to receive, upon exercise, the excess of the (a) fair market value of one share of stock on the date of exercise over
(b) the SAR exercise price determined by the Committee. The award agreement shall specify the exercise price, which shall be at
last the fair market value on the date of grant. SARs may be granted in tandem with another award. The Board or Committee shall
determine all other terms and requirements relating to the SAR, including method of exercise and settlement. SARs are subject to
the minimum vesting requirement, shall have a term of not more than ten years from the date of grant, and may be transferable to
a family member if specified in the award agreement.
Restricted Stock and Restricted Stock Units
Restricted stock means one
or more shares of common stock awarded subject to restrictions, and restricted stock units means a bookkeeping entry representing
the equivalent of one share of common stock awarded subject to restrictions. The restriction may be a period of time or other and
additional restrictions, and the restricted stock or stock unit may not be transferred, pledged or encumbered during the restricted
period or while subject to restrictions. Restricted stock units may be settled in stock, cash, or a combination of both, as determined
by the Compensation Committee. Unless otherwise specified in the award agreement, the holder of restricted stock shall have the
right to vote and to receive dividends, and the holder of a stock unit shall not. Restricted stock and restricted stock units are
subject to the minimum vesting requirements.
Dividend Equivalent Rights
A dividend equivalent rights
is an award entitling the grantee to receive credits based on cash distribution that would have been paid on the shares of common
stock specified in the dividend equivalent right (or such other award to which is relates). The Compensation Committee is authorized
to grant dividend equivalents to a participant in connection with an award under the 2020 Plan (other than options or SARs), or
without regard to any other award. Dividend equivalents will entitle the participant to receive cash or common stock equal in value
to dividends paid, or other periodic payments made, with respect to a specified number of shares of common stock. Dividend equivalents
may be paid or distributed when accrued or at the end of any applicable vesting period, or will be deemed to have been reinvested
in additional common stock or in awards under the 2020 Plan, and will be subject to such risks of forfeiture as the Compensation
Committee may specify. Dividend equivalent rights paid on awards subject to performance criteria will not vest unless such performance
goals for such awards are achieved, and if such performance goals are not achieved, the payments made in connection with the dividend
equivalent rights will be repaid to the Company. Grants of dividend equivalent rights are subject to the minimum vesting requirements.
|
- 2020 Proxy Statement
|
56
|
|
|
|
Performance Units and Performance Shares
A performance share means
a performance award denominated in shares of common stock, the value of which is determined as a function of the extent to which
corresponding performance criteria have been achieved. Performance units means a performance award denominated in a stock unit,
the value of which is determined as a function of the extent to which corresponding performance criteria have been achieved. The
Compensation Committee may award performance shares and performance units in such amounts and upon such terms as the Compensation
Committee may determine. Each performance share will have an initial value that is equal to the fair market value of a share of
common stock on the date of grant. Each award of performance units or performance shares will have an actual or target number of
shares of common stock set by the Compensation Committee. The Compensation Committee may set performance goals in its discretion
which, depending on the extent to which they are met, will determine the value or number of performance units or performance shares
that will be paid out to a participant. The Compensation Committee may, in its sole discretion, pay earned performance units or
performance shares in the form of cash or in shares of common stock (or a combination of both) equal to the value of the earned
performance units or performance shares. Any shares of common stock issued based upon performance units or performance shares may
be granted subject to any restrictions that the Compensation Committee deems appropriate. The Committee may provide for payment
of dividends or dividend equivalents to the grantee in cash or additional shares, subject in all cases to deferral and payment
on a contingent basis based on earning of the performance shares or units with respect to which the dividends or dividend equivalents
are paid. Performance shares and performance units are subject to minimum vesting requirements.
Unrestricted Stock
The Compensation Committee
may award unrestricted stock, free of any restrictions such as vesting requirements, in such amounts and upon such terms as the
Compensation Committee may determine.
Share Usage
We are committed to sound
equity compensation practices because we recognize that equity compensation awards dilute stockholder equity. Our equity compensation
practices are intended to be competitive and consistent with market practices, and we believe our historical share usage has been
responsible and mindful of stockholder interests.
Set forth below is information
regarding shares currently outstanding under the 2016 Plan and prior plans. The Company made its annual award grant to employees
in February 2020 and those awards are included in the data below.
Selected Data as of February
28, 2020:
Stock options outstanding
|
4,903,894
|
Weighted average exercise price
|
$34.89
|
Weighted average remaining contractual life
|
4.2 years
|
Restricted stock units outstanding (unvested)
|
865,616
|
Performance-based restricted stock units outstanding (unvested)
|
1,547,995
|
Shares remaining for grant under the 2016 Plan1
|
621,523
|
(1)
|
Any
remaining shares under the 2016 Plan will not be available for grant after the effective date of the 2020 Plan, if approved.
|
For purposes of evaluating
our equity compensation program, stockholders may wish to consider two metrics: historical burn rate and overhang.
|
Historical burn rate: Our historical burn rate is equal to the number of shares subject to equity awards granted during a period, in proportion to our outstanding shares. Our burn rate was 1.33% for 2017, 1.53% for 2018 and 1.73% for 2019, and our three-year average burn rate for 2017 through 2019 was 1.53%.
|
|
Overhang: Our overhang is the number of shares subject to unvested equity awards outstanding as of February 28, 2020 plus the number of shares available for future grants of equity awards in proportion to our shares outstanding as of that date. As of February 28, 2020, our overhang was 2.9%.
|
The 2016 Plan used a fungible
share pool, under which the number of shares available reduced at varying rates based upon the type of award given. The 2020 Plan
will not be a fungible plan and will not use a fungible share pool.
More detail regarding the
overhang and dilution associated with the current 2016 Plan, the 2020 Plan as proposed, and our prior plans is below. The information
is as of February 28, 2020. As of that date, there were 118,286,673 shares of our common stock outstanding. We replaced all prior
plans with the 2016 Plan at the 2016 Annual Meeting. No additional awards will be made under those prior plans, and therefore the
table below reflects that no shares are available for future issuance under those plans. Assuming approval by the stockholders
at the Annual Meeting, all remaining shares available for issuance under the 2016 Plan will be cancelled, and the 2020 Plan will
be the sole equity compensation plan under which future awards can be made.
|
- 2020 Proxy Statement
|
57
|
|
|
|
Outstanding full-value awards assuming that the outstanding awards achieve maximum performance under the 2016 Plan and prior plans
|
|
2,413,611
shares or 2.04% of our outstanding
shares
|
Number of shares subject to outstanding stock options under the 2016 and prior plans
|
|
4,903,894 shares
or 4.15% of our outstanding
shares
|
Weighted average exercise price of outstanding options under the 2016 Plan and prior plans
|
|
$34.89
|
Weighted average remaining term of outstanding options under the 2016 plan and prior plans
|
|
4.2 years
|
Total shares subject to outstanding awards under the 2016 Plan and prior plans
|
|
7,317,505 shares
or 6.19% of our outstanding
shares
|
Total shares available for future awards under the 2016 Plan
|
|
621,523
|
Current overhang percentage based on total number of shares subject to outstanding awards under the 2016 plan and prior plans
|
|
2.9%
|
New shares being authorized under the 2020 Plan
|
|
4,430,000
|
Potential dilution (including 4,430,000 additional shares and canceling all remaining available 2016 plan shares) as a percentage of outstanding shares
|
|
9.93%
|
Total potential fully-diluted overhang under the prior plans, the 2016 Plan and the 2020 Plan
|
|
6.7%
|
Based on the closing price
on the NYSE for our shares of common stock on February 28, 2020 of $33.47 per share, the aggregate market value as of that date
of the 4,430,000 shares of common stock requested for issuance under the 2020 Plan is $148,272,100.
If the 2020 Plan is approved,
the Company’s total potential dilution from the shares available for issuance under the 2020 Plan and the 2016 Plan would
increase from 6.19% as of February 28, 2020 to 9.93%. The Compensation Committee has considered this potential dilution level and
believes that the resulting dilution levels would be within normal competitive ranges.
In determining the number
of shares to request for approval by our stockholders under the 2020 Plan, our management team worked with advisors and the Compensation
Committee to evaluate a number of factors including our recent share usage and criteria expected to be utilized by institutional
proxy advisory firms in evaluating this proposal. We are also mindful of the ratio of our stock-based compensation to our performance
over time. In addition, the Compensation Committee also reviewed, among other things, projected future share usage and projected
future forfeitures. Subject to assumptions, the Committee currently anticipates that the proposed 4,430,000 shares of common stock
under the 2020 Plan are expected to satisfy the Company’s equity compensation needs for approximately 3 years.
If the 2020 Plan is approved,
we intend to utilize the shares authorized under the 2020 Plan to continue our practice of incentivizing key individuals through
annual equity grants. Our Compensation Committee retains full discretion under the 2020 Plan to determine the number and amount
of awards to be granted under the 2020 Plan, subject to the terms of the 2020 Plan, and future benefits that may be received by
participants under the 2020 Plan are not determinable at this time.
Adjustment of Shares Subject to 2020 Plan
In the event of an equity
restructuring, including any stock dividend, stock split, spin-off, rights offering, or large nonrecurring cash dividend, the authorization
limits regarding the number of shares under this plan, the maximum number of shares of stock that may be issued under Incentive
Stock Options and the Maximum amount of stock issued under Awards shall be adjusted proportionately, and the Committee shall make
such adjustments to the Plan and the outstanding awards as it deems necessary and appropriate, in its sole discretion, to prevent
dilution or enlargement of benefits or potential benefits. In addition, upon the occurrence or in anticipation of a share combination,
merger, consolidate or other corporate transaction, including those in which adjustments are mandatory, the Committee may, in its
sole discretion, vest, equitably convert, substitute or otherwise settle outstanding awards.
Change in Control
Under the 2020 Plan, a “Change
in Control” generally means the occurrence of any of the following events: (1) acquisition of beneficial ownership of more
than 50% of (A) the then outstanding shares of common stock of the Company or (B) the combined voting power of the outstanding
voting securities entitled to vote in director elections; (2) individuals constituting the Board as of the date of the Plan ceasing
to continue to constitute at least a majority of the Board, unless election or nomination of such director was approved by a vote
of at least a majority of the directors constituting the incumbent board; (3) the closing of a reorganization, merger or consolidation
or sale of all or substantially all of the assets of the Company or (4) stockholder approval of a Business Combination, and (5)
approval by the stockholders of the Company of a complete liquidation of dissolution of the Company. The Compensation Committee
may specify in an award agreement the treatment of that award in the event of a Change in Control.
|
- 2020 Proxy Statement
|
58
|
|
|
|
Federal Income Tax Consequences
The following summarizes
the federal income tax consequences of awards that may be granted under the 2020 Plan.
Incentive Stock Options
An option holder will not
realize taxable income upon the grant of an incentive stock option under the 2020 Plan. In addition, an option holder generally
will not realize taxable income upon the exercise of an incentive stock option. An option holder’s alternative minimum taxable
income, however, will be increased by the amount by which the aggregate fair market value of the shares underlying the option,
which is generally determined as of the date of exercise, exceeds the aggregate exercise price of the option. Further, except in
the case of an option holder’s death or disability, if an option is exercised more than three months after the option holder’s
termination of employment, the option will cease to be treated as an incentive stock option and will be subject to taxation under
the rules applicable to non-qualified stock options, as summarized below.
If an option holder sells
the option shares acquired upon exercise of an incentive stock option, the tax consequences of the disposition will depend upon
whether the disposition is “qualifying” or “disqualifying.” The disposition of the option shares will be
a qualifying deposition if it is made at least two years after the date on which the incentive stock option was granted and at
least one year after the date on which the incentive stock option was exercised. If the disposition of the option shares is qualifying,
any excess of the sale price of the option shares over the exercise price of the option will be treated as long-term capital gain
taxable to the option holder at the time of the sale. If the disposition is a disqualifying disposition, the excess of the fair
market value of the option shares on the date of disposition over the exercise price will be taxable income to the option holder
at the time of the disposition. Of that income, the amount up to the excess of the fair market value of the shares at the time
the option was exercised over the exercise price will be ordinary income for income tax purposes and the balance, if any, will
be long-term or short-term capital gain, depending upon whether or not the shares were sold more than one year after the option
was exercised.
Unless an option holder engages
in a disqualifying disposition, the Company will not be entitled to a deduction with respect to an incentive stock option. If an
option holder engages in a disqualifying disposition, the Company will be entitled to a deduction equal to the amount of compensation
income taxable to the option holder.
If an option holder pays
the exercise price of an incentive stock option by tendering shares with a fair market value equal to part or all of the exercise
price, the exchange of shares will be treated as a nontaxable exchange, except that this treatment will not apply if the option
holder acquired the shares being tendered pursuant to the exercise of an incentive stock option and has not satisfied the special
holding period requirements summarized above. The tax basis of the shares tendered to pay the exercise price will be treated as
the substituted tax basis for an equivalent number of shares received, and the new shares will be treated as having been held for
the same holding period as the holding period that expired with respect to the tendered shares.
Non-Qualified Stock Options
An option holder will not
realize taxable income upon the grant of a non-qualified stock option. When an option holder exercises the option, however, the
difference between the exercise price of the option and the fair market value of the shares subject to the option on the date of
exercise will constitute compensation income taxable to the option holder. The Company will, subject to any applicable limitations
under Code Section 162(m), generally be entitled to a deduction equal to the amount of compensation income taxable to the option
holder if the Company complies with applicable reporting requirements.
If an option holder tenders
shares in payment of part or all of the exercise price of a non-qualified stock option, no gain or loss will be recognized with
respect to the shares tendered, even if the shares were acquired pursuant to the exercise of an incentive stock option. In such
an event, the option holder will be treated as receiving an equivalent number of shares pursuant to the exercise of the option
in a nontaxable exchange. The tax basis of the shares tendered will be treated as the substituted tax basis for an equivalent number
of shares received, and the shares received will be treated as having been held for the same holding period as the holding period
that expired with respect to the tendered shares. The difference between the aggregate exercise price and the aggregate fair market
value of the shares received pursuant to the exercise of the option will be taxed as ordinary income, just as if the option holder
had paid the exercise price in cash.
|
- 2020 Proxy Statement
|
59
|
|
|
|
Restricted Stock
A grantee of restricted stock
will not recognize any taxable income for federal income tax purposes in the year of the award if the common stock is subject to
restrictions (that is, the restricted stock is nontransferable and subject to a substantial risk of forfeiture). The grantee, however,
may elect under Section 83(b) of the Internal Revenue Code to recognize compensation income in the year of the award in an amount
equal to the fair market value of the shares on the date of the award, determined without regard to the restrictions. If the grantee
does not make such a Section 83(b) election, the fair market value of the shares on the date on which the restrictions lapse will
be treated as compensation income to the grantee and will be taxable in the year in which the restrictions lapse. The Company,
subject to any applicable limitations under Code Section 162(m), generally will be entitled to a deduction for compensation paid
equal to the amount treated as compensation income to the grantee in the year in which the grantee is taxed on the income.
Dividend Equivalents Rights
Grantees under the 2020 Plan
who receive awards of dividend equivalent rights will be required to recognize ordinary income in the amount distributed to the
grantee pursuant to the award. If the Company complies with applicable reporting requirements of the Internal Revenue Code, it
will, subject to any applicable limitations under Code Section 162(m), generally be entitled to a business expense deduction in
the same amount and generally at the same time as the grantee recognizes ordinary income.
Restricted Stock Units and Performance Awards
A distribution of common
stock or a payment of cash in satisfaction of stock units or performance awards will be taxable as ordinary income when the distribution
or payment is actually or constructively received by the recipient. The amount taxable as ordinary income is the aggregate fair
market value of the common stock determined as of the date it is received or the amount of the cash payment. The Company will,
subject to any applicable limitations under Code Section 162(m), generally be entitled to deduct the amount of such payments when
such payments are taxable as compensation to the recipient if the Company complies with applicable reporting requirements.
Stock Appreciation Rights
The grant of SARs will not
result in taxable income to the participant or a deduction to the Company. Upon exercise of a SAR, the holder will recognize ordinary
income in an amount equal to the cash or the fair market value of the common stock received by the holder. The Company will, subject
to any applicable limitations under Code Section 162(m), generally be entitled to a deduction equal to the amount of any compensation
income taxable to the grantee, and, as to SARs that are settled in shares of common stock, if the Company complies with applicable
reporting requirements.
Unrestricted Stock
A holder of shares of unrestricted
stock will be required to recognize ordinary income in an amount equal to the fair market value of the shares on the date of the
award, reduced by the amount, if any, paid for such shares. The Company will, subject to any applicable limitations under Code
Section 162(m), generally be entitled to deduct the amount of any compensation income taxable to the grantee if it complies with
applicable reporting requirements.
Upon the holder’s disposition
of shares of unrestricted stock, any gain realized in excess of the amount reported as ordinary income will be reportable by the
holder as a capital gain, and any loss will be reportable as a capital loss. Capital gain or loss will be long-term if the holder
has held the shares for more than one year. Otherwise, the capital gain or loss will be short-term.
Tax Withholding
Payment of the taxes imposed
on awards made under the 2020 Plan may be made by withholding from payments otherwise due and owing to the holder. Subject to the
prior approval of the Company, the holder may elect to satisfy such obligations: (1) by causing the Company to withhold shares
of common stock otherwise issuable or (2) by delivering to the Company shares of common stock already owned by the holder. The
maximum number of shares of common stock that may be withheld from any award to satisfy any applicable withholding requirements
cannot exceed such number of shares having a fair market value equal to the statutory amount required by the Company to be withheld
and paid with respect to such award.
|
- 2020 Proxy Statement
|
60
|
|
|
|
Performance Objectives
Section 162(m) of the Internal
Revenue Code limits public companies to an annual deduction for federal income tax purposes of $1,000,000 for compensation paid
to their chief executive officer, chief financial officer, the three most highly compensated executive officers determined at the
end of each year and certain other covered employees who previously fell into any of these categories. Prior to the Tax Cuts and
Jobs Act of 2017 (“TCJA”) changes to Section 162(m), performance-based compensation was excluded from such $1,000,000
deduction limitation. The pre-TCJA deductibility for performance-based compensation will not apply to the 2020 Plan.
Any performance award granted
under the 2020 Plan shall be earned, vested and payable (as applicable) upon the attainment of performance goals established by
the Compensation Committee based upon one or more performance criteria, together with the satisfaction of any other conditions,
such as continued service, as the Compensation Committee may determine to be appropriate on an absolute or relative basis, subject
to the change in control provisions of the 2020 Plan. Performance goals for performance awards may be based on one or more of,
but not limited to, the following business criteria: net earnings or net income; operating earnings; pretax earnings; pre-tax earnings
per share; earnings per share; share price, including growth measures and total stockholder return; earnings before interest and
taxes; earnings before interest, taxes, depreciation and/or amortization; earnings before interest, taxes, depreciation and/or
amortization as adjusted to exclude any one or more of the following: stock-based compensation expense; income from discontinued
operations; gain on cancellation of debt; debt extinguishment and related costs; restructuring, separation and/or integration charges
and costs; reorganization and/or recapitalization charges and costs; impairment charges; gain or loss related to investments; sales
and use tax settlement; and gain on non-monetary transaction; sales or revenue growth, whether in general, by type of product or
service, or by type of customer; gross or operating margins; return measures, including total stockholder return, return on assets,
capital, investment, equity, sales or revenue; cash flow, including: operating cash flow; free cash flow, defined as earnings before
interest, taxes, depreciation and/or amortization (as adjusted to exclude any one or more of the items that may be excluded pursuant
to earnings before interest, taxes, depreciation and/or amortization above) less capital expenditures; cash flow return on equity;
and cash flow return on investment; productivity ratios; expense targets; market share; working capital targets; completion of
acquisitions of businesses or companies (including metrics resulting from the same such as revenue or margin); completion of divestitures
and asset sales; debt repayment targets, and debt/equity ratios; bookings or completion of orders (including metrics resulting
from the same such as revenue or margin); project bookings, milestones or completion (including metrics related to the same such
as revenue or margin); and any combination of the foregoing business criteria.
The business criteria may
be used to measure the performance of our company, any subsidiary or affiliate of our Company as a whole or any business unit of
our Company, any subsidiary or affiliate of our Company or any combination thereof, as the Compensation Committee deems appropriate.
The Compensation Committee also may compare the performance measures listed above against the performance of a group of comparative
companies, or a published or special index that the Compensation Committee, in its sole discretion, deems appropriate. We may use
the share price performance measure as compared to various stock market indices. The Compensation Committee also has the authority
to provide for accelerated vesting of any award based on the achievement of performance goals pursuant to the performance measures
listed above. The amounts payable for achievement shall be defined by the applicable award agreement and may be different between
grantees, as determined by the Committee.
New Plan Benefits
No awards under the 2020
Plan have been granted or will be granted unless and until the 2020 Plan is approved by the Company’s stockholders at the
Annual Meeting. If approved, grants of awards under the 2020 Plan will be in the discretion of the Compensation Committee and any
other committee authorized to grant awards under the 2020 Plan. Accordingly, it is not possible as of the date of this Proxy Statement
to determine the nature or amount of any awards under the 2020 Plan that may be subject to future grants to employees, officers
and directors of the Company and its subsidiaries or affiliates who will be eligible to participate in the 2020 Plan.
Registration with the SEC
We intend to file a Registration
Statement on Form S-8 relating to the issuance of additional shares of common stock under the 2020 Plan with the SEC pursuant to
the Securities Act of 1933, as amended, as soon as practicable after approval of the 2020 Plan by our stockholders.
|
- 2020 Proxy Statement
|
61
|
|
|
|
Equity Compensation Plan Information
The following table summarizes
Colfax Corporation’s equity plan information as of December 31, 2019.
|
|
|
|
|
|
Number of securities
|
|
|
Number of securities
|
|
|
|
remaining available for
|
|
|
to be issued
|
|
Weighted-average
|
|
future issuance under
|
|
|
upon exercise of
|
|
exercise price
|
|
equity compensation
|
|
|
outstanding options,
|
|
of outstanding
|
|
plans (excluding
|
|
|
warrants, and rights
|
|
options, warrants,
|
|
securities reflected in
|
Plan Category
|
|
(a)
|
|
and rights (b)(1)
|
|
column (a))(c)
|
Equity
compensation plans approved by Company stockholders
|
|
6,606,859
|
|
$34.93
|
|
2,663,654
|
Stock
options
|
|
4,675,281
|
|
$34.93
|
|
|
Restricted
stock units
|
|
595,376
|
|
–
|
|
|
Performance-based
restricted stock units
|
|
1,336,202
|
(2)
|
–
|
|
|
Equity
compensation plans not approved by Company stockholders
|
|
–
|
|
–
|
|
–
|
TOTAL
|
|
6,606,859
|
|
$34.93
|
|
2,663,654
|
(1)
|
The weighted average exercise price does not take into account the shares issuable upon outstanding restricted stock units and performance-based restricted stock units vesting, which have no exercise price.
|
(2)
|
This number assumes shares will be issued at the maximum vesting amount for outstanding performance-based restricted stock units.
|
Vote Required
The affirmative vote of the
holders of a majority of shares present in person or represented by proxy at the Annual Meeting and entitled to vote is required
to approve the Colfax Corporation 2020 Omnibus Incentive Plan.
Board Recommendation
The Board recommends that
our stockholders approve the 2020 Plan because appropriate equity incentives are important to attract and retain high quality officers
and employees, to link compensation to Company performance, to encourage employee and director ownership in our Company, and to
align the interests of participants to those of our stockholders. The approval of the 2020 Plan will enable us to continue to provide
such incentives.
The
Board unanimously recommends that stockholders vote “FOR” the
approval of the Colfax Corporation 2020 Omnibus Incentive Plan.
|
|
- 2020 Proxy Statement
|
62
|
|
|
|
|
BENEFICIAL OWNERSHIP OF OUR
COMMON STOCK
|
The following table sets forth certain information
as of March 16, 2020 (unless otherwise specified), with respect to the beneficial ownership of our common stock by each person
who is known to own beneficially more than 5% of the outstanding shares of common stock, each person currently serving as a director,
each nominee for director, each named executive officer
(as listed below), and all directors and executive officers as a group. Unless otherwise indicated, to our knowledge, each person
has sole dispositive and voting power over the shares in the table.
Beneficial Owner
|
|
Shares Beneficially Owned
|
|
|
Percent of
Class
|
|
5% Holder and Director
|
|
|
|
|
|
|
|
|
Mitchell P. Rales
|
|
|
10,257,859
|
(1)
|
|
|
8.6
|
%
|
5% Holders
|
|
|
|
|
|
|
|
|
T. Rowe Price Associates, Inc.
|
|
|
16,566,794
|
(2)
|
|
|
14.0
|
%
|
BlackRock, Inc.
|
|
|
9,618,958
|
(3)
|
|
|
8.1
|
%
|
Steven M. Rales
|
|
|
8,420,373
|
(4)
|
|
|
7.1
|
%
|
The Vanguard Group
|
|
|
8,026,168
|
(5)
|
|
|
6.8
|
%
|
Principal Global Investors, LLC
|
|
|
6,865,138
|
(6)
|
|
|
5.8
|
%
|
Dimensional Fund Advisors LP
|
|
|
6,089,699
|
(7)
|
|
|
5.1
|
%
|
Cooke & Bieler, LP
|
|
|
5,909,634
|
(8)
|
|
|
5.0
|
%
|
Directors
|
|
|
|
|
|
|
|
|
Patrick W. Allender
|
|
|
307,095
|
(9)(10)
|
|
|
*
|
|
Thomas S. Gayner
|
|
|
82,292
|
(10)
|
|
|
*
|
|
Rhonda L. Jordan
|
|
|
107,186
|
(10)(11)
|
|
|
*
|
|
Liam J. Kelly
|
|
|
1,842
|
(10)
|
|
|
|
|
A. Clayton Perfall
|
|
|
76,044
|
(10)(12)
|
|
|
*
|
|
Rajiv Vinnakota
|
|
|
51,027
|
(10)
|
|
|
*
|
|
Didier Teirlinck
|
|
|
26,245
|
(10)
|
|
|
*
|
|
Sharon Wienbar
|
|
|
36,063
|
(10)
|
|
|
*
|
|
Named Executive Officers and Directors
|
|
|
|
|
|
|
|
|
Matthew L. Trerotola
|
|
|
957,993
|
|
|
|
*
|
|
Named Executive Officers
|
|
|
|
|
|
|
|
|
Christopher M. Hix
|
|
|
313,127
|
|
|
|
*
|
|
Daniel A. Pryor
|
|
|
691,601
|
(13)(14)
|
|
|
*
|
|
Shyam Kambeyanda
|
|
|
177,291
|
(13)(15)
|
|
|
*
|
|
Brady Shirley
|
|
|
18,982
|
(13)
|
|
|
|
|
Ian Brander
|
|
|
7,374
|
|
|
|
*
|
|
All of our directors and executive officers as a group
(17 persons)
|
|
|
13,142,449
|
(13)
|
|
|
10.8
|
%
|
*
|
Represents beneficial ownership of less than 1%
|
|
|
(1)
|
Includes 2,010,507 shares held directly, 6,000,000 shares held by limited liability companies
of which Mr. Rales is the trustee of the sole member, 19,388 shares held by Capital Yield Corporation, of which Mr. Mitchell
Rales and Mr. Steven Rales are the sole stockholders, 679,264 shares held by the Mitchell P. Rales Family Trust, 28,700 shares
held in trust for his daughters and 1,520,000 shares of common stock underlying tangible equity units (TEUs) that may be settled
into shares of common stock by the holder at any time. The number of shares of common stock underlying Mr. Mitchell Rales’
TEUs is based on the amount that may be acquired if the prepaid stock purchase contracts were settled prior to January 15,
2021. The actual number of shares the reporting person may acquire will depend on when the prepaid stock purchase contracts
are settled. Mr. Mitchell Rales has sole voting power and sole dispositive power with respect to 8,718,471 shares of common
stock and the 1,520,000 shares underlying TEUs, and shared voting power and shared dispositive power with respect to 19,388
shares of common stock. 6,000,000 shares of Colfax common stock are pledged to secure a line of credit. This entity and Mr.
Mitchell Rales are in compliance with this line of credit. The business address of Mr. Mitchell Rales, and the limited liability
company, is 11790 Glen Road, Potomac, MD 20854.
|
|
|
(2)
|
The amount shown and the following information is derived from a Schedule 13G/A filed
February 14, 2020 by T. Rowe Price Associates, Inc. (“Price Associates”), which sets forth Price Associates’
beneficial ownership as of December 31, 2019. According to the Schedule 13G/A, Price Associates has sole voting power over
6,150,197 shares and sole dispositive power over 16,566,794 shares. The business address of Price Associates is 100 E. Pratt
Street, Baltimore, MD 21202.
|
|
|
(3)
|
The amount shown and the following information is derived from a Schedule 13G filed February
10, 2020 by BlackRock, Inc. (“BlackRock”), which sets forth BlackRock’s beneficial ownership as of December
31, 2019. According to the Schedule 13G, BlackRock has sole voting power over 9,259,410 shares and sole dispositive power
over 9,618,958 shares. The business address of BlackRock is BlackRock, Inc. 55 East 52nd Street, New York, NY 10055.
|
|
- 2020 Proxy Statement
|
63
|
|
|
|
(4)
|
Includes 8,400,985 shares owned directly and 19,388 shares held by
Capital Yield Corporation, of which Mr. Mitchell Rales and Mr. Steven Rales are the sole stockholders. Mr. Steven Rales has
sole voting power and sole dispositive power with respect to 8,400,985 shares of common stock, and shared voting power and
shared dispositive power with respect to 19,388 shares of common stock. The business address of Steven M. Rales is 2200 Pennsylvania
Avenue, N.W., Suite 800 W, Washington, D.C. 20037-1701.
|
|
|
(5)
|
The amount shown and the following information is derived from a Schedule 13G/A filed
February 12, 2020 by The Vanguard Group (“Vanguard”), which sets forth Vanguard’s beneficial ownership as
of December 31, 2019. According to the Schedule 13G/A, Vanguard has sole voting power over 44,265 shares, shared voting power
of 12,287 shares, sole dispositive power over 7,980,251 shares, and shared dispositive power over 45,917 shares. Vanguard
Fiduciary Trust Company (“VFTC”), a wholly-owned subsidiary of The Vanguard Group, Inc., is the beneficial owner
of 33,630 shares or .02% of the Common Stock outstanding of the Company as a result of its serving as investment manager of
collective trust accounts. Vanguard Investments Australia, Ltd. (“VIA”), a wholly-owned subsidiary of The Vanguard
Group, Inc., is the beneficial owner of 22,922 shares or .01% of the Common Stock outstanding of the Company as a result of
its serving as investment manager of Australian investment offerings. The business address of Vanguard is 100 Vanguard Blvd.,
Malvern, PA 19355.
|
|
|
(6)
|
The amount shown and the following information is derived from a Schedule 13G/A filed
February 18, 2020 by Principal Global Investors, LLC (“Principal”), which sets forth Principal’s beneficial
ownership as of December 31, 2019. According to the Schedule 13G/A, Principal has shared voting and dispositive power over
6,865,138 shares. The business address of Principal is 801 Grand Avenue, Des Moines, IA 50392.
|
|
|
(7)
|
The amount shown and the following information is derived from a Schedule 13G filed February
12, 2020 by Dimensional Fund Advisors LP (“Dimensional”), which sets forth Dimensional’s beneficial ownership
as of December 31, 2019. According to the Schedule 13G, Dimensional has sole voting power over 5,985,990 shares and sole dispositive
power over 6,089,699 shares. The business address of Dimensional is Building One 6300 Bee Cave Road, Austin, Texas, 78746.
|
|
|
(8)
|
The amount shown and the following information is derived from a Schedule 13G filed February
14, 2020 by Cooke & Bieler, LP (“Cooke & Bieler”), which sets forth Cooke & Bieler’s beneficial
ownership as of December 31, 2019. According to the Schedule 13G, Cooke & Bieler has shared voting power over 4,927,924
shares and shared dispositive power over 5,909,634 shares. The business address of Cooke & Bieler is 1700 Market Street,
Suite 3222, Philadelphia, PA 19103.
|
|
|
(9)
|
Includes 23,648 shares owned by the JWA Irrevocable Trust #1, 45,412 shares held by the
JWA GRAT #4, 77,679 shares held by the JWA GRAT #5, 52,160 shares held by the JWA 2014 Trust, and 20,000 shares held by an
irrevocable trust, of which Patrick Allender is a trustee. Mr. Allender disclaims beneficial ownership of all shares held
by the JWA irrevocable trust, JWA GRATs, and the JWA 2014 Trust, except to the extent of his pecuniary interest therein.
|
|
|
(10)
|
Beneficial ownership by directors (other than Mitchell P. Rales) includes: (i) for each
of Messrs. Allender and Gayner and Ms. Jordan, 32,217 DRSUs or DSUs that have vested or will vest within 60 days of March
16, 2020 and will be delivered following the conclusion of service on the Board and 27,903 shares that such individuals have
the right to acquire upon the exercise of director stock options that have vested or will vest within 60 days of March 16,
2020, (ii) for Mr. Perfall, 20,005 DRSUs or DSUs that have vested or will vest within 60 days of March 16, 2020 and will
be delivered following the conclusion of service on the Board and 27,903 shares that Mr. Perfall has the right to acquire
upon the exercise of director stock options that have vested or will vest within 60 days of March 16, 2020, (iii) for Mr.
Vinnakota, 15,470 DRSUs or DSUs that have vested or will vest within 60 days of March 16, 2020 and will be delivered following
the conclusion of service on the Board and 27,903 shares that Mr. Vinnakota has the right to acquire upon the exercise of
director stock options that have vested or will vest within 60 days of March 16, 2020, (iv) for Mr. Teirlinck, 7,891 DRSUs
or DSUs that have vested or will vest within 60 days of March 16, 2020 and will be delivered following the conclusion of service
on the Board and 12,240 shares that Mr. Teirlinck has the right to acquire upon the exercise of director stock options that
have vested or will vest within 60 days of March 16, 2020, (v) for Ms. Wienbar, 11,317 DRSUs or DSUs that have vested or will
vest within 60 days of March 16, 2020 and will be delivered following the conclusion of service on the Board and 16,478 shares
that Ms. Wienbar has the right to acquire upon the exercise of director stock options that have vested or will vest within
60 days of March 16, 2020, (vi) for Mr. Kelly, 1,842 shares that Mr. Kelly has the right to acquire upon the exercise of director
stock options that have vested or will vest within 60 days of March 16, 2020, and (vii) DSUs received in lieu of annual cash
retainers and committee chairperson retainers that will be delivered following the conclusion of service on the Board as follows:
Mr. Allender—27,109, Mr. Gayner—22,172, Ms. Jordan— 22,066, Mr. Perfall— 20,689, Mr. Teirlinck—
6,114, and Ms. Wienbar— 8,268. For more information on these awards, see Director Compensation above.
|
|
|
(11)
|
Includes 18,010 shares held by a family trust, 6,191 shares held by her spouse and 799
shares held in a trust account for her spouse.
|
|
|
(12)
|
Includes 7,447 shares held by a trust.
|
|
|
(13)
|
Beneficial ownership by named executive officers and our executive officers as a group
includes shares that such individuals have the right to acquire upon the exercise of options that have vested or will vest
within 60 days of March 16, 2020. The number of shares included in the table as beneficially owned which are subject to such
options is as follows: Mr. Trerotola— 835,562, Mr. Hix— 298,658, Mr. Pryor— 606,992, Mr. Kambeyanda—
130,128, and Mr. Shirley—18,982, all of our current executive officers as a group— 1,923,146.
|
|
|
(14)
|
Includes 3,000 shares held by trusts for his children and 1,920 shares held in his 401(k)
account.
|
|
|
(15)
|
Includes 22,759 RSUs that will vest within 60 days of March 16, 2020.
|
|
- 2020 Proxy Statement
|
64
|
|
|
|
|
GENERAL MATTERS
|
Outstanding Stock and Voting Rights
The Board has fixed the close of business on April
2, 2020 (the “Record Date”) as the record date for determining the stockholders entitled to notice of, and to vote
at, the Annual Meeting. Only stockholders of record on that date will be entitled to vote. Proxies will be voted as specified in
the stockholder’s proxy. In the absence of specific instructions, proxies will be voted in accordance with the Company’s
recommendations and in the discretion of the proxy holders on any other matter which properly comes before the meeting or any adjournment
or postponement thereof. The Board has selected Mitchell P. Rales and Matthew L. Trerotola to act as proxies with full power of
substitution.
Any stockholder of record giving a proxy has the
power to revoke the proxy at any time before it is exercised by either (i) delivering a written notice of revocation to Colfax
Corporation at 420 National Business Parkway, 5th Floor, Annapolis Junction, Maryland 20701, Attn: Corporate Secretary,
(ii) delivering prior to the Annual Meeting a properly executed and subsequently dated proxy, or (iii) attending the Annual Meeting
and voting in person. Attendance at the Annual Meeting will not cause your previously granted proxy to be revoked unless you specifically
so request. A beneficial stockholder who owns common stock in street name, meaning through a bank, broker or other nominee, should
contact that entity to revoke a previously given proxy.
The Company will bear the total expense of this solicitation,
including reimbursement paid to brokerage firms and others for their expenses in forwarding material regarding the Annual Meeting
to beneficial owners. Solicitation of proxies may be made personally or by mail, telephone, Internet, e-mail or facsimile by officers
and other management employees of the Company, who will receive no additional compensation for their services.
The holders of shares of the Company’s common
stock are entitled to vote at the Annual Meeting. As of the Record Date, 118,327,405 shares of the Company’s common stock
were outstanding. Each outstanding share of the Company’s common stock entitles the holder to one vote on all matters brought
before the Annual Meeting.
A list of stockholders of record as of the Record
Date will be available for inspection during ordinary business hours at our corporate headquarters located at 420 National Business
Parkway, 5th Floor, Annapolis Junction, Maryland 20701, for 10 days prior to the date of our Annual Meeting. The list
will also be available for inspection at the Annual Meeting.
The quorum necessary to conduct business at the Annual
Meeting consists of a majority of the shares of the Company’s stock outstanding on the Record Date and entitled to vote at
the Annual Meeting, either present in person or represented by proxy. Abstentions and broker non-votes (described below) are counted
for purposes of determining the presence or absence of a quorum. In accordance with the Company’s Amended and Restated Bylaws
(the “Bylaws”), to be elected each director nominee must receive a majority of the votes cast with respect to that
director’s election. Incumbent directors nominated for election by the Board are required, as a condition to such nomination,
to submit a conditional letter of resignation to the Chairman of the Board. In the event that a nominee for director does not receive
a majority of the votes cast at the Annual Meeting with respect to his or her election, the Board will promptly consider whether
to accept or reject the conditional resignation of that nominee, or whether other action should be taken. The Board will then take
action and will publicly disclose its decision and the rationale behind it no later than 90 days following the certification of
election results.
The affirmative vote of a majority of the shares
present in person or represented by proxy at the Annual Meeting and entitled to vote is required for ratification of the appointment
of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December
31, 2020, for approval of the advisory vote approving the compensation of our named executive officers, and for approval of the
Colfax Corporation 2020 Omnibus Incentive Plan.
Abstentions will have no effect on the election of
directors but will have the same effect as a vote against ratification of the appointment of Ernst & Young LLP, approval of
the advisory vote approving the compensation of our named executive officers and approval of the Colfax Corporation 2020 Omnibus
Incentive Plan.
Under the rules of the New York Stock Exchange (the
“NYSE”), brokerage firms may vote in their discretion on behalf of clients who have not furnished voting instructions
on the ratification of the selection of our registered public accounting firm. In contrast, the remaining proposals are “non-routine”
items. This means brokerage firms that have not received voting instructions from their clients may not vote on these proposals
(a “broker non-vote”). Broker non-votes will not be considered in determining the number of votes necessary for election
and, therefore, will have no effect on the outcome of the vote for the election of directors. Further, broker non-votes will have
no effect on the advisory vote to approve the compensation of our named executive officers or the proposal to approve the Colfax
Corporation 2020 Omnibus Incentive Plan.
Only stockholders as of the Record Date are entitled
to attend the Annual Meeting in person. The names of stockholders of record will be on a list at the Annual Meeting and such stockholders
may gain entry with a government-issued photo identification, such as a driver’s license, state-issued ID card, or passport.
Beneficial stockholders who own common stock in street name, meaning through a bank, broker or other nominee, must present a government-issued
photo identification and proof of beneficial stock ownership as of the Record Date (such as the Notice of Internet Availability,
a copy of the proxy card received if one was sent to the stockholder or an account statement or other similar evidence showing
stock ownership as of the Record Date) in order to gain entry to the Annual Meeting. Representatives of an entity that owns stock
of the Company must present government-issued photo identification, evidence that they are the entity’s authorized representative
or proxyholder and, if the entity is a beneficial owner, proof of the entity’s beneficial stock ownership
|
- 2020 Proxy Statement
|
65
|
|
|
|
as of the Record Date. A person who is not a stockholder
will be entitled to admission only if he or she presents a valid legal proxy from a stockholder of record and government-issued
photo identification. Each stockholder may appoint only one proxy holder or representative to attend the meeting on his or her
behalf.
Please note that the use of cameras (including cell
phones with photographic capabilities), recording devices and other electronic devices is strictly prohibited at the meeting.
We are actively monitoring the public health and
travel safety concerns relating to the coronavirus (COVID-19) and the advisories or mandates that federal, state, and local governments,
and related agencies, have issued and may issue. In the event it is not possible or advisable to hold our Annual Meeting as currently
planned, we will announce any additional or alternative arrangements for the meeting, which may include a change in venue or holding
the meeting solely by means of remote communication. Please monitor our press releases, available at http://ir.colfaxcorp.com,
and our filings with the SEC for updated information. If you are planning to attend our Annual Meeting, please check http://ir.colfaxcorp.com
the week of the meeting. As always, we encourage you to vote your shares prior to the Annual Meeting.
Stockholder Proposals and Nominations
Requirements for Stockholder
Proposals to be Considered for Inclusion in our Proxy Materials. To be considered for inclusion in next year’s proxy
statement pursuant to Rule 14a-8 of the Exchange Act, stockholder proposals must be received by our Corporate Secretary at our
principal executive offices no later than the close of business on December 10, 2020.
Requirements for Stockholder
Proposals to be Brought Before an Annual Meeting. Our Bylaws provide that, for a stockholder to nominate a candidate for election
to the Board or propose any other business to be considered at an annual meeting other than through a proposal presented pursuant
to Rule 14a-8 of the Exchange Act, the stockholder must have given timely notice thereof in writing to the Secretary of the Company
at Colfax Corporation, 420 National Business Parkway, 5th Floor, Annapolis Junction, Maryland 20701, Attn: Corporate
Secretary. To be timely for an annual meeting, the stockholder’s notice must be delivered to or mailed and received by the
Secretary not less than the close of business 90 days nor more than 120 days before the anniversary date of the preceding annual
meeting; accordingly, for the 2020 annual meeting, notice must be delivered to or mailed and received by the Secretary no later
than the close of business on February 20, 2021 and no earlier than January 21, 2021. However, if the annual meeting is set for
a date that is more than 30 days before or more than 70 days after such anniversary, the Company must receive the notice not earlier
than the 120th day prior to the annual meeting date and not later than the close of business on the later of the 90th
day prior to such annual meeting or the tenth day following the day when the Company makes a public announcement of the
annual meeting date. Such notice must provide the information required by Section 2.2 of our Bylaws with respect to each matter,
other than stockholder nominations of directors, that the stockholder proposes to bring before the annual meeting. Notice of stockholder
nominations must provide the information required by Section 3.3 of our Bylaws. Both Section 2.2 and Section 3.3 of our Bylaws
mandate certain additional information to be provided by a stockholder who wishes to introduce business or nominate a director
candidate. The chairman of the annual meeting may refuse to acknowledge or introduce any nomination or proposal if notice thereof
is not received within the applicable deadlines or does not otherwise comply with our Bylaws. If the stockholder does not provide
notice of a nomination or proposal within the applicable deadlines or does not comply with the requirements of Rule 14a-4(c) under
the Exchange Act, we may exercise discretionary voting authority under proxies that we solicit to vote in accordance with our
best judgment on any such nomination or proposal.
Delivery of Documents to Stockholders Sharing
an Address
SEC rules permit the delivery of a single copy of
a company’s annual report and proxy statement, or notice of internet availability of proxy materials, as applicable, to any
household at which two or more stockholders reside if they appear to be members of the same family. This procedure, referred to
as householding, reduces the volume of duplicate information stockholders receive and reduces mailing and printing expenses.
The broker, bank or other nominee for any stockholder
who is a beneficial owner of the Company’s stock may deliver only one copy of the Company’s Annual Report to Stockholders
and Proxy Statement, or the Company’s Notice, as applicable, to multiple stockholders who share the same address, unless
that broker, bank or other nominee has received contrary instructions from one or more of the stockholders. We will deliver promptly,
upon written or oral request, a separate copy of the Company’s Annual Report to Stockholders and Proxy Statement, or the
Company’s Notice, as applicable, to any stockholder at a shared
address to which a single copy of the documents was delivered. A stockholder who wishes to receive a separate copy of the Company’s
Annual Report to Stockholders and Proxy Statement, or the Company’s Notice, as applicable, now or in the future, should submit
a written request to Investor Relations, Colfax Corporation, 420 National Business Parkway, 5th Floor, Annapolis Junction,
Maryland 20701 or call (301) 323-9000 and ask for Investor Relations. Beneficial owners sharing an address who are receiving multiple
copies of the Company’s Annual Report to Stockholders and Proxy Statement, or the Company’s Notice, as applicable,
and wish to receive a single copy of such materials in the future will need to contact their broker, bank or other nominee to request
that only a single copy of each document be mailed to all stockholders at the shared address in the future.
|
- 2020 Proxy Statement
|
66
|
|
|
|
Additional Information
A copy of the Company’s Annual Report to Stockholders
for the fiscal year ended December 31, 2019 has been made available concurrently with this Proxy Statement to all stockholders
entitled to notice of and to vote at the Annual Meeting. The Annual Report is not incorporated into this Proxy Statement and is
not considered proxy-soliciting material.
The Company filed its Annual
Report on Form 10-K with the SEC on February 24, 2020. The Company will mail without charge, upon written request, a copy of its
Annual Report on Form 10-K for the fiscal year ended December 31, 2019, including financial statements but excluding exhibits.
Exhibits, if requested, will be furnished upon the payment of a fee determined by the Company, such fee to be limited to the Company’s
reasonable expenses in furnishing the requested exhibit or exhibits. Please send a written request to Investor Relations, Colfax
Corporation, 420 National Business Parkway, 5th Floor, Annapolis Junction, Maryland 20701, or access these materials
on the Company’s website at www.colfaxcorp.com on the Investors page.
Other Matters
As of the date of this Proxy Statement, the Board
does not intend to present any matters other than those described herein at the Annual Meeting and is unaware of any matters to
be presented by other parties. If other matters are properly brought before the meeting for action by the stockholders, proxies
returned to us will be voted in accordance with the recommendation of the Board or, in the absence of such a recommendation, in
accordance with the judgment of the proxy holder.
By Order of the Board of Directors
Bradley J. Tandy
Secretary
|
- 2020 Proxy Statement
|
67
|
|
|
|
APPENDIX A
|
COLFAX CORPORATION 2020 OMNIBUS INCENTIVE PLAN
|
Colfax Corporation, a Delaware corporation, sets
forth herein the terms of its 2020 Omnibus Incentive Plan, as follows:
The Plan is intended to enhance the Company’s
and its Affiliates’ (as defined herein) ability to attract and retain highly qualified officers, directors, and key employees,
and to motivate such persons to serve the Company and its Affiliates and to expend maximum effort to improve the business results
and earnings of the Company, by providing to such persons an opportunity to acquire or increase a direct proprietary interest in
the operations and future success of the Company.
For purposes of interpreting the Plan and related
documents (including Award Agreements), the following capitalized terms shall have the respective meanings set forth below:
|
2.1
|
“Affiliate” means, with
respect to the Company, any company or other trade or business that controls, is controlled by or is under common control
with the Company within the meaning of Rule 405 of Regulation C under the Securities Act, including, without limitation, any
Subsidiary. For purposes of granting stock options or stock appreciation rights, an entity may not be considered an Affiliate
if it results in noncompliance with Code Section 409A.
|
|
|
|
|
2.2
|
“Award” means a grant of an Option,
Stock Appreciation Right, Restricted Stock, Unrestricted Stock, Stock Unit, Dividend Equivalent Right, Performance Share,
Performance Unit or Substitute Award under the Plan.
|
|
|
|
|
2.3
|
“Award Agreement” means the written
agreement between the Company and a Grantee that evidences and sets out the terms and conditions of an Award. An Award Agreement
may be provided in any medium, including any electronic medium.
|
|
|
|
|
2.4
|
“Benefit Arrangement” has the meaning
set forth in Section 15.
|
|
|
|
|
2.5
|
“Board” means the Board of Directors
of the Company.
|
|
|
|
|
2.6
|
“Business Combination” has the meaning
set forth in Section 2.8(3).
|
|
|
|
|
2.7
|
“Cause” means, as determined by the
Board or the Committee and unless otherwise provided in an Award Agreement or other applicable agreement with the Company:
(i) gross negligence or willful misconduct in connection with the performance of duties; (ii) conviction of a criminal offense
(other than minor traffic offenses); (iii) material breach of any term of any employment, consulting or other services, confidentiality,
intellectual property or non-competition agreements, if any, between the Service Provider and the Company or any Affiliate.
|
|
|
|
|
2.8
|
“Change in Control” means the occurrence
of any of the following:
|
|
(1)
|
the acquisition by any individual, entity or group (within the meaning
of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”) of beneficial ownership (within the meaning
of Rule 13d-3 promulgated under the Exchange Act) of more than fifty percent (50%) of either: (A) the then-outstanding shares
of common stock of the Company (the “Company Common Stock”) or (B) the combined voting power of the then-outstanding
voting securities of the Company entitled to vote generally in the election of directors (“Voting Stock”);
provided, however, that for purposes of this subsection (1), the following acquisitions shall not constitute
a Change in Control: (i) any acquisition directly from the Company, (ii) any acquisition by the Company, (iii) any acquisition
by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary, (iv) any acquisition
by any Person (or more than one Person acting as a group) that owns more than fifty (50) percent of the Company Common Stock
or Voting Stock and acquires additional shares, or (v) any acquisition by any Person pursuant to a transaction which complies
with clauses (A), (B) and (C) of subsection (3) below; or
|
|
|
|
|
(2)
|
individuals who, as of the date hereof, constitute the Board (as modified by this subsection
(2), the “Incumbent Board”), cease for any reason (other than death or disability) to constitute at least
a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof
whose election, or nomination for election by the Company’s stockholders, was approved by a vote of at least a majority
of the directors then comprising the Incumbent Board (either by a specific vote or by approval of the proxy statement of the
Company in which such person is named as a nominee for director, without objection to such nomination) shall be considered
as though such individual were a member of the Incumbent Board, but excluding for this purpose, any such individual whose
initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or
removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than
the Board; or
|
|
|
|
|
(3)
|
consummation of a reorganization, merger or consolidation or sale or other disposition of
all or substantially all of the assets of the Company (a “Business Combination”), in each case, unless,
following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial
owners, respectively, of the Company Common Stock and Voting Stock immediately prior to such Business Combination beneficially
own, directly or indirectly, more than fifty percent (50%) of, respectively, the then-outstanding shares of common stock and
the combined voting power of the then-outstanding
|
|
- 2020 Proxy Statement
|
68
|
|
|
|
|
|
voting securities entitled to vote generally in the election of directors,
as the case may be, of the entity resulting from such Business Combination (including, without limitation, an entity which
as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly
or through one or more subsidiaries) in substantially the same proportions relative to each other as their ownership, immediately
prior to such Business Combination, of the Company Common Stock and Voting Stock of the Company, as the case may be, (B) no
Person (excluding any entity resulting from such Business Combination or any employee benefit plan (or related trust) sponsored
or maintained by the Company or such entity resulting from such Business Combination) beneficially owns, directly or indirectly,
more than fifty percent (50%), respectively, the then-outstanding shares of common stock of the entity resulting from such
Business Combination, or the combined voting power of the then-outstanding voting securities of such corporation except to
the extent that such ownership existed prior to the Business Combination and (C) at least a majority of the members of the
board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the
time of the execution of the initial agreement, or of the action of the Board providing for such Business Combination; or
|
|
|
|
|
(4)
|
approval by the stockholders of the Company of a complete liquidation or dissolution of the
Company.
|
A “Change in Control” will be
deemed to occur (i) with respect to a Change in Control pursuant to subsection (1) above, on the date that any Person becomes the
beneficial owner of more than fifty percent (50%) of either the Company Common Stock or the Voting Stock, (ii) with respect to
a Change in Control pursuant to subsection (2) above, on the date the members of the Incumbent Board first cease for any reason
(other than death or disability) to constitute at least a majority of the Board, (iii) with respect to a Change in Control pursuant
to subsection (3) above, on the date the applicable transaction closes and (iv) with respect to a Change in Control pursuant to
subsection (4) above, on the date of the stockholder approval. Notwithstanding the foregoing provisions, a “Change in Control”
shall not be deemed to have occurred for purposes of this Agreement solely because of a change in control of any Subsidiary by
which the Employee may be employed.
|
2.9
|
“Code” means the Internal
Revenue Code of 1986, as now in effect or as hereafter amended.
|
|
|
|
|
2.10
|
“Committee” means a committee of, and
designated from time to time by resolution of, the Board, which shall be constituted as provided in Section 3.
|
|
|
|
|
2.11
|
“Company” means Colfax Corporation,
a Delaware corporation, or its successors.
|
|
|
|
|
2.12
|
“Company Common Stock” has the meaning
set forth in Section 2.8(1).
|
|
|
|
|
2.13
|
“Disability” means the Grantee is unable
to perform each of the essential duties of such Grantee’s position by reason of a medically determinable physical or
mental impairment which is potentially permanent in character or which can be expected to last for a continuous period of
not less than twelve (12) months; provided, however, that, with respect to rules regarding expiration of an Incentive Stock
Option following termination of the Grantee’s Service, Disability shall mean the Grantee is unable to engage in any
substantial gainful activity by reason of a medically determinable physical or mental impairment which can be expected to
result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months.
|
|
|
|
|
2.14
|
“Dividend Equivalent Right” and “Dividend
Equivalent” means a right, granted to a Grantee under Section 13 hereof, to receive cash, Stock, other
Awards or other property in an amount equal in value to the dividends paid with respect to all or a specified number of shares
of Stock, or other periodic payments.
|
|
|
|
|
2.15
|
“Effective Date” means the date on
which the Plan is approved by the Company’s stockholders.
|
|
|
|
|
2.16
|
“Exchange Act” means the Securities
Exchange Act of 1934, as now in effect or as hereafter amended.
|
|
|
|
|
2.17
|
“Exercise Price” means (a) in the case
of an Option, the amount for which a share of Stock may be purchased upon exercise of such Option, as set forth in the applicable
Award Agreement, and (b) in the case of a Stock Appreciation Right, the per share of Stock amount, as specified in the applicable
Award Agreement, which is subtracted from the Fair Market Value of a share of Stock in determining the amount payable upon
exercise of such SAR.
|
|
|
|
|
2.18
|
“Fair Market Value” means the value
of a share of Stock, determined as follows: if on the Grant Date or other determination date the Stock is listed on an established
national or regional stock exchange, is admitted to quotation on The Nasdaq Stock Market, Inc. or is publicly traded on an
established securities market, the Fair Market Value of a share of Stock shall be the closing price of the Stock on such exchange
or in such market (if there is more than one such exchange or market the Board or the Committee shall determine the appropriate
exchange or market) on the Grant Date or such other determination date (or if there is no such reported closing price, the
Fair Market Value shall be the average between the highest bid and lowest asked prices or between the high and low sale prices
on such trading day) or, if no sale of Stock is reported for such trading day, on the next preceding day on which any sale
shall have been reported. If the Stock is not listed on such an exchange, quoted on such system or traded on such a market,
Fair Market Value shall be the value of the Stock as determined by the Board or the Committee in good faith in a manner consistent
with Code Section 409A.
|
|
|
|
|
2.19
|
“Family Member” means a person who
is a spouse, former spouse, child, stepchild, grandchild, parent, stepparent, grandparent, niece, nephew, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother, sister, brother-in-law, or sister-in-law, including adoptive relationships, of the Grantee,
any person sharing the Grantee’s household (other than a tenant or employee), a trust in which any one or more of these
persons have more than fifty percent (50%) of the beneficial interest, a foundation in which any one or more of these persons
(or the Grantee) control the management of assets, and any other entity in which one or more of these persons (or the Grantee)
own more than fifty percent (50%) of the voting interests.
|
|
- 2020 Proxy Statement
|
69
|
|
|
|
|
2.20
|
“Full Value Award” means
any Award, other than an Option or Stock Appreciation Right, that is settled by the issuance of shares of Stock (or, at the
direction of the Committee, settled in cash or other consideration by reference to the value of shares of Stock).
|
|
|
|
|
2.21
|
“Grant Date” means the date on which
the Board or Committee, as applicable, adopts a resolution or takes other appropriate action, granting an Award to a Service
Provider or, if a later date is set forth in such resolution, then such later date as set forth therein.
|
|
|
|
|
2.22
|
“Grantee” means a person who receives
or holds an Award under the Plan.
|
|
|
|
|
2.23
|
“Incentive Stock Option” means an “incentive
stock option” within the meaning of Section 422 of the Code, or the corresponding provision of any subsequently enacted
tax statute, as amended from time to time.
|
|
|
|
|
2.24
|
“Incumbent Board” has the meaning set
forth in Section 2.8(2).
|
|
|
|
|
2.25
|
“Minimum Vesting Requirements” means,
notwithstanding any provision of this Plan to the contrary, on and after the Effective Date, the Committee shall not award
more than five percent (5%) of the aggregate number of shares of Stock that are available for grant under this Plan as of
the Effective Date pursuant to Awards that are solely subject to vesting conditions or performance periods that are less than
one (1) year following the Grant Date of the applicable Award, subject, in each case to the Committee’s authority under
this Plan to vest Awards earlier, as the Committee deems appropriate, upon the occurrence of a Change in Control, in the event
of a Service Provider’s termination of employment or Service or otherwise as permitted by this Plan.
|
|
|
|
|
2.26
|
“Net Exercise” means a Grantee’s
ability (if authorized by the Board or the Committee) to exercise an Option by directing the Company to deduct from the shares
of Stock issuable upon exercise of his or her Option a number of shares of Stock having an aggregate Fair Market Value equal
to the sum of the aggregate Option Price therefor plus the amount of the Grantee’s tax withholding described in Section
18.3 (if any), whereupon the Company shall issue to the Grantee the net remaining number of shares of Stock after such
deduction.
|
|
|
|
|
2.27
|
“Non-qualified Stock Option” means
an Option that is not an Incentive Stock Option.
|
|
|
|
|
2.28
|
“Option” means an option to purchase
one or more shares of Stock pursuant to the Plan that is either an Incentive Stock Option or a Non-qualified Stock Option.
|
|
|
|
|
2.29
|
“Option Price” means the Exercise Price
for each share of Stock subject to an Option.
|
|
|
|
|
2.30
|
“Other Agreement” has the meaning set
forth in Section 15.
|
|
|
|
|
2.31
|
“Outside Director” means a member of
the Board who is not an officer or employee of the Company.
|
|
|
|
|
2.32
|
“Performance Award” means an Award
made subject to the attainment of one or more performance goals (as described in Section 14) over a Performance Period
of up to ten (10) years.
|
|
|
|
|
2.33
|
“Performance-Based Compensation” means
compensation under an Award that is intended to constitute performance-based compensation within the meaning of Code Section
409A.
|
|
|
|
|
2.34
|
“Performance Measures” means measures
as described in Section 14 and Appendix A on which the performance goals are based.
|
|
|
|
|
2.35
|
“Performance Period” means the period
of time not in excess of ten (10) years during which the performance goals must be met in order to determine the degree of
payout and/or vesting with respect to a Performance Award.
|
|
|
|
|
2.36
|
“Performance Share” means a Performance
Award under Section 14 hereof and subject to the terms of this Plan, denominated in Stock, the value of which at the
time it is payable is determined as a function of the extent to which corresponding performance criteria have been achieved.
|
|
|
|
|
2.37
|
“Performance Unit” means a Performance
Award under Section 14 hereof and subject to the terms of this Plan, denominated in Stock Units, the value of which
at the time it is payable is determined as a function of the extent to which corresponding performance criteria have been
achieved.
|
|
|
|
|
2.38
|
“Person” has the meaning set forth
in Section 2.8(1).
|
|
|
|
|
2.39
|
“Plan” means this Colfax Corporation
2020 Omnibus Incentive Plan, as the same may be amended from time to time.
|
|
|
|
|
2.40
|
“Prior Plan” means the Colfax Corporation 2016 Omnibus Incentive
Plan.
|
|
|
|
|
2.41
|
“Purchase Price” means the purchase
price paid by a Grantee for each share of Stock pursuant to a grant of Restricted Stock or Unrestricted Stock.
|
|
|
|
|
2.42
|
“Reporting Person” means a person who
is required to file reports under Section 16(a) of the Exchange Act.
|
|
|
|
|
2.43
|
“Repricing” and “Repriced”
means lowering of the Option Price or SAR Exercise Price or any other action that has the same effect or is treated as
a repricing under generally accepted accounting principles, and includes a cancellation of an Option or SAR when its Option
Price or SAR Exercise Price exceeds the Fair Market Value of the underlying Stock and exchange for another Option, SAR or
other Award or a cash payment.
|
|
|
|
|
2.44
|
“Restricted Period” has the meaning
set forth in Section 10.2.
|
|
|
|
|
2.45
|
“Restricted Stock” means one or more
shares of Stock, awarded to a Grantee pursuant to Section 10 hereof.
|
|
|
|
|
2.46
|
“SAR Exercise Price” means the per
share Exercise Price of an SAR granted to a Grantee under Section 9 hereof.
|
|
- 2020 Proxy Statement
|
70
|
|
|
|
|
2.47
|
“Securities Act” means
the Securities Act of 1933, as now in effect or as hereafter amended.
|
|
|
|
|
2.48
|
“Service” means (i) such term as defined
in an applicable Award Agreement, if the Award Agreement so defines such term, or (ii) if not defined in an applicable Award
Agreement, service as a Service Provider to the Company or an Affiliate. Unless otherwise stated in the applicable Award Agreement,
a Grantee’s change in position or duties and periods of leave following which a Service Provider is expected to return
to service with the Company or an Affiliate shall not result in interrupted or terminated Service, so long as such Grantee
continues to be a Service Provider to the Company or an Affiliate. Any periods of garden leave prior to a Service Provider’s
termination of service with the Company or an Affiliate shall not be considered periods of “Service” hereunder,
unless the Committee determines otherwise. Subject to the preceding, whether a termination of Service shall have occurred
for purposes of the Plan shall be determined by the Board or the Committee, which determination shall be final, binding and
conclusive.
|
|
|
|
|
2.49
|
“Service Provider” means an employee,
officer or director of the Company or an Affiliate, currently providing services to the Company or an Affiliate.
|
|
|
|
|
2.50
|
“Share Counting” has the meaning set
forth in Section 4.4.
|
|
|
|
|
2.51
|
“Stock” means the common stock, par
value $0.001 per share, of the Company.
|
|
|
|
|
2.52
|
“Stock Appreciation Right” or “SAR”
means a right granted to a Grantee under Section 9 hereof.
|
|
|
|
|
2.53
|
“Stock Unit” means a bookkeeping
entry representing the equivalent of one share of Stock awarded to a Grantee pursuant to Section 10
hereof.
|
|
|
|
|
2.54
|
“Subsidiary” means any “subsidiary
corporation” of the Company within the meaning of Section 424(f) of the Code.
|
|
|
|
|
2.55
|
“Substitute Award” means an Award granted
upon assumption of, or in substitution for, an outstanding award previously granted by a company or other entity acquired
by the Company or any Affiliate or with which the Company or any Affiliate combines.
|
|
|
|
|
2.56
|
“Ten Percent Stockholder” means an
individual who owns more than ten percent (10%) of the total combined voting power of all classes of outstanding stock of
the Company, its parent or any of its Subsidiaries, within the meaning of Section 422(b)(6) of the Code. In determining stock
ownership, the attribution rules of Section 424(d) of the Code shall be applied.
|
|
|
|
|
2.57
|
“Total Available Shares” has the meaning
set forth in Section 4.1.
|
|
|
|
|
2.58
|
“Unrestricted Stock” means one or more
shares of Stock, awarded to a Grantee pursuant to Section 11 hereof.
|
|
|
|
|
2.59
|
“Voting Stock” has the meaning set
forth in Section 2.8(1).
|
SECTION 3.
|
ADMINISTRATION OF THE PLAN
|
|
3.1
|
Board. The Board shall have such powers
and authorities related to the administration of the Plan as are consistent with the Company’s certificate of incorporation
and by-laws and applicable law. The Board shall have full power and authority to take all actions and to make all determinations
required or provided for under the Plan, any Award or any Award Agreement, and shall have full power and authority to take
all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of the
Plan that the Board deems to be necessary or appropriate to the administration of the Plan, any Award or any Award Agreement.
All such actions and determinations shall be by the affirmative vote of a majority of the members of the Board present at
a meeting or by unanimous consent of the Board executed in writing in accordance with the Company’s certificate of incorporation
and by-laws and applicable law. The interpretation and construction by the Board of any provision of the Plan, any Award or
any Award Agreement shall be final, binding and conclusive.
|
|
|
|
|
3.2
|
Committee. The Board hereby delegates to the Compensation
Committee of the Board, which shall be the Committee hereunder until such time as a replacement Committee is so designated
by the Board, such powers and authorities related to the administration and implementation of the Plan, as set forth in Section
3.1 above and Section 3.3 below.
|
|
(i)
|
Except as provided in Subsection (ii) and except as the Board may otherwise
determine, the Committee, and any successor thereto appointed by the Board to administer the Plan shall consist of two or
more Outside Directors of the Company who meet such requirements as may be established from time to time by the Securities
and Exchange Commission for plans intended to qualify for exemption under Rule 16b-3 (or its successor) under the Exchange
Act, and who comply with the independence requirements of the stock exchange on which the Stock is listed.
|
|
|
|
|
(ii)
|
The Board may also appoint one or more separate committees, each composed of one or more
directors of the Company who need not be Outside Directors or one or more officers of the Company who need not be members
of the Board, who may, within specified parameters, administer the Plan with respect to employees or other Service Providers
who are not officers or directors of the Company, may grant Awards under the Plan to such employees or other Service Providers,
and may determine all terms of such Awards.
|
|
|
|
|
(iii)
|
The Committee may delegate to any appropriate officer or employee of the Company or an Affiliate
responsibility for performing ministerial and administrative functions under the Plan.
|
|
|
|
|
(iv)
|
In the event that the Committee’s authority is delegated to any officer or employee
in accordance with this Section 3.2, any actions undertaken by such person in accordance with the Committee’s
delegation of authority shall have the same force and effect as if undertaken directly by the Committee, and any reference
in the Plan to the Committee shall, to the extent consistent with the terms and limitations of such delegation, be deemed
to include a reference to such officer or employee.
|
|
- 2020 Proxy Statement
|
71
|
|
|
|
In the event that the Plan, any Award or any Award
Agreement entered into hereunder provides for any action to be taken by or determination to be made by the Board, such action may
be taken or such determination may be made by the Committee if the power and authority to do so has been delegated to the Committee
by the Board as provided for in this Section. Unless otherwise expressly determined by the Board, any such action or determination
by the Committee shall be final, binding and conclusive. To the extent permitted by law, the Committee may delegate its authority
under the Plan to a member of the Board.
|
3.3
|
Committee Authority. Subject to the
other terms and conditions of the Plan, the Committee shall have full and final authority to:
|
|
(i)
|
designate Grantees;
|
|
|
|
|
(ii)
|
determine the type or types of Awards to be made to a Grantee;
|
|
|
|
|
(iii)
|
determine the number of shares of Stock to be subject to an Award;
|
|
|
|
|
(iv)
|
subject to the Minimum Vesting Requirements, establish the terms, conditions, restrictions
and other provisions of each Award (including, but not limited to, the exercise price of any Option, the nature and duration
of any restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer, or forfeiture
of an Award or the shares of Stock subject thereto, and any terms or conditions that may be necessary to qualify Options as
Incentive Stock Options);
|
|
|
|
|
(v)
|
prescribe the form of each Award Agreement evidencing an Award, which need not be identical
for each Grantee;
|
|
|
|
|
(vi)
|
Grant Awards;
|
|
|
|
|
(vii)
|
Establish performance conditions and goals for Performance Awards, and verify the level of
performance attained with respect to such performance conditions and goals;
|
|
|
|
|
(viii)
|
Adopt sub-plans or supplements to, or alternative versions of, the Plan as the Committee
deems necessary or desirable to comply with laws or regulations or to accommodate the tax policy or custom of, foreign jurisdictions.
|
|
|
|
|
(ix)
|
correct any defect, supply any omission or reconcile any inconsistency in this Plan, any
Award or any Award Agreement,
|
|
|
|
|
(x)
|
establish, adopt or revise rules, guidelines and policies for the administration of the Plan;
|
|
|
|
|
(xi)
|
amend, modify, or supplement the terms of any outstanding Award. Such authority specifically
includes the authority, in order to effectuate the purposes of the Plan but without amending the Plan, to modify Awards to
eligible individuals who are foreign nationals or are individuals who are employed outside the United States to recognize
differences in local law, tax policy, or custom. Notwithstanding the foregoing, no amendment, modification or supplement of
any Award shall, without the consent of the Grantee, materially impair the Grantee’s rights under such Award. In addition,
notwithstanding anything in the Plan to the contrary, the Committee shall not have the discretion to accelerate the vesting
of any outstanding Awards, except that the Committee may accelerate the vesting of Awards in the event of a Grantee’s
death or Disability or as provided in Section 17 of the Plan; and
|
|
|
|
|
(xii)
|
make all other decisions and determinations, and take such other actions with respect to
the Plan or any Award as the Committee shall deem necessary, appropriate or advisable for the administration of the Plan and
any Award.
|
The express grant of any specific power to the Committee,
and the taking of any action by the Committee, shall not be construed as limiting any power or authority of the Committee. The
Company may retain the right in an Award Agreement to cause a forfeiture of the gain realized by a Grantee on account of actions
taken by the Grantee in violation or breach of or in conflict with any employment agreement, non-competition agreement, any agreement
prohibiting solicitation of employees or clients of the Company or any Affiliate thereof or any confidentiality obligation with
respect to the Company or any Affiliate thereof or otherwise in competition with the Company or any Affiliate thereof, to the extent
specified in such Award Agreement applicable to the Grantee. Furthermore, the Company may annul an Award if the Grantee is an employee
of the Company or an Affiliate thereof and is terminated for Cause.
|
3.4
|
Deferral Arrangement. The Board or
the Committee may permit or require the deferral of any Award payment into a deferred compensation arrangement, subject to
such rules and procedures as it may establish, which may include provisions for the payment or crediting of interest or dividend
equivalents, including converting such credits into deferred Stock equivalents. Any such deferrals shall be made in a manner
that complies with Code Section 409A.
|
|
|
|
|
3.5
|
No Liability. No member of the Board or of the
Committee shall be liable for any action or determination made in good faith with respect to the Plan or any Award or Award
Agreement.
|
|
|
|
|
3.6
|
Share Issuance/Book-Entry. Notwithstanding any
provision of this Plan to the contrary, the issuance of shares of Stock under the Plan may be evidenced in such a manner as
the Board or Committee, in its discretion, deems appropriate, including, without limitation, book-entry registration on a
non-certificated basis or issuance of one or more Stock certificates, subject to applicable law and the rules of the applicable
stock exchange. Any reference to the issuance of Stock certificates to a Grantee shall be deemed to include any such issuance
of the Stock.
|
SECTION 4.
|
STOCK SUBJECT TO THE PLAN
|
|
4.1
|
Number of Shares. Subject to the Share
Counting rules set forth in Section 4.4 and to adjustment as provided in Section 17, the aggregate number of
shares of Stock reserved and available for issuance pursuant to Awards granted under the Plan shall be 4,430,000 shares, which
number may be increased by the number of shares available for issuance under a stockholder-approved plan of a business entity
that is a party to an acquisition, merger or other transaction in which the Company or an Affiliate acquires the business
entity (as appropriately adjusted, if necessary, to reflect such transaction) (“Total Available Shares”).
|
|
- 2020 Proxy Statement
|
72
|
|
|
|
|
4.2
|
Incentive Stock Options. The maximum
number of shares of Stock that may be issued upon exercise of Incentive Stock Options granted under the Plan shall be 4,430,000
shares, subject to adjustment as provided in Section 17.
|
|
|
|
|
4.3
|
Prior Plan. On or after the Effective Date, no
further awards shall be granted under the Prior Plan, it being understood that awards granted under the Prior Plan as of the
Effective Date shall remain in full force and effect under the Prior Plan according to their respective terms.
|
|
|
|
|
4.4
|
Share Counting.
|
|
(i)
|
The number of shares of Stock covered by an Award,
or to which an Award relates, shall be subtracted from the Total Available Shares reserve as of the Grant Date.
|
|
|
|
|
(ii)
|
To the extent an Award is canceled, terminates, expires, is forfeited
or lapses for any reason (in whole or in part), any unissued or forfeited shares of Stock subject to the Award shall be added
back to the Total Available Shares reserve and available again for issuance pursuant to Awards granted under the Plan.
|
|
|
|
|
(iii)
|
Any shares of Stock related to Awards that are settled in cash
or other consideration in lieu of shares of Stock shall be added back to the Total Available Shares reserve and available
again for issuance pursuant to Awards granted under the Plan.
|
|
|
|
|
(iv)
|
Shares of Stock withheld or deducted from an Award by the Company
to satisfy tax withholding requirements relating to Options or Stock Appreciation Rights shall not be added back to the Total
Available Shares reserve and shall not again be available for issuance pursuant to Awards granted under the Plan, but shares
of Stock withheld or deducted by the Company to satisfy tax withholding requirements relating to Full Value Awards shall be
added back to the Total Available Shares reserve and available again for issuance pursuant to Awards granted under the Plan.
Shares of Stock delivered by a Grantee to the Company to satisfy tax withholding requirements shall be treated in the same
way as shares of Stock withheld or deducted from an Award as specified above for purposes of Share Counting under this Section
4.4.
|
|
|
|
|
(v)
|
If the full number of shares of Stock subject to an Option or
a Stock-settled Stock Appreciation Right is not issued upon exercise of such Option or Stock Appreciation Right for any reason,
including by reason of a net settlement or Net Exercise, all such shares of Stock that were covered by the exercised Option
or SAR shall not be added back to the Total Available Shares reserve and shall not again be available for issuance pursuant
to Awards granted under the Plan.
|
|
|
|
|
(vi)
|
If the Exercise Price of an Option is satisfied by the Grantee
delivering shares of Stock to the Company (by either actual delivery or attestation), such shares of Stock shall not be added
to the Total Available Shares reserve and shall not be available for issuance pursuant to Awards granted under the Plan.
|
|
|
|
|
(vii)
|
To the extent that the full number of shares of Stock subject
to a Performance Award (other than an Option or Stock Appreciation Right) is not issued by reason of failure to achieve maximum
performance goals, the number of shares of Stock not issued shall be added back to the Total Available Shares reserve and
shall be available again for issuance pursuant to Awards granted under the Plan.
|
|
|
|
|
(viii)
|
Shares of Stock repurchased on the open market with the proceeds
of an Option exercise shall not be added to the Total Available Shares reserve and shall not be available for issuance pursuant
to Awards granted under the Plan.
|
|
|
|
|
(ix)
|
Any Dividend Equivalent denominated in shares of Stock shall
be counted against the Total Available Shares in such amount and at such time as the Dividend Equivalent first constitutes
a commitment to issue shares of Stock.
|
|
|
|
|
(x)
|
Substitute Awards granted shall not count against the Total Available Shares reserve.
|
|
4.5
|
Source of Shares of Stock. Shares of
Stock issued under the Plan may consist, in whole or in part, of authorized but unissued shares or treasury shares of Stock.
|
|
|
|
|
4.6
|
Fractional Shares of Stock. No fractional shares
of Stock shall be issued under or pursuant to the Plan or any Award and the Committee shall determine, in its sole discretion,
whether cash shall be given in lieu of fractional shares of Stock or whether such fractional shares of Stock shall be eliminated
by rounding down.
|
SECTION 5.
|
EFFECTIVE DATE, DURATION AND AMENDMENTS
|
|
5.1
|
Effective Date. The Plan shall be effective on the Effective
Date.
|
|
|
|
|
5.2
|
Term. The Plan shall terminate automatically on
the ten (10) year anniversary of the Effective Date set forth in Section 5.1 and may be terminated on any earlier date
as provided in Section 5.3. Any Awards of Incentive Stock Options shall be granted within the time periods provided
in Section 8.3. No termination of the Plan shall have any effect on any Awards then outstanding under the Plan.
|
|
|
|
|
5.3
|
Amendment and Termination of the Plan. The Board
may, at any time and from time to time, amend, suspend, or terminate the Plan as to any shares of Stock as to which Awards
have not been made. An amendment shall be contingent on approval of the Company’s stockholders to the extent stated
by the Board, required by applicable law or required by applicable stock exchange listing requirements. No Awards shall be
made after termination of the Plan. No amendment, suspension, or termination of the Plan shall, without the consent of the
Grantee, materially impair rights or obligations under any Award theretofore awarded under the Plan.
|
|
- 2020 Proxy Statement
|
73
|
|
|
|
SECTION 6.
|
AWARD ELIGIBILITY AND LIMITATIONS
|
|
6.1
|
Service Providers. Subject to this
Section 6, Awards may be made under the Plan to any Service Provider to the Company or of any Affiliate, including
any Service Provider who is an officer or director of the Company or of any Affiliate, as the Board or the Committee shall
determine and designate from time to time.
|
|
|
|
|
6.2
|
Successive Awards and Substitute Awards. An eligible
person may receive more than one Award, subject to such restrictions as are provided herein. Notwithstanding Sections 8.1
and 9.1, the Option Price of an Option or the grant price of an SAR that is a Substitute Award may be less than one hundred
percent (100%) of the Fair Market Value of a share of Stock on the original date of grant; provided, that the Option Price
or grant price is determined in accordance with the principles of Code Section 424, Code Section 409A, and the regulations
thereunder. Substitute Awards may be granted (on such terms and conditions as the Committee determines appropriate) in assumption
of, or in substitution or exchange for, stock and stock-based awards held by employees, directors and other service providers
of another entity who, pursuant to an acquisition (whether by purchase, merger or other Change in Control) by the Company
or an Affiliate, become employees, directors or other service providers of the Company or an Affiliate.
|
|
|
|
|
6.3
|
Limitation on Awards to Outside Directors. The
aggregate dollar value of equity-based (based on the Grant Date’s Fair Market Value of equity-based Awards) and cash
compensation granted under this Plan or otherwise during any calendar year to any Outside Director shall not exceed Three
Hundred Fifty Thousand Dollars ($350,000); provided, however, that in the calendar year in which an Outside Director first
joins the Board or is first designated as Chairman of the Board or Lead Director, the maximum aggregate dollar value of equity-based
and cash compensation granted to the Outside Director may be up to two hundred percent (200%) of the foregoing limit.
|
|
|
|
|
6.4
|
Maximum Awards. Subject to adjustment as provided
in Section 17, the maximum number of shares of Stock underlying Awards to any one Grantee during any fiscal year of
the Company shall be 1,000,000.
|
SECTION 7.
|
AWARD AGREEMENT
|
Each Award granted pursuant to the Plan shall be
evidenced by an Award Agreement, in such form or forms as the Board or the Committee shall from time to time determine. Award Agreements
granted from time to time or at the same time need not contain similar provisions but shall be consistent with the terms of the
Plan. Each Award Agreement evidencing an Award of Options shall specify whether such Options are intended to be Non-qualified Stock
Options or Incentive Stock Options, and in the absence of such specification such Options shall be deemed Non-qualified Stock Options.
SECTION 8.
|
TERMS AND CONDITIONS OF OPTIONS
|
|
8.1
|
Option Price. The Option Price of each
Option shall be fixed by the Board or the Committee and stated in the Award Agreement evidencing such Option. Except for Substitute
Awards, the Option Price of each Option shall be at least the Fair Market Value on the Grant Date of a share of Stock; provided,
however, that in the event that a Grantee is a Ten Percent Stockholder, the Option Price of an Option granted to such
Grantee that is intended to be an Incentive Stock Option shall be not less than one hundred ten percent (110%) of the Fair
Market Value of a share of Stock on the Grant Date. In no case shall the Option Price of any Option be less than the par value
of a share of Stock.
|
|
|
|
|
8.2
|
Vesting. Subject to Sections 8.3 and 17 hereof,
each Option granted under the Plan shall become exercisable at such times and under such conditions (including conditions
based on achievement of performance goals and/or future service requirements) as shall be determined by the Board or the Committee
and stated in the Award Agreement. Except for Substitute Awards and the Minimum Vesting Requirements, exceptions, Options
shall have a vesting period of at least twelve (12) months from the Grant Date. For purposes of this Section 8.2, fractional
numbers of shares of Stock subject to an Option shall be rounded down to the next nearest whole number.
|
|
|
|
|
8.3
|
Term. Each Option granted under the Plan shall
terminate, and all rights to purchase shares of Stock thereunder shall cease, upon the expiration of ten (10) years from the
date such Option is granted, or under such circumstances and on such date prior thereto as is set forth in the Plan or as
may be fixed by the Board or the Committee and stated in the Award Agreement relating to such Option; provided, however, that
(i) in the event that the Grantee is a Ten Percent Stockholder, an Option granted to such Grantee that is intended to be an
Incentive Stock Option shall not be exercisable after the expiration of five (5) years from its Grant Date; and (ii) such
term shall be automatically extended by thirty (30) days (but to no longer than ten (10) years for any Option that intended
to be an Incentive Stock Option or to no longer than five (5) years for any Option that intended to be an Incentive Stock
Option and is granted to a Ten Percent Stockholder) in the event that the original term of the Option is set to expire during
a closed window period applicable to the Grantee. Any Award of an Incentive Stock Option must be made prior to April 3, 2030.
|
|
|
|
|
8.4
|
Termination of Service. Each Award Agreement shall
set forth the extent to which the Grantee shall have the right to exercise the Option following termination of the Grantee’s
Service. Such provisions shall be determined in the sole discretion of the Board or the Committee, need not be uniform among
all Options granted pursuant to the Plan, and may reflect distinctions based on the reasons for termination of Service.
|
|
|
|
|
8.5
|
Limitations on Exercise of Option. Notwithstanding
any other provision of the Plan, in no event may any Option be exercised, in whole or in part, prior to the date the Plan
is approved by the stockholders of the Company as provided herein or after the occurrence of an event referred to in Section
17 hereof which results in termination of the Option.
|
|
- 2020 Proxy Statement
|
74
|
|
|
|
|
8.6
|
Method of Exercise. Subject to such
rules and procedures as may be established by the Board or the Committee, the provisions of this Section 8.6 shall
apply to the exercise of Options. An Option that is exercisable may be exercised by the Grantee’s delivery to the Company
of written notice of exercise on any business day, at the Company’s principal office, on the form specified by the Company.
Such notice shall specify the number of shares of Stock with respect to which the Option is being exercised; and, subject
to Section 12, unless the Board or Committee in its discretion permits payment through a “cashless exercise”
or Net Exercise procedure, shall be accompanied by payment in full of the Option Price of the shares of Stock for which the
Option is being exercised plus the amount (if any) of federal and/or other taxes which the Company may, in its judgment, be
required to withhold with respect to an Award. The minimum number of shares of Stock with respect to which an Option may be
exercised, in whole or in part, at any time shall be the lesser of (i) one hundred (100) shares or such lesser number set
forth in the applicable Award Agreement and (ii) the maximum number of shares available for purchase under the Option at the
time of exercise.
|
|
|
|
|
8.7
|
Rights of Holders of Options. An individual
holding or exercising an Option shall have none of the rights of a stockholder (for example, the right to receive cash or
dividend payments or distributions attributable to the subject shares of Stock or to direct the voting of the subject
shares of Stock) until the shares of Stock covered thereby are fully paid for and issued to the Grantee. Except as
provided in Section 17 hereof, no adjustment shall be made for dividends, distributions or other rights for which the
record date is prior to the date of such issuance.
|
|
|
|
|
8.8
|
Delivery of Stock. Promptly after the exercise
of an Option by a Grantee and the payment in full of the Option Price, such Grantee shall be entitled to the issuance of the
shares of Stock subject to the Option pursuant to Section 3.6.
|
|
|
|
|
8.9
|
Transferability of Options. Except as provided
in Section 8.10, during the lifetime of a Grantee, only the Grantee (or, in the event of legal incapacity or incompetency,
the Grantee’s guardian or legal representative) may exercise an Option. Except as provided in Section 8.10, no
Option shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent
and distribution.
|
|
|
|
|
8.10
|
Family Transfers. If authorized in the applicable
Award Agreement, a Grantee may transfer, not for value, all or part of an Option which is not an Incentive Stock Option to
any Family Member. For the purpose of this Section 8.10, a “not for value” transfer is a transfer which
is (i) a gift, (ii) a transfer under a domestic relations order in settlement of marital property rights; or (iii) a
transfer to an entity in which more than fifty percent (50%) of the voting interests are owned by Family Members (or the
Grantee) in exchange for an interest in that entity. Following a transfer under this Section 8.10, any such Option
shall continue to be subject to the same terms and conditions as were applicable immediately prior to transfer.
Subsequent transfers of transferred Options are prohibited except to Family Members of the original Grantee in accordance
with this Section 8.10 or by will or the laws of descent and distribution. The events of termination of Service of Section
8.4 hereof shall continue to be applied with respect to the original Grantee, following which the Option shall be
exercisable by the transferee only to the extent, and for the periods specified, in Section 8.4.
|
|
|
|
|
8.11
|
Limitations on Incentive Stock Options. An Option
shall constitute an Incentive Stock Option only (i) if the Grantee of such Option is an employee of the Company or any Subsidiary
of the Company; (ii) to the extent specifically provided in the related Award Agreement; and (iii) to the extent that the
aggregate Fair Market Value (determined at the time the Option is granted) of the shares of Stock with respect to which all
Incentive Stock Options held by such Grantee become exercisable for the first time during any calendar year (under the Plan
and all other plans of the Company and its Affiliates) does not exceed One Hundred Thousand Dollars ($100,000). This limitation
shall be applied by taking Options into account in the order in which they were granted.
|
|
|
|
|
8.12
|
Notice of Disqualifying Disposition. If any Grantee
shall make any disposition of shares of Stock issued pursuant to the exercise of an Incentive Stock Option under the circumstances
described in Code Section 421(b) (relating to certain disqualifying dispositions), such Grantee shall notify the Company of
such disposition within ten (10) days thereof.
|
|
|
|
|
8.13
|
No Reloads. Award Agreements for Options shall
not contain any provision entitling a Grantee to the automatic grant of additional Options in connection with the exercise
of the original Option.
|
|
|
|
|
8.14
|
No Repricing. Except as contemplated by the provisions
of Section 17, outstanding Options will not be repriced without the prior approval of the Company’s stockholders.
|
SECTION 9.
|
TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS
|
|
9.1
|
Right to Payment and Grant Price. A
Stock Appreciation Right shall confer on the Grantee to whom it is granted a right to receive, upon exercise thereof, the
excess of (A) the Fair Market Value of one share of Stock on the date of exercise over (B) the SAR Exercise Price as determined
by the Board or the Committee. The Award Agreement for an SAR shall specify the SAR Exercise Price, which shall be at least
the Fair Market Value of a share of Stock on the Grant Date. SARs may be granted in conjunction with all or part of an Option
granted under the Plan or at any subsequent time during the term of such Option, in conjunction with all or part of any other
Award or without regard to any Option or other Award; provided that an SAR that is granted subsequent to the Grant Date of
a related Option must have a SAR Exercise Price that is no less than the Fair Market Value of one share of Stock on the Grant
Date of the SAR.
|
|
|
|
|
9.2
|
Other Terms. The Board or the Committee shall determine
at the Grant Date, the time or times at which and the circumstances under which an SAR may be exercised in whole or in part
(including based on achievement of performance goals and/or future service requirements), the time or times at which SARs
shall cease to be or become exercisable following termination of Service or upon other conditions, the method of exercise,
method of settlement, form of consideration payable in settlement, method
|
|
- 2020 Proxy Statement
|
75
|
|
|
|
|
|
by or forms in which Stock will be delivered or deemed to be delivered
to Grantees, whether or not an SAR shall be in tandem or in combination with any other Award, and any other terms and conditions
of any SAR. Notwithstanding the foregoing, except for Substitute Awards and the Minimum Vesting Requirements exceptions, SARs
shall have a vesting period of at least twelve (12) months from the Grant Date.
|
|
|
|
|
9.3
|
Term. Each SAR granted under the Plan shall terminate,
and all rights thereunder shall cease, upon the expiration of ten years from the date such SAR is granted, or under such circumstances
and on such date prior thereto as is set forth in the Plan or as may be fixed by the Board or the Committee and stated in
the Award Agreement relating to such SAR; provided, however, that such term shall be automatically extended
by thirty (30) days in the event that the original term of the SAR is set to expire during a closed window period applicable
to the Grantee.
|
|
|
|
|
9.4
|
Transferability of SARS. Except as provided in
Section 9.5, during the lifetime of a Grantee, only the Grantee (or, in the event of legal incapacity or incompetency,
the Grantee’s guardian or legal representative) may exercise a SAR. Except as provided in Section 9.5, no SAR
shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution.
|
|
|
|
|
9.5
|
Family Transfers. If authorized in the applicable
Award Agreement, a Grantee may transfer, not for value, all or part of a SAR to any Family Member. For the purpose of this
Section 9.5, a “not for value” transfer is a transfer which is (i) a gift, (ii) a transfer under a
domestic relations order in settlement of marital property rights; or (iii) a transfer to an entity in which more than
fifty percent of the voting interests are owned by Family Members (or the Grantee) in exchange for an interest in that
entity. Following a transfer under this Section 9.5, any such SAR shall continue to be subject to the same terms
and conditions as were applicable immediately prior to transfer. Subsequent transfers of transferred SARs are prohibited
except to Family Members of the original Grantee in accordance with this Section 9.5 or by will or the laws of
descent and distribution.
|
|
|
|
|
9.6
|
No Repricing. Except as contemplated by the provisions
of Section 17, outstanding Stock Appreciation Rights will not be repriced without the prior approval of the Company’s
stockholders.
|
SECTION 10.
|
TERMS AND CONDITIONS OF RESTRICTED STOCK AND STOCK UNITS
|
|
10.1
|
Grant of Restricted Stock or Stock Units.
Each Award of Restricted Stock or Stock Units shall be evidenced by an Award Agreement and may be made for no consideration
(other than par value of the shares of Stock which is deemed paid by Services already rendered). Settlement of each Award
of Stock Units shall be in cash, Stock, other property or a combination thereof, in the discretion of the Committee.
|
|
|
|
|
10.2
|
Restrictions; Minimum Vesting. At the time a grant
of Restricted Stock or Stock Units is made, the Board or the Committee may, in its sole discretion, establish a period of
time (a “Restricted Period”) applicable to such Restricted Stock or Stock Units. Each Award of Restricted
Stock or Stock Units may be subject to a different Restricted Period. The Board or the Committee may, in its sole discretion,
at the time a grant of Restricted Stock or Stock Units is made, prescribe restrictions in addition to or other than the expiration
of the Restricted Period. Notwithstanding the foregoing, except for Substitute Awards and the Minimum Vesting Requirements
exceptions, Awards of Restricted Stock or Stock Units subject solely to continued Service with the Company or an Affiliate
shall have a vesting period of at least twelve (12) months from the Grant Date. Neither Restricted Stock nor Stock Units may
be sold, transferred, assigned, pledged or otherwise encumbered or disposed of during the Restricted Period or prior to the
satisfaction of any other restrictions prescribed by the Board or the Committee with respect to such Restricted Stock or Stock
Units.
|
|
|
|
|
10.3
|
Restricted Stock Certificates. The Company shall
issue, in the name of each Grantee to whom Restricted Stock has been granted, stock certificates or book-entry registered
shares pursuant to Section 3.6 representing the total number of shares of Restricted Stock granted to the Grantee,
as soon as reasonably practicable after the Grant Date. The Secretary of the Company shall hold such certificates for the
Grantee’s benefit until such time as the Restricted Stock is forfeited to the Company or the restrictions lapse, or
such certificates or book-entry registered shares shall be delivered to the Grantee, provided, however, that
such certificates or book-entry registered shares shall bear a legend or legends that comply with the applicable securities
laws and regulations and makes appropriate reference to the restrictions imposed under the Plan and the Award Agreement.
|
|
|
|
|
10.4
|
Rights of Holders of Restricted Stock. Unless the
Board or the Committee otherwise provides in an Award Agreement, holders of Restricted Stock shall have the right to vote
such Stock and the right to receive any dividends declared or paid with respect to such Stock. The Board or the Committee
may provide that any dividends paid on Restricted Stock must be reinvested in shares of Stock, which may or may not be subject
to the same vesting conditions and restrictions applicable to such Restricted Stock. All distributions, if any, received by
a Grantee with respect to Restricted Stock as a result of any stock split, stock dividend, combination of shares, or other
similar transaction shall be subject to the restrictions applicable to the original Award.
|
|
|
|
|
10.5
|
Rights of Holders of Stock Units.
|
|
(i)
|
Voting and Dividend Rights. Holders
of Stock Units shall have no rights as stockholders of the Company. The Board or the Committee may provide in an Award Agreement
evidencing a grant of Stock Units that the holder of such Stock Units shall be entitled to receive, upon the Company’s
payment of a cash dividend on its outstanding Stock, a cash payment for each Stock Unit held equal to the per-share dividend
paid on the Stock. Such Award Agreement may also provide that such cash payment will be deemed reinvested in additional Stock
Units at a price per unit equal to the Fair Market Value of a share of Stock on the date that such dividend is paid.
|
|
- 2020 Proxy Statement
|
76
|
|
|
|
|
(ii)
|
Creditor’s Rights. A holder of
Stock Units shall have no rights other than those of a general creditor of the Company. Stock Units represent an unfunded
and unsecured obligation of the Company, subject to the terms and conditions of the applicable Award Agreement.
|
|
10.6
|
Purchase of Restricted Stock. The Grantee
shall be required, to the extent required by applicable law, to purchase the Restricted Stock from the Company at a Purchase
Price equal to the greater of (i) the aggregate par value of the shares of Stock represented by such Restricted Stock, or
(ii) the Purchase Price, if any, specified in the Award Agreement relating to such Restricted Stock. The Purchase Price shall
be payable in a form described in Section 12 or, in the discretion of the Board or the Committee, in consideration
for past Services rendered to the Company or an Affiliate.
|
|
|
|
|
10.7
|
Delivery of Stock. Upon the expiration or termination
of any Restricted Period and the satisfaction of any other conditions prescribed by the Board or the Committee, the restrictions
applicable to shares of Restricted Stock or Stock Units shall lapse, and, unless otherwise provided in the Award Agreement,
a stock certificate or book-entry registration for such shares shall be delivered, free of all such restrictions, to the Grantee
or the Grantee’s beneficiary or estate, as the case may be. Neither the Grantee, nor the Grantee’s beneficiary
or estate, shall have any further rights with regard to a Stock Unit once the share of Stock represented by the Stock Unit
(or cash or other property, as applicable) has been delivered.
|
SECTION 11.
|
TERMS AND CONDITIONS OF UNRESTRICTED STOCK AWARDS
|
The Board or the Committee may, in its sole discretion,
grant (or sell at par value or such other higher Purchase Price determined by the Board or the Committee) an Award of Unrestricted
Stock to any Grantee pursuant to which such Grantee may receive shares of Stock free of any restrictions (“Unrestricted
Stock”) under the Plan. Awards of Unrestricted Stock may be granted or sold as described in the preceding sentence in
respect of past Services and other valid consideration, or in lieu of, or in addition to, any cash compensation due to such Grantee.
SECTION 12.
|
FORM OF PAYMENT FOR OPTIONS AND RESTRICTED STOCK
|
|
12.1
|
General Rule. Payment of the Option
Price for the shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock shall be made
in cash or in cash equivalents acceptable to the Company.
|
|
|
|
|
12.2
|
Surrender of Stock. To the extent the Award Agreement
so provides, payment of the Option Price for shares of Stock purchased pursuant to the exercise of an Option or the Purchase
Price for Restricted Stock may be made all or in part through the tender to the Company of shares of Stock, which shall be
valued, for purposes of determining the extent to which the Option Price or Purchase Price has been paid thereby, at their
Fair Market Value on the date of exercise or surrender.
|
|
|
|
|
12.3
|
Cashless Exercise; Net Exercise. With respect to
an Option only (and not with respect to Restricted Stock), to the extent permitted by law and to the extent the Award Agreement
so provides, payment of the Option Price for shares purchased pursuant to the exercise of an Option may be made all or in
part by (i) delivery (on a form acceptable to the Board or the Committee) of an irrevocable direction to a licensed securities
broker acceptable to the Company to sell shares of Stock and to deliver all or part of the sales proceeds to the Company in
payment of the Option Price and any withholding taxes described in Section 18.3, or (ii) a Net Exercise.
|
|
|
|
|
12.4
|
Other Forms of Payment. To the extent the Award
Agreement so provides, payment of the Option Price for shares purchased pursuant to exercise of an Option or the Purchase
Price for Restricted Stock may be made in any other form that is consistent with applicable laws, regulations and rules.
|
SECTION 13.
|
TERMS AND CONDITIONS OF DIVIDEND EQUIVALENT RIGHTS
|
|
13.1
|
Dividend Equivalent Rights. A
Dividend Equivalent Right is an Award entitling the recipient to receive credits based on cash distributions that would
have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if
such shares of Stock had been issued to and held by the recipient. A Dividend Equivalent Right may be granted hereunder
to any Grantee, provided that no Dividend Equivalent Rights may be granted in connection with, or related to, an
Award of Options or SARs. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award
Agreement. Dividend Equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or at the
end of any applicable vesting period, or may be deemed to be reinvested in additional shares of Stock, which may
thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of
reinvestment. Dividend Equivalent Rights may be settled in cash or Stock or a combination thereof, in a single
installment or installments, all determined in the sole discretion of the Board or the Committee. A Dividend
Equivalent Right granted as a component of another Award may provide that such Dividend Equivalent Right shall be
settled upon exercise, settlement, or payment of, or lapse of restrictions on, such other Award, and that such Dividend
Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. A Dividend
Equivalent Right granted as a component of another Award also may contain terms and conditions which are different
from the terms and conditions of such other Award, provided that Dividend Equivalent Rights credited pursuant
to a Dividend Equivalent Right granted as a component of another Award which vests or is earned based upon the
achievement of performance goals shall not vest or become payable unless such performance goals for such underlying
Award are achieved, and if such performance goals are not achieved, the Grantee of such Dividend Equivalent Rights
shall promptly forfeit and repay to the Company payments made in connection with such Dividend Equivalent Rights.
Awards of Dividend Equivalent rights shall be subject to the Minimum Vesting Requirements.
|
|
- 2020 Proxy Statement
|
77
|
|
|
|
SECTION 14.
|
TERMS AND CONDITIONS OF PERFORMANCE SHARES AND PERFORMANCE UNITS AWARDS
|
|
14.1
|
Grant of Performance Units/Performance Shares.
Subject to the terms and provisions of this Plan, the Board or Committee, at any time and from time to time, may grant
Awards of Performance Units and/or Performance Shares to Grantees in such amounts and upon such terms as the Board or Committee
shall determine.
|
|
|
|
|
14.2
|
Award Agreement. Each Award of Performance Shares
or Performance Units shall be evidenced by an Award Agreement that shall specify the number of Performance Shares or Performance
Units subject to the Award, the performance objectives (which may include Performance Measures), the Performance Period applicable
to the Award, any other conditions or restrictions on the Award, and such other terms and conditions as the Board or Committee,
in its discretion, determines and as are consistent with this Plan. Each Performance Share shall have an initial value equal
to the Fair Market Value of a Share on the Grant Date.
|
|
|
|
|
14.3
|
Performance Objectives. Any grant of Performance
Shares or Performance Units shall specify performance objectives (which may include Performance Measures), which, if achieved,
will result in payment or early payment of the Award. Each grant shall specify a minimum acceptable level of achievement of
the performance objectives and shall set forth a formula for determining the number of Performance Shares or Performance Units
that will be earned if performance is at or above minimum level, but falls short of full achievement of the specified performance
objectives. Before the Performance Shares or Performance Units shall be earned and paid, the Committee must determine the
level of achievement of the performance objectives.
|
|
|
|
|
14.4
|
Timing For Establishing Performance Goals. For
Performance Awards other than Options that are intended to qualify as “performance-based compensation” for purposes
of Code Section 409A, performance goals shall be established not later than ninety (90) days after the beginning of any performance
period applicable to such Awards, or at such other date as may be required or permitted for “performance-based compensation”
under Code Section 409A and the regulations issued thereunder.
|
|
|
|
|
14.5
|
Settlement of Performance Awards; Other Terms.
Settlement of Performance Awards shall be in cash, Stock, other property or a combination thereof, in the discretion of the
Committee. The Committee may, in its discretion, reduce the amount of a settlement otherwise to be made in connection with
such Performance Awards. The Committee shall specify the circumstances in which such Performance Awards shall be paid or forfeited
in the event of termination of Service by the Grantee prior to the end of a performance period or settlement of Performance
Awards.
|
|
|
|
|
14.6
|
Performance Measures. Any Performance Measure(s)
may be used to measure the performance of the Company, any Subsidiary, and/or any Affiliate as a whole or any business unit
of the Company, any Subsidiary, and/or any Affiliate or any combination thereof, as the Committee may deem appropriate, or
any of the Performance Measures as compared to the performance of a group of comparator companies, or published or special
index that the Committee, in its sole discretion, deems appropriate, or the Company may select share price, including growth
measures and total stockholder return as compared to various stock market indices. The Committee also has the authority to
provide for accelerated vesting of any Performance Award based on the achievement of performance goals pursuant to the Performance
Measures.
|
|
(i)
|
Evaluation of Performance. The Committee
may provide in any Award Agreement that any evaluation of performance may include or exclude any of the following events that
occur during a Performance Period: (a) asset write-downs; (b) litigation or claim judgments or settlements; (c) the effect
of changes in tax laws, accounting principles, or other laws or provisions affecting reported results; (d) any reorganization
and restructuring programs; (e) events or circumstances that are unusual in nature or infrequently occurring; (f) acquisitions
or divestitures; and (g) foreign exchange gains and losses.
|
|
|
|
|
(ii)
|
Adjustment of Performance-Based Compensation. Awards
that are intended to qualify as Performance-Based Compensation may be adjusted upward or downward, either on a formula or
discretionary basis, or any combination as the Committee determines.
|
|
14.7
|
Dividends and Dividend Equivalents.
The Committee may, at the Grant Date of Performance Shares or Performance Units, provide for payment of dividends or dividend
equivalents to the Grantee either in cash or in additional Shares, subject in all cases to deferral and payment on a contingent
basis based on Grantee’s earning of the Performance Shares or Performance Units with respect to which such dividend
equivalents or dividends are paid.
|
|
|
|
|
14.8
|
Minimum Vesting Requirements. Except for Substitute
Awards and the Minimum Vesting Requirements exceptions, Awards of Performance Shares and Performance Units shall have a vesting
period of at least twelve (12) months from the Grant Date.
|
SECTION 15.
|
PARACHUTE LIMITATIONS
|
Notwithstanding any other provision of this Plan
or of any Award Agreement or other agreement, contract, or understanding heretofore or hereafter entered into by a Grantee with
the Company or any Affiliate, except an agreement, contract, or understanding that expressly addresses Section 280G or Section
4999 of the Code (an “Other Agreement”), and notwithstanding any formal or informal plan or other arrangement
for the direct or indirect provision of compensation to the Grantee (including groups or classes of Grantees or beneficiaries of
which the Grantee is a member), whether or not such compensation is deferred, is in cash, or is in the form of a benefit to or
for the Grantee (a “Benefit Arrangement”), if the Grantee is a “disqualified individual,” as defined
in Section 280G(c) of the Code, any Option, Restricted Stock, Stock Unit, Performance Share or Performance Unit held by that Grantee
and any right to receive any payment or other benefit under this Plan shall not become exercisable or vested (i) to the extent
that such right to exercise, vesting, payment, or benefit, taking into account all other rights, payments, or benefits to or for
the Grantee under this Plan, all Other Agreements, and all Benefit Arrangements, would cause any payment or benefit to the Grantee
under this Plan to be considered a “parachute payment” within the meaning of Section 280G(b)(2) of the Code as then
in effect (a “Parachute Payment”), and (ii) if, as a result of receiving a Parachute Payment, the aggregate
after-tax amounts received by the Grantee from the Company under this Plan, all Other Agreements, and all Benefit Arrangements
would be less than the maximum after-tax amount that could be received by the Grantee without causing any such
|
- 2020 Proxy Statement
|
78
|
|
|
|
payment or benefit to be considered a Parachute Payment.
In the event that the receipt of any such right to exercise, vesting, payment, or benefit under this Plan, in conjunction with
all other rights, payments, or benefits to or for the Grantee under any Other Agreement or any Benefit Arrangement would cause
the Grantee to be considered to have received a Parachute Payment under this Plan that would have the effect of decreasing the
after-tax amount received by the Grantee as described in clause (ii) of the preceding sentence, then the Grantee shall have the
right, in the Grantee’s sole discretion, to designate those rights, payments, or benefits under this Plan, any Other Agreements,
and any Benefit Arrangements that should be reduced or eliminated so as to avoid having the payment or benefit to the Grantee under
this Plan be deemed to be a Parachute Payment.
SECTION 16.
|
REQUIREMENTS OF LAW
|
|
16.1
|
General. The Company shall not be required
to sell or issue any shares of Stock under any Award if the sale or issuance of such shares of Stock would constitute a violation
by the Grantee, any other individual exercising an Option, or the Company of any provision of any law or regulation of any
governmental authority, including without limitation any federal or state securities laws or regulations. If at any time the
Company shall determine, in its discretion, that the listing, registration or qualification of any shares of Stock subject
to an Award upon any securities exchange or under any governmental regulatory body is necessary or desirable as a condition
of, or in connection with, the issuance or purchase of shares of Stock hereunder, no shares of Stock may be issued or sold
to the Grantee or any other individual exercising an Option pursuant to such Award unless such listing, registration, qualification,
consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay
caused thereby shall in no way affect the date of termination of the Award. Without limiting the generality of the foregoing,
in connection with the Securities Act, upon the exercise of any Option or any SAR that may be settled in shares of Stock or
the delivery of any shares of Stock underlying an Award, unless a registration statement under such Securities Act is in effect
with respect to the shares of Stock covered by such Award, the Company shall not be required to sell or issue such shares
unless the Board has received evidence satisfactory to it that the Grantee or any other individual exercising an Option may
acquire such shares pursuant to an exemption from registration under the Securities Act. Any determination in this connection
by the Board shall be final, binding, and conclusive. The Company may, but shall in no event be obligated to, register any
securities covered hereby pursuant to the Securities Act. The Company shall not be obligated to take any affirmative action
in order to cause the exercise of an Option or a SAR or the issuance of shares of Stock pursuant to the Plan to comply with
any law or regulation of any governmental authority. As to any jurisdiction that expressly imposes the requirement that an
Option (or SAR that may be settled in shares of Stock) shall not be exercisable until the shares of Stock covered by such
Option (or SAR) are registered or are exempt from registration, the exercise of such Option (or SAR) under circumstances in
which the laws of such jurisdiction apply shall be deemed conditioned upon the effectiveness of such registration or the availability
of such an exemption.
|
|
|
|
|
16.2
|
Rule 16b-3. During any time when the Company has
a class of equity security registered under Section 12 of the Exchange Act, it is the intent of the Company that Awards
pursuant to the Plan and the exercise of Options and SARs granted hereunder will qualify for the exemption provided by Rule
16b-3 under the Exchange Act. To the extent that any provision of the Plan or action by the Board does not comply with the
requirements of Rule 16b-3, it shall be deemed inoperative to the extent permitted by law and deemed advisable by the Board,
and shall not affect the validity of the Plan. In the event that Rule 16b-3 is revised or replaced, the Board may exercise
its discretion to modify this Plan in any respect necessary to satisfy the requirements of, or to take advantage of any features
of, the revised exemption or its replacement.
|
SECTION 17.
|
ADJUSTMENTS FOR CHANGES IN CAPITALIZATION
|
|
17.1
|
Mandatory Adjustments. In the event
of an ‘‘equity restructuring” (as such term is defined in Financial Accounting Standards Board Accounting
Standards Codification Topic 718, ‘‘Compensation — Stock Compensation”), including any stock dividend,
stock split, spin-off, rights offering, or large nonrecurring cash dividend, the authorization limits under Sections 4.1,
4.2, and 6.4 shall be adjusted proportionately, and the Committee shall make such adjustments to the Plan and outstanding
Awards as it deems necessary or appropriate, in its sole discretion, to prevent dilution or enlargement of benefits or potential
benefits intended to be made available under the Plan, including: (a) adjustment of the number and kind of shares or securities
that may be issued under the Plan; (b) adjustment of the number and kind of shares or securities subject to outstanding Awards;
(c) adjustment of the Exercise Price of outstanding Stock Options and Stock Appreciation Rights or the measure to be used
to determine the amount of the benefit payable on an Award; (d) adjustment to market price-based performance goals or performance
goals set on a per-Share basis; and (e) any other adjustments that the Committee determines to be equitable. Notwithstanding
the foregoing, the Committee shall not make any adjustments to outstanding Stock Options or SARs to the extent that it causes
such Stock Options or SARs to provide for a deferral of compensation subject to Code Section 409A. Without limiting the foregoing,
in the event of a subdivision of the outstanding Common Stock (a stock split), a dividend payable in Shares, or a combination
or consolidation of the outstanding Common Stock into a lesser number of Shares, the authorization limits under Sections 4.1,
4.2 and 6.4 shall automatically be adjusted proportionately, and the Shares then subject to each outstanding Award shall automatically,
without the necessity for any additional action by the Committee, be adjusted proportionately without any change in the aggregate
Exercise Price therefor.
|
|
|
|
|
17.2
|
Discretionary Adjustments. Upon the occurrence
or in anticipation of any share combination, exchange or reclassification, recapitalization, merger, consolidation or other
corporate reorganization affecting the Common Stock, or any transaction described in Section 17.1, in addition to any
of the actions described in Section 17.1, the Committee may, in its sole discretion, provide: (a) that Awards will
be settled in cash rather than Shares; (b) that Awards will become immediately vested and exercisable
|
|
- 2020 Proxy Statement
|
79
|
|
|
|
|
|
and will expire after a designated period of time to the extent not then
exercised; (c) that Awards will be equitably converted, adjusted or substituted in connection with such transaction; (d) that
outstanding Awards may be settled by payment in cash or cash equivalents equal to the excess of the Fair Market Value of the
underlying Shares as of a specified date associated with the transaction, over the Exercise Price of the Award; (e) that performance
targets and Performance Periods for Performance Awards will be modified; or (f) any combination of the foregoing. The Committee’s
determination need not be uniform and may be different for different Participants whether or not such Participants are similarly
situated.
|
|
|
|
|
17.3
|
No Fractional Shares, etc. After giving effect
to any adjustment pursuant to the provisions of this Section 17, the number of Shares subject to any Award
denominated in whole Shares shall always be a whole number, unless otherwise determined by the Committee. Any
discretionary adjustments made pursuant to the provisions of this Section 17 shall be subject to the provisions of Section
5. To the extent any adjustments made pursuant to this Section 17 cause Incentive Stock Options to cease to
qualify as Incentive Stock Options, such Stock Options shall be deemed to be Non-Qualified Stock Options.
|
|
|
|
|
17.4
|
No Limitations on Company. The making of Awards
pursuant to the Plan shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications,
reorganizations, or changes of its capital or business structure or to merge, consolidate, dissolve, or liquidate, or to sell
or transfer all or any part of its business or assets.
|
SECTION 18.
|
GENERAL PROVISIONS
|
|
18.1
|
Disclaimer of Rights. No provision
in the Plan or in any Award or Award Agreement shall be construed to confer upon any individual the right to remain in the
employ or service of the Company or any Affiliate, or to interfere in any way with any contractual or other right or authority
of the Company either to increase or decrease the compensation or other payments to any individual at any time, or to terminate
any employment or other relationship between any individual and the Company. In addition, notwithstanding anything contained
in the Plan to the contrary, unless otherwise stated in the applicable Award Agreement, no Award granted under the Plan shall
be affected by any change of duties or position of the Grantee, so long as such Grantee continues to be a director, officer,
consultant or employee of the Company or an Affiliate. The obligation of the Company to pay any benefits pursuant to this
Plan shall be interpreted as a contractual obligation to pay only those amounts described herein, in the manner and under
the conditions prescribed herein. The Plan shall in no way be interpreted to require the Company to transfer any amounts to
a third party trustee or otherwise hold any amounts in trust or escrow for payment to any Grantee or beneficiary under the
terms of the Plan.
|
|
|
|
|
18.2
|
Nonexclusivity of the Plan. Neither the adoption
of the Plan nor the submission of the Plan to the stockholders of the Company for approval shall be construed as creating
any limitations upon the right and authority of the Board to adopt such other incentive compensation arrangements (which arrangements
may be applicable either generally to a class or classes of individuals or specifically to a particular individual or particular
individuals) as the Board in its discretion determines desirable, including, without limitation, the granting of stock options
otherwise than under the Plan.
|
|
|
|
|
18.3
|
Withholding Taxes. The Company or an Affiliate,
as the case may be, shall have the right to deduct from payments of any kind otherwise due to a Grantee any federal, state,
or local taxes of any kind required by law to be withheld with respect to the vesting of or other lapse of restrictions applicable
to an Award or upon the issuance of any shares of Stock upon the exercise of an Option or pursuant to an Award. At the time
of such vesting, lapse, or exercise, the Grantee shall pay to the Company or the Affiliate, as the case may be, any amount
that the Company or the Affiliate may reasonably determine to be necessary to satisfy such withholding obligation. Subject
to the prior approval of the Company or the Affiliate, which may be withheld by the Company or the Affiliate, as the case
may be, in its sole discretion, the Grantee may elect to satisfy such obligations, in whole or in part, (i) by causing the
Company or the Affiliate to withhold shares of Stock otherwise issuable to the Grantee or (ii) by delivering to the Company
or the Affiliate shares of Stock already owned by the Grantee. The shares of Stock so delivered or withheld shall have an
aggregate Fair Market Value equal to such withholding obligations. The Fair Market Value of the shares of Stock used to satisfy
such withholding obligation shall be determined by the Company or the Affiliate as of the date that the amount of tax to be
withheld is to be determined. A Grantee who has made an election pursuant to this Section 18.3 may satisfy his or her withholding
obligation only with shares of Stock that are not subject to any repurchase, forfeiture, unfulfilled vesting, or other similar
requirements. The maximum number of shares of Stock that may be withheld from any Award to satisfy any federal, state or local
tax withholding requirements upon the exercise, vesting, lapse of restrictions applicable to such Award or payment of shares
pursuant to such Award, as applicable, cannot exceed such number of shares having a Fair Market Value equal to the maximum
amount to be withheld and paid to any such federal, state or local taxing authority with respect to such exercise, vesting,
lapse of restrictions or payment of shares, or such amount that will not cause an adverse accounting consequence or cost to
the Company.
|
|
|
|
|
18.4
|
Captions. The use of captions in this Plan or any
Award Agreement is for the convenience of reference only and shall not affect the meaning of any provision of the Plan or
such Award Agreement.
|
|
|
|
|
18.5
|
Other Provisions. Each Award granted under the
Plan may contain such other terms and conditions not inconsistent with the Plan as may be determined by the Board or the Committee,
in its sole discretion.
|
|
|
|
|
18.6
|
Number and Gender. With respect to words used in
this Plan, the singular form shall include the plural form, the masculine gender shall include the feminine gender, etc.,
as the context requires.
|
|
- 2020 Proxy Statement
|
80
|
|
|
|
|
18.7
|
Severability. If any provision of the
Plan or any Award Agreement shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the
remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions
shall remain enforceable in any other jurisdiction.
|
|
|
|
|
18.8
|
Governing Law. The validity and construction of
this Plan and the instruments evidencing the Awards hereunder shall be governed by the laws of the State of Delaware, other
than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Plan
and the instruments evidencing the Awards granted hereunder to the substantive laws of any other jurisdiction.
|
|
|
|
|
18.9
|
Section 409A of the Code. The Board intends to
comply with Section 409A of the Code (“Section 409A”), or an exemption to Section 409A, with regard to
Awards hereunder that constitute nonqualified deferred compensation within the meaning of Section 409A. To the extent that
the Board or the Committee determines that a Grantee would be subject to the additional 20% tax imposed on certain nonqualified
deferred compensation plans pursuant to Section 409A as a result of any provision of any Award granted under this Plan, such
provision shall be deemed amended to the minimum extent necessary to avoid application of such additional tax. The nature
of any such amendment shall be determined by the Board. Notwithstanding the foregoing, the Company, the Board and the Committee
shall have no liability to a Grantee, or any other party, if an Award that is intended to be exempt from, or compliant with,
Section 409A of the Code is not so exempt or compliant.
|
|
|
|
|
18.10
|
Clawback/Recoupment. Notwithstanding any other
provisions herein to the contrary, any performance based compensation, or any other amount, paid to a Grantee pursuant to
an Award, which is subject to recovery under any law, government regulation, stock exchange listing requirement, or any policy
adopted by the Company will be subject to such deductions and clawback as may be required to be made pursuant to such law,
government regulation, stock exchange listing requirement, or policy adopted by the Company.
|
|
- 2020 Proxy Statement
|
81
|
|
|
|
APPENDIX A
|
net earnings or net income;
|
|
operating earnings;
|
|
pretax earnings;
|
|
pre-tax earnings per share;
|
|
earnings per share;
|
|
share price, including growth measures and total stockholder return;
|
|
earnings before interest and taxes;
|
|
earnings before interest, taxes, depreciation and/or amortization;
|
|
earnings before interest, taxes, depreciation and/or amortization as adjusted to exclude
any one or more of the following:
|
|
–
|
stock-based compensation expense;
|
|
–
|
income from discontinued operations;
|
|
–
|
gain on cancellation of debt;
|
|
–
|
debt extinguishment and related costs;
|
|
–
|
restructuring, separation and/or integration charges and costs;
|
|
–
|
reorganization and/or recapitalization charges and costs;
|
|
–
|
impairment charges;
|
|
–
|
gain or loss related to investments;
|
|
–
|
sales and use tax settlement; and
|
|
–
|
gain on non-monetary transaction.
|
|
sales or revenue growth, whether in general, by type of product or service,
or by type of customer;
|
|
gross or operating margins;
|
|
return measures, including total shareholder return, return on assets, capital, investment,
equity, sales or revenue;
|
|
cash flow, including:
|
|
–
|
operating cash flow;
|
|
–
|
free cash flow, defined as earnings before interest, taxes, depreciation and/or amortization
(as adjusted to exclude any one or more of the items that may be excluded pursuant to earnings before interest, taxes, depreciation
and/or amortization above) less capital expenditures;
|
|
–
|
cash flow return on equity; and
|
|
–
|
cash flow return on investment.
|
|
productivity ratios;
|
|
expense targets;
|
|
market share;
|
|
working capital targets;
|
|
completion of acquisitions of businesses or companies (including
metrics resulting from the same such as revenue or margin);
|
|
completion of divestitures and asset sales;
|
|
debt repayment targets, and debt/equity ratios;
|
|
bookings or completion of orders (including metrics resulting from
the same such as revenue or margin);
|
|
project bookings, milestones or completion (including metrics related
to the same such as revenue or margin); and
|
|
any combination of the foregoing business criteria.
|
|
- 2020 Proxy Statement
|
82
|
|
|
|
Colfax (NYSE:CFXA)
Graphique Historique de l'Action
De Mar 2025 à Avr 2025
Colfax (NYSE:CFXA)
Graphique Historique de l'Action
De Avr 2024 à Avr 2025